1. Search Result

Search Result

Results for "target s/is ocitrate Dehydrogen ASe (IDH)" in MCE Product Catalog:

3125

Inhibitors & Agonists

106

Screening Libraries

21

Dye Reagents

10

Biochemical Assay Reagents

132

Peptides

9

Inhibitory Antibodies

402

Natural
Products

72

Recombinant Proteins

36

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas
  • HY-104036
    IDH-305

    Isocitrate Dehydrogenase (IDH) Cancer
    IDH-305 is an orally available, mutant-selective and brain-penetrant IDH1 inhibitor that targets IDH1 (R132) mutation. IDH-305 exhibits greater than 200 fold selectivity for mutant IDH1 isoforms vs. WT (IC50= 27 nM (IDH1 R132H), 28 nM (IDH1 R132C), 6.14 µM (IDH1 WT)).
  • HY-104068
    Naphthol AS-E

    Histone Acetyltransferase Epigenetic Reader Domain Cancer
    Naphthol AS-E is a potent and cell-permeable inhibitor of KIX-KID interaction. Naphthol AS-E directly binds to the KIX domain of CBP (Kd:8.6 µM), blocks the interaction between the KIX domain and the KID domain of CREB with IC50 of 2.26 µM. Naphthol AS-E can be used for cancer research.
  • HY-112289
    IDH889

    Isocitrate Dehydrogenase (IDH) Cancer
    IDH889 is an orally available, brain penetrant, allosteric and mutant specific inhibitor of isocitrate dehydrogenase 1 (IDH1). IDH889 has potent selectivity for IDH1 R132* mutations, with IC50s of 0.02 μM, 0.072 μM and 1.38 μM for IDH1 R132H, IDH1 R132C and IDH1 wt, respectively. IDH889 shows potent cellular inhibition of R-2-hydroxyglutarate (2-HG) production with an IC50 of 0.014 μM.
  • HY-131312
    Mutant IDH1-IN-6

    Isocitrate Dehydrogenase (IDH) Cancer
    Mutant IDH1-IN-6 is a potent, selective and orally active mutant isocitrate dehydrogenase (IDH) inhibitor with IC50s of 6.27 nM, 3.71 nM, 36.9 nM and 11.5 nM for IDH1 R132H, IDH1 R132C, IDH2 R140Q and IDH2 R172K mutant enzymes, respectively. Mutant IDH1-IN-6 is less active at inhibiting the IDH wild-type enzymes.
  • HY-12475
    Mutant IDH1-IN-1

    Isocitrate Dehydrogenase (IDH) Cancer
    Mutant IDH1-IN-1 is a mutant-selective IDH1 inhibitor with with IC50s of 4, 42, 80 and 143 nM against mutant IDH1 R132C/R132C, IDH1 R132H/R132H, IDH1 R132H/WT and wild type IDH1, respectively.
  • HY-112601
    IDH1 Inhibitor 1

    Isocitrate Dehydrogenase (IDH) Cancer
    IDH1 Inhibitor 1 is a potent, orally bioavailable, brain-penetrant and selective mutant IDH1 inhibitor with IC50s of 0.021 μM, 0.045 μM, and 2.52 μM for IDH1 R132H, IDH1 R132C, and IDH1 WT, respectively. Anticancer activity.
  • HY-13972
    Mutant IDH1 inhibitor

    Isocitrate Dehydrogenase (IDH) Cancer
    Mutant IDH1 inhibitor is a potent mutant IDH1 R132H inhibitor with IC50 of < 72 nM.
  • HY-18717
    Mutant IDH1-IN-2

    Isocitrate Dehydrogenase (IDH) Cancer
    Mutant IDH1-IN-2 is a inhibitor of mutant Isocitrate dehydrogenase (IDH) proteins, with IC50 of in LS-MS biochemical assay, IC50 of 16.6 nM in Fluorescence biochemical assay.
  • HY-114459
    Mutant IDH1-IN-4

    Isocitrate Dehydrogenase (IDH) Cancer
    Mutant IDH1-IN-4 (compound 434) is an inhibitor of mutant Isocitrate dehydrogenase 1 (IDH 1), with IC50 values of ≤ 0.5 μM for mutant IDH1 in R132H, HT1080 and U87R132H cells.
  • HY-107977
    IDH1 Inhibitor 3

    Isocitrate Dehydrogenase (IDH) Cancer
    IDH1 Inhibitor 3 (compound 6f) is a mutant isocitric dehydrogenase 1 (IDH1) inhibitor, with an IC50 of 45 nM for IDH1 R132H.
  • HY-18082
    AGI-5198

    IDH-C35

    Isocitrate Dehydrogenase (IDH) Cancer
    AGI-5198 (IDH-C35) is a potent and selective mutant IDH1 R132H inhibitor with an IC50 of 0.07 μM.
  • HY-128661
    IDH1 Inhibitor 2

    Isocitrate Dehydrogenase (IDH) Metabolic Disease
    IDH1 Inhibitor 2 (compound 13) is a potent IDH1 inhibitor via a direct covalent modification of His315, with an IC50 of 110 nM.
  • HY-18690
    Enasidenib

    AG-221

    Isocitrate Dehydrogenase (IDH) Cancer
    Enasidenib is an oral, potent, reversible, selective inhibitor of the IDH2 mutant enzymes, with IC50s of 100 and 400 nM against IDH2 R140Q and IDH2 R172K, respectively.
  • HY-135396
    (1S,2S)-Bortezomib

    Proteasome Apoptosis Cancer
    (1S,2S)-Bortezomib is an enantiomer of Bortezomib. Bortezomib is a cell-permeable, reversible, and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki of 0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is an anti-cancer agent and the first therapeutic proteasome inhibitor to be used in humans.
  • HY-102075B
    TMP780

    ROR Inflammation/Immunology
    TMP780 is an inverse agonist of RORγt with an IC50 of 13 nM. RORγt is a tractable drug target for the treatment of cutaneous inflammatory disorders.
  • HY-104042
    Vorasidenib

    AG-881

    Isocitrate Dehydrogenase (IDH) Cancer
    Vorasidenib (AG-881) is an orally available, brain penetrant second-generation dual mutant isocitrate dehydrogenases 1 and 2 (mIDH1/2) inhibitor. Vorasidenib (AG-881) exhibits nanomolar inhibition of (D)-2-hydroxyglutarate (D-2-HG), and the IC50 ranges of 0.04~22 nM against IDH1 R132C, IDH1 R132G, IDH1 R132H and IDH1 R132S and 7~14 nM against IDH2 R140Q and 130 nM against IDH2 R172K.
  • HY-B0546
    Procaine

    Histone Demethylase DNA/RNA Synthesis Neurological Disease Cancer
    Procaine is a DNA-demethylating agent. Procaine acts through multiple targets and has a slow onset and a short duration of action.
  • HY-B0546A
    Procaine hydrochloride

    Histone Demethylase DNA/RNA Synthesis Neurological Disease Cancer
    Procaine hydrochloride is a DNA-demethylating agent. Procaine hydrochloride acts through multiple targets and has a slow onset and a short duration of action.
  • HY-106991A
    Amustaline dihydrochloride

    S-303 dihydrochloride

    HIV Bacterial Infection
    Amustaline (S-303) dihydrochloride, a nucleic acid-targeted alkylator, is an efficient pathogen inactivation agent for blood components containing red blood cells. Amustaline dihydrochloride has three components: an acridine anchor (an intercalator that targets nucleic acids non-covalently), an effector (a bis-alkylator group that reacts with nucleophiles), and a linker (a small flexible carbon chain containing a labile ester bond that hydrolyzes at neutral pH to yield non-reactive breakdown products).
  • HY-14622A
    Necrostatin 2 racemate

    Necrostatin 1S; Nec-1S; 7-Cl-O-Nec1

    RIP kinase Cancer
    Necrostatin 2 racemate (Nec-1S), the Nec-1 stable, is a potent and specific RIPK1 inhibitor lacking the IDO-targeting effect.
  • HY-114176B
    (S,R,S)-AHPC-C4-NH2 dihydrochloride

    VH032-C4-NH2 dihydrochloride

    E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-C4-NH2 dihydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used for EED-Targeted PROTAC.
  • HY-114176A
    (S,R,S)-AHPC-C4-NH2

    VH032-C4-NH2

    E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-C4-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used for EED-Targeted PROTAC.
  • HY-18371
    TC-S 7009

    HIF/HIF Prolyl-Hydroxylase Inflammation/Immunology
    TC-S 7009 is a potent and selective HIF-2α inhibitor with a Kd of 81 nM. TC-S 7009 is more selective for HIF-2α than HIF-1α (Kd ≫ 5 μM). TC-S 7009 disrupts HIF-2α heterodimerization, decreases DNA-binding activity, and reduces HIF-2α target gene expression.
  • HY-129941
    (S,R,S)-AHPC-C10-NH2

    VH032-C10-NH2

    E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-C10-NH2 (VH032-C10-NH2) is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used for BET-Targeted PROTAC.
  • HY-129941A
    (S,R,S)-AHPC-C10-NH2 dihydrochloride

    VH032-C10-NH2 dihydrochloride

    E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-C10-NH2 dihydrochloride (VH032-C10-NH2 dihydrochloride) is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used for BET-Targeted PROTAC.
  • HY-135124
    DC44SMe

    ADC Cytotoxin Cancer
    DC44SMe, a phosphate prodrug of cytotoxic DNA alkylator DC44, can be used in the synthesis of Antibody-drug Conjugate (ADC). DC44SMe exhibits IC50s of 2.0 nM, 2.8 nM, and 1.9 nM for Ramos, Namalwa, and HL60/s cancer cells, respectively. DC44SMe can be used for the targeted treatment of cancer.
  • HY-135123
    DC4SMe

    ADC Cytotoxin Cancer
    DC4SMe, a phosphate prodrug of cytotoxic DNA alkylator DC4, can be used in the synthesis of Antibody-drug Conjugate (ADC). DC4SMe exhibits IC50s of 1.9 nM, 2.9 nM, and 1.8 nM for Ramos, Namalwa, and HL60/s cancer cells, respectively. DC4SMe can be used for the targeted treatment of cancer.
  • HY-125845A
    (S,S,S)-AHPC hydrochloride

    (S,S,S)-VH032-NH2 hydrochloride

    Ligand for E3 Ligase Cancer
    (S,S,S)-AHPC hydrochloride is a von Hippel-Lindau (VHL) amino building block. (S,S,S)-AHPC (Compound 27) is a ligand used as a negative control for (S,R,S)-AHPC. (S,R,S)-AHPC is the VH032-based VHL ligand used in the recruitment of the VHL protein.
  • HY-17518A
    (S,S)-Valifenalate

    (S,S)-IR5885; (S,S)-Valiphenal

    Fungal Infection
    (S,S)-Valifenalate ((S,S)-IR5885) is an acylamino acid fungicide and is used to control a wide range of fungi belonging to the class of Oomycetes. (S,S)-Valifenalate ((S,S)-IR5885) interferes with the cell-wall synthesis thus affecting the growth stages of the pathogens controlled, both outside (on the spores) or inside the plant (on the mycelium).
  • HY-N0328
    alpha-Mangostin

    α-Mangostin

    Reactive Oxygen Species Apoptosis Bacterial Fungal Virus Protease Cancer
    alpha-Mangostin (α-Mangostin) is a dietary xanthone with broad biological activities, such as antioxidant, anti-allergic, antiviral, antibacterial, anti-inflammatory and anticancer effects. It is an inhibitor of mutant IDH1 (IDH1-R132H) with a Ki of 2.85 μM.
  • HY-103299
    KG-501

    Naphthol AS-E phosphate

    Epigenetic Reader Domain Inflammation/Immunology
    KG-501 is a CREB inhibitor, with an IC50 of 6.89 μM.
  • HY-114176
    (S,R,S)-AHPC-C4-NH2 hydrochloride

    VH032-C4-NH2 hydrochloride; VHL Ligand-Linker Conjugates 13; E3 ligASe Ligand-Linker Conjugates 28

    E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-C4-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used for EED-Targeted PROTAC.
  • HY-130638
    (S,R,S)-AHPC-O-Ph-PEG1-NH-Boc

    VH032-O-Ph-PEG1-NH-Boc

    E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-O-Ph-PEG1-NH-Boc (VH032-O-Ph-PEG1-NH-Boc) is a synthesized E3 ligase ligand-linker conjugate which is used for the EED-targeted PROTAC.
  • HY-130711
    (S,R,S)-AHPC-C3-NH2

    VH032-C3-NH2

    E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-C3-NH2 (VH032-C3-NH2) is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology. (S,R,S)-AHPC-C3-NH2 can be used in the synthesis of a series of PROTACs, such as UNC6852 (HY-130708). UNC6852 is an EED-targeted bivalent chemical degrader.
  • HY-130802
    5-Aminouridine

    Fungal Influenza Virus Cancer Infection
    5-Aminouridine can modify nucleobases and can be incorporated into the target DNA. 5-Aminouridine exhibits a wide range of biological activity and it inhibits the growth of tumors, fungi and viruses.
  • HY-129545
    DS-1001b

    Isocitrate Dehydrogenase (IDH) Cancer
    DS-1001b is a mutant IDH-1 (Isocitrate Dehydrogenase-1) inhibitor extracted from patent WO2016052697A1, Example 168, and has antitumor activity.
  • HY-14658A
    (S)-Thalidomide

    (S)-(-)-Thalidomide

    Apoptosis Metabolic Disease Inflammation/Immunology
    (S)-Thalidomide ((S)-(-)-Thalidomide) is the S-enantiomer of Thalidomide. (S)-Thalidomide has immunomodulatory, anti-inflammatory, antiangiogenic and pro-apoptotic effects. (S)-Thalidomide induces teratogenic effects by binding to cereblon (CRBN) .
  • HY-50856A
    Ruxolitinib (S enantiomer)

    S-Ruxolitinib; S-INCB18424

    JAK Cancer
    Ruxolitinib S enantiomer is the S-enantiomer of Ruxolitinib. Ruxolitinib S enantiomer is a JAK inhibitor
  • HY-W074930
    (S)-Tenofovir

    (S)-GS 1278; (S)-PMPA; (S)-TDF

    HIV HBV Infection
    (S)-Tenofovir ((S)-GS 1278) is the less active S-enantiomer of Tenofovir. Tenofovir is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B (HBV).
  • HY-Y1069
    (S)-Malic acid

    (S)-Hydroxybutanedioic acid; (S)-E 296

    Endogenous Metabolite Metabolic Disease
    (S)-Malic acid ((S)-2-Hydroxysuccinic acid) is a dicarboxylic acid in naturally occurring form, contributes to the pleasantly sour taste of fruits and is used as a food additive.
  • HY-114226
    Olutasidenib

    FT-2102

    Isocitrate Dehydrogenase (IDH) Cancer Inflammation/Immunology
    Olutasidenib (FT-2102) is a highly potent, orally active, brain penetrant and selective inhibitor of mutant Isocitrate dehydrogenase 1 (IDH1), with IC50 values of 21.2 nM and 114 nM for IDH1- R132H and IDH1- R132C, respectively . Olutasidenib (FT-2102) is under the study in the treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) .
  • HY-14855A
    (S)-Tedizolid

    (S)-TR 700; (S)-DA 7157

    Bacterial Antibiotic Infection
    (S)-Tedizolid is the S-enantiomer of Tedizolid. Tedizolid is a novel oxazolidinone with activity against Gram-positive pathogens. (S)-Tedizolid is the less active isomer.
  • HY-107661A
    S-(+)-Arundic Acid

    (S)ONO-2506; (S)-2-Propyloctanoic acid

    Others Others
    S-(+)-Arundic Acid ((S)ONO-2506) is the S-enantiomer of Arundic Acid. Arundic acid is an astrocyte-modulating agent, has the potential for stroke and Alzheimer’s disease research.
  • HY-78131A
    (S)-(+)-Ibuprofen

    (S)-Ibuprofen

    COX Inflammation/Immunology
    (S)-(+)-Ibuprofen ((S)-Ibuprofen), a S(+)-enantiomer of Ibuprofen, is a potent COX-1 and COX-2 inhibitor with IC50s of 2.1 μM and 1.6 μM, respectively. (S)-(+)-Ibuprofen has analgesic, anti-inflammatory, anticancer and antipyretic effects.
  • HY-N2037B
    (S)-Higenamine

    (S)-Norcoclaurine

    Endogenous Metabolite Others
    (S)-Higenamine ((S)-Norcoclaurine), a S-enantiomer of Higenamine, is the entry compound in benzylisoquinoline alkaloid biosynthesis. (S)-Higenamine is produced by the condensation of dopamine and 4-hydroxyphenylacetaldehyde (4-HPAA) by norcoclaurine synthase (NCS).
  • HY-19540
    GSK864

    Isocitrate Dehydrogenase (IDH) Cancer
    GSK864 is an isocitrate dehydrogenase 1 (IDH1) mutant inhibitor; inhibits IDH1 mutants R132C, R132H, and R132G with IC50 values of 8.8, 15.2 and 16.6 nM.
  • HY-40354C
    (3S,4S)-Tofacitinib

    JAK Inflammation/Immunology
    (3S,4S)-Tofacitinib is the less active S-enantiomer of Tofacitinib. Tofacitinib inhibits JAK3 with IC50 of 1 nM.
  • HY-B0432B
    (S)-Propafenone

    (S)-SA-79

    Others Cardiovascular Disease
    (S)-Propafenone ((S)-SA-79) is the S-enantiomer of Propafenone. (S)-Propafenone ((S)-SA-79) exerts beta-blocking action and the sodium channel-dependent antiarrhythmic class 1 activity.
  • HY-15452A
    Selisistat S-enantiomer

    EX-527 (S-enantiomer)

    Sirtuin Cancer
    Selisistat S-enantiomer (EX-527 S-enantiomer) is the S-enantiomer of Selisistat, with an IC50 of 123 nM for SIRT1. Selisistat S-enantiomer is much more potent than Selisistat R-enantiomer.
  • HY-15734
    AGI-6780

    Isocitrate Dehydrogenase (IDH) Cancer
    AGI-6780 that potently and selectively inhibits the tumor-associated mutant IDH2 R140Q with IC50 of 23±1.7 nM. AGI-6780 is less potent against IDH2 WT with IC50 of 190±8.1 nM.
  • HY-B0352A
    (S)-Mirtazapine

    (S)-Org3770; (S)-6-Azamianserin

    5-HT Receptor Neurological Disease
    (S)-Mirtazapine ((S)-Org3770) is a S(+)-enantiomer of Mirtazapine with pronociceptive properties in an animal model of acute thermal nociception. (S)-Mirtazapine is a stereoselective 5-HT2 receptor antagonist. (S)-Mirtazapine is metabolized by CYP2D6 and CYP1A2.
  • HY-16742A
    Gepotidacin S enantiomer

    GSK2140944 S enantiomer

    Bacterial Infection
    Gepotidacin S enantiomer is an S enantionmer of gepotidacin.
  • HY-B0589C
    (3S,5S)-Atorvastatin

    Cytochrome P450 Metabolic Disease
    (3S,5S)-Atorvastatin is a inactive enantiomer of Atorvastatin. (3S,5S)-Atorvastatin can activate pregnane X receptor (PXR). Atorvastatin is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids.
  • HY-12872B
    Nazartinib S-enantiomer

    EGF816 (S-enantiomer)

    Others Others
    Nazartinib S-enantiomer (EGF816 S-enantiomer) is the less active S-enantiomer of Nazartinib. Nazartinib (EGF816) is an EGFR inhibitor.
  • HY-135336A
    (S)-Verapamil hydrochloride

    (S)-(-)-Verapamil hydrochloride

    Leukotriene Receptor Calcium Channel Apoptosis Cancer
    (S)-Verapamil hydrochloride (S(-)-Verapamil hydrochloride) inhibits leukotriene C4 (LTC4) and calcein transport by MRP1. (S)-Verapamil hydrochloride leads to the death of potentially resistant tumor cells.
  • HY-10502A
    Tipifarnib (S enantiomer)

    IND-58359 S enantiomer; (S)-(-)-R-115777

    Farnesyl Transferase Cancer
    Tipifarnib S enantiomer is the S-enantiomer of Tipifarnib. Tipifarnib is a potent and specific farnesyltransferase (FTase) inhibitor with IC50 of 0.6 nM. Tipifarnib S enantiomer is the less active isomer.
  • HY-B0006B
    (S)-Carvedilol

    (S)-BM 14190

    Adrenergic Receptor Cardiovascular Disease
    (S)-Carvedilol, the S-enantiomer of Carvedilol, is a non-selective β/α-1 blocker. (S)-Carvedilol exerts protection against the vascular or cardiac toxicity of Doxorubicin (DOX).
  • HY-130816
    (S,R,S)-AHPC-O-Ph-PEG1-NH2

    VH032-O-Ph-PEG1-NH2

    E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-O-Ph-PEG1-NH2 (VH032-O-Ph-PEG1-NH2) is E3 ligase ligand-linker conjugate and incorporates a VHL ligand for the E3 ubiquitin ligase, and a PROTAC linker. (S,R,S)-AHPC-O-Ph-PEG1-NH2 is used in PROTAC EED degrader-1 (HY-130614). PROTAC EED degrader-1 is a PROTAC targeting EED with a pKD of 9.02.
  • HY-16713A
    (S)-(-)-5-Fluorowillardiine hydrochloride

    (5S)-Fluorowillardiine hydrochloride; (S)-5-Fluorowillardiine hydrochloride

    iGluR Neurological Disease
    (S)-(-)-5-Fluorowillardiine hydrochloride is a potent and specific AMPAR agonist.
  • HY-16713
    (S)-(-)-5-Fluorowillardiine

    (5S)-Fluorowillardiine; (S)-5-Fluorowillardiine

    iGluR Neurological Disease
    (S)-(-)-5-Fluorowillardiine is a potent and specific AMPAR agonist.
  • HY-130979
    EED226-COOH

    Ligand for Target Protein for PROTAC Cancer
    EED226-COOH is an EED226-derived ligand for target protein EED ligand for PROTAC, binds to a ligand for VHL via linker to form UNC6852 (HY-130708) to degrade PRC2.
  • HY-78841
    (2S,4S)-Sacubitril

    Others Cardiovascular Disease
    (2S,4S)-Sacubitril is the impurity of Sacubitril. Sacubitril is a potent NEP inhibitor that can be used for the research of heart failure.
  • HY-18299B
    (S)-Purvalanol B

    (S)-NG 95

    Others Others
    (S)-Purvalanol B is the S enantiomer of Purvalanol B. Purvalanol B is a cyclin-dependent kinase inhibitor.
  • HY-16901A
    Firsocostat (S enantiomer)

    ND-630 (S enantiomer); GS-0976 (S enantiomer); NDI-010976 (S enantiomer)

    Others Others
    Firsocostat S enantiomer (ND-630 S enantiomer) is the less active S enantiomer of Firsocostat. Firsocostat is an acetyl-CoA carboxylase (ACC) inhibitor.
  • HY-130798
    (S,R,S)-AHPC-amido-C5-acid

    E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-amido-C5-acid incorporates a VHL ligand for the E3 ubiquitin ligase, and a PROTAC linker. (S,R,S)-AHPC-amido-C5-acid can be used to design XY028-133 (HY-129180).
  • HY-15382
    FTY720 (S)-Phosphate

    (S)-FTY720P; (S)-FTY720 phosphate

    LPL Receptor Inflammation/Immunology
    FTY720 (S)-Phosphate is an agonist of S1P receptor 1 (S1PR1), used in the research of acute inflammatory diseases such as acute lung injury.
  • HY-10936
    S 18986

    iGluR Neurological Disease
    S 18986 is a selective, orally active, brain penetrant positive allosteric modulator of AMPA-type receptors. S 18986 shows cognitive enhancing properties in rodents. S 18986 activates the release of noradrenaline and acetylcholine in rat hippocampus and enhances rat memory in object-recognition tests.
  • HY-B0612E
    (S)-Lercanidipine hydrochloride

    Calcium Channel Cardiovascular Disease
    (S)-Lercanidipine hydrochloride is the S-enantiomer of Lercanidipine hydrochloride. (S)-lercanidipine hydrochloride is a potent calcium channel blocker.
  • HY-N2037C
    (S)-Higenamine hydrobromide

    (S)-Norcoclaurine hydrobromide

    Endogenous Metabolite Others
    (S)-Higenamine ((S)-Norcoclaurine) hydrobromide, a S-enantiomer of Higenamine, is the entry compound in benzylisoquinoline alkaloid biosynthesis. (S)-Higenamine hydrobromide is produced by the condensation of dopamine and 4-hydroxyphenylacetaldehyde (4-HPAA) by norcoclaurine synthase (NCS).
  • HY-100020
    BAY-1436032

    Isocitrate Dehydrogenase (IDH) Cancer
    BAY-1436032 is a novel pan-mutant isocitrate dehydrogenase 1 (IDH1) inhibitor.
  • HY-18690A
    Enasidenib mesylate

    AG-221 mesylate

    Isocitrate Dehydrogenase (IDH) Cancer
    Enasidenib mesylate is a first-in-class, oral, potent, reversible, selective inhibitor of the IDH2 mutant enzymes.
  • HY-105008
    Secoisolariciresinol diglucoside

    (S,S)-SDG; (S,S)-LGM2605

    Others Inflammation/Immunology Neurological Disease Cardiovascular Disease
    Secoisolariciresinol diglucoside ((S,S)-SDG), the main lignan in wholegrain flaxseed, is known for its beneficial effects including anti-inflammatory, antioxidant, anti-mutagenic, anti-microbial, anti-obesity, hypolipidemic, and neuroprotective effects.
  • HY-135383
    (3S,5S)-Pitavastatin calcium

    Others Metabolic Disease
    (3S,5S)-Pitavastatin cacium is the 3-epimer of Pitavastatin. Pitavastatin is a potent HMG-CoA reductase inhibitor.
  • HY-U00281
    S16961

    S169611

    nAChR Neurological Disease
    S16961 is a nicotinic receptor agonist.
  • HY-133412
    DBCO-NHCO-S-S-NHS ester

    ADC Linker Cancer
    DBCO-NHCO-S-S-NHS ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
  • HY-133413
    DBCO-CONH-S-S-NHS ester

    ADC Linker Cancer
    DBCO-CONH-S-S-NHS ester is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
  • HY-112257
    S-23

    Androgen Receptor Metabolic Disease
    S-23 is an orally active selective androgen receptor modulator (SARM) with a Ki of 1.7 nM. S-23 induces androgen receptor (AR)-mediated transcriptional activation in CV-1 cells. S-23 increases prostate, seminal vesicle, and levator ani muscle weights in castrated rats.
  • HY-16940
    24(S)-Hydroxycholesterol

    24S-OHC; 24S-HC; Cerebrosterol

    LXR iGluR Endogenous Metabolite Metabolic Disease
    24(S)-Hydroxycholesterol (24S-OHC), the major brain cholesterol metabolite, plays an important role to maintain homeostasis of cholesterol in the brain. 24(S)-Hydroxycholesterol (24S-OHC) is one of the most efficient endogenous LXR agonist known and is present in the brain and in the circulation at relatively high levels. 24(S)-Hydroxycholesterol (24S-OHC) is a very potent, direct, and selective positive allosteric modulator of NMDARs with a mechanism that does not overlapthat of other allosteric modulators.
  • HY-U00403
    Cipropride S enantiomer

    Others Others
    Cipropride (S enantiomer) is the S enantiomer of cipropride; cipropride is an antiemetic drug.
  • HY-141016
    (S,R,S)-AHPC-PEG2-acid

    PROTAC Linker Cancer
    (S,R,S)-AHPC-PEG2-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
  • HY-B2137
    S-(+)-Ketoprofen

    (S)-Ketoprofen; Dexketoprofen

    COX Inflammation/Immunology
    S-(+)-Ketoprofen is a potent inhibitor of both COX-1 and COX-2 with IC50s of 1.9 and 27 nM, respectively.
  • HY-125098
    Illudin S

    DNA Alkylator/Crosslinker Apoptosis Cancer Infection
    Illudin S, a cytotoxic Illudin, is a natural sesquiterpene with strong anti-tumour and antiviral activities. Illudin S has genotoxic activities. Illudin S blocks the G1-S phase interface of the cell cycle in human leukemia cells.
  • HY-108263A
    (S)-3-Hydroxy Midostaurin

    (S)-CGP52421

    FLT3 Drug Metabolite Cancer
    (S)-3-Hydroxy Midostaurin ((S)-CGP52421) is a potent kinases inhibitor with IC50 values of <400 nM for 13 kinases (VEGFR-2, TRK-A, FLT3, et). (S)-3-Hydroxy Midostaurin is a minor metabolite of midostaurin (PKC412; HY-10230) undergoing by the hepatic CYP3A4 enzyme. (S)-3-Hydroxy Midostaurin has the potential for acute myeloid leukemia (AML).
  • HY-78131AS
    (S)-(+)-Ibuprofen D3

    (S)-Ibuprofen D3

    COX Inflammation/Immunology
    (S)-(+)-Ibuprofen D3 ((S)-Ibuprofen D3) is a deuterium labeled (S)-(+)-Ibuprofen. (S)-(+)-Ibuprofen is the S(+)-enantiomer of Ibuprofen that inhibits COX-1 and COX-2 activity with IC50s of 2.1 μM and 1.6 μM. (S)-(+)-Ibuprofen has analgesic, antiinflammatory and antipyretic effects.
  • HY-19323A
    (S)-Ceralasertib

    (S)-AZD6738

    ATM/ATR Cancer
    (S)-Ceralasertib ((S)-AZD6738) is extracted from patent WO2011154737A1, Compound II, exhibits an IC50 of 2.578 nM. (S)-Ceralasertib is a potent and selective sulfoximine morpholinopyrimidine ATR inhibitor with excellent preclinical physicochemical and pharmacokinetic (PK) characteristics. (S)-Ceralasertib is developed improving aqueous solubility and eliminates CYP3A4 time-dependent inhibition.
  • HY-116463B
    (2S,3S)-E1R

    Sigma Receptor Neurological Disease
    (2S,3S)-E1R (Compound 2d) is an enantiomer of E1R. (2S,3S)-E1R is a sigma-1 receptor positive allosteric modulator (Sig1R PAM) for the treatment of cognition/memory disorders.
  • HY-W009177
    S-Methylglutathione

    Others Others
    S-Methylglutathione is an S-substitued glutathione and a stronger nucleophile than GSH. S-Methylglutathione has inhibitory effect on glyoxalase 1.
  • HY-135336AS
    (S)-Verapamil D7 hydrochloride

    (S)-(-)-Verapamil D7 hydrochloride

    Leukotriene Receptor Calcium Channel Apoptosis Cancer
    (S)-Verapamil D7 hydrochloride ((S)-(-)-Verapamil D7 hydrochloride) is a deuterium labeled (S)-Verapamil hydrochloride. (S)-Verapamil hydrochloride (S(-)-Verapamil hydrochloride) inhibits leukotriene C4 (LTC4) and calcein transport by MRP1. (S)-Verapamil hydrochloride leads to the death of potentially resistant tumor cells.
  • HY-19298
    S-8921

    Others Metabolic Disease
    S-8921 is an ileal Na +/bile acid cotransporter (IBAT) inhibitor.
  • HY-108036A
    (S)-Pro-xylane

    (S)-Hydroxypropyl tetrahydropyrantriol

    Others Others
    (S)-Pro-xylane ((S)-Hydroxypropyl tetrahydropyrantriol) is the S-enantiomer of Pro-xylane (HY-108036). Pro-xylane, a biologically active C-glycoside in aqueous media, acts as an activator of glycosaminoglycans (GAGs) biosynthesis.
  • HY-134592
    Piperidine-GNE-049-N-Boc

    Ligand for Target Protein for PROTAC Cancer
    Piperidine-GNE-049-N-Boc is a ligand for target protein for PROTAC of dCBP-1 (HY-134582). dCBP-1 is a potent and selective heterobifunctional degrader of p300/CBP.
  • HY-138862
    (S,R,S)-AHPC-C1-Br

    E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-C1-Br is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used in PROTAC technology.
  • HY-12871C
    Atuveciclib S-Enantiomer

    BAY-1143572 S-Enantiomer

    CDK Cancer
    Atuveciclib S-Enantiomer (BAY-1143572 S-Enantiomer) is a potent and selective CDK9 inhibitor, which inhibits CDK9/CycT1 with an IC50 of 16 nM.
  • HY-16785B
    Veledimex (S enantiomer)

    INXN-1001 (S enantiomer); RG-115932 (S enantiomer)

    Interleukin Related Cytochrome P450 Cancer
    Veledimex S enantiomer (INXN-1001 S enantiomer) is the S enantiomer of veledimex. Veledimex is an oral activator ligand for a proprietary gene therapy promoter system, and a moderate inhibitor of and substrate for CYP3A4/5.
  • HY-14200
    (S)-Rasagiline

    TVP1022; S-PAI

    Monoamine Oxidase Neurological Disease
    (S)-Rasagiline (TVP1022) is the relatively inactive S-enantiomer form of Rasagiline. Rasagiline is a highly potent selective irreversible MAO inhibitor with IC50s of 4.43 nM and 412 nM for rat brain MAO B and A activity, respectively.
  • HY-14200A
    (S)-Rasagiline mesylate

    TVP1022 mesylate; S-PAI mesylate

    Monoamine Oxidase Neurological Disease
    (S)-Rasagiline (TVP1022) mesylate is the relatively inactive S-enantiomer form of Rasagiline mesylate. Rasagiline mesylate is a highly potent selective irreversible MAO inhibitor with IC50s of 4.43 nM and 412 nM for rat brain MAO B and A activity, respectively.
  • HY-136165
    (S,R,S)-AHPC-PEG3-propionic acid

    E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-PEG3-propionic acid is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 3-unit PEG linker used in PROTAC technology.
  • HY-13749C
    (S)-Sitagliptin phosphate

    (S)-MK-0431 phosphate

    Dipeptidyl Peptidase Autophagy Metabolic Disease
    (S)-Sitagliptin phosphate is the less active S-enantiomer of Sitagliptin phosphate. Sitagliptin phosphate (MK-0431 phosphate) is a potent inhibitor of DPP4 with an IC50 of 19 nM in Caco-2 cell extracts.
  • HY-B0352AS
    (S)-Mirtazapine D3

    (S)-Org3770 D3; (S)-6-Azamianserin D3

    5-HT Receptor Neurological Disease
    (S)-Mirtazapine D3 ((S)-Org3770 D3) is a deuterium labeled (S)-Mirtazapine. (S)-Mirtazapine is a S(+)-enantiomer of Mirtazapine with pronociceptive properties in an animal model of acute thermal nociception.(S)-Mirtazapine is a stereoselective 5-HT2 receptor antagonist. (S)-Mirtazapine is metabolized by CYP2D6 and CYP1A2.
  • HY-131959
    (S,R,S)-AHPC-PEG5-Boc

    E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-PEG5-Boc is a E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used for Cdc20 degrader CP5V.
  • HY-112164B
    IACS-8968 S-enantiomer

    IDO/TDO Inhibitor (S-enantiomer)

    Indoleamine 2,3-Dioxygenase (IDO) Cancer
    IACS-8968 (S-enantiomer) is the S-enantiomer of IACS-8968. IACS-8968 is a dual IDO and TDO inhibitor, with pIC50s of 6.43 for IDO and <5 for TDO, respectively.
  • HY-W010271
    (2S,3R,4S)-4-Hydroxyisoleucine

    (2S,3R,4S)-4-Hydroxy-L-isoleucine

    Others Metabolic Disease
    (2S,3R,4S)-4-Hydroxyisoleucine is an orally active compound isolated from Trigonella foenum-graecum, with anti-diabetes and anti-diabetic nephropathy activity.
  • HY-140128
    DBCO-S-S-PEG3-biotin

    PROTAC Linker Cancer
    DBCO-S-S-PEG3-biotin is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
  • HY-123109
    (S,R,S)-AHPC-Boc

    VH032-Boc

    Ligand for E3 Ligase Cancer
    (S,R,S)-AHPC-Boc (VH032-Boc) is a ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. (S,R,S)-AHPC-Boc is used in PROTAC technology.
  • HY-N4200
    S-Dihydrodaidzein

    Others Endocrinology Metabolic Disease
    S-Dihydrodaidzein is the (S)-enantiomer of dihydrodaidzein which is one of the most prominent dietary phytoestrogens.
  • HY-B1370A
    (S)-Hydroxychloroquine

    (S)-HCQ

    Parasite Toll-like Receptor (TLR) SARS-CoV Autophagy Infection
    (S)-Hydroxychloroquine ((S)-HCQ) is the enantiomer of Hydroxychloroquine. Hydroxychloroquine, a synthetic antimalarial drug, inhibits Toll-like receptor 7/9 (TLR7/9) signaling, and shows efficiently inhibits SARS-CoV-2 infection in vitro.
  • HY-19822B
    Elacestrant S enantiomer dihydrochloride

    RAD1901 S enantiomer dihydrochloride

    Estrogen Receptor/ERR Cancer
    Elacestrant S enantiomer dihydrochloride (RAD1901 S enantiomer dihydrochloride) is an low activity enantiomer of elacestrant dihydrochloride. Elacestrant (RAD1901) dihydrochloride is a selective and orally available estrogen receptor (ERR) degrader with IC50 values of 48 and 870 nM for ERα and ERβ, respectively.
  • HY-125365
    Rifamycin S

    Bacterial Reactive Oxygen Species Antibiotic Infection
    Rifamycin S is a quinone and an antibiotic agnet against Gram-positive bacteria (including MRSA). Rifamycin S is the oxidized forms of a reversible oxidation-reduction system involving two electrons. Rifamycin S generates reactive oxygen species (ROS) and inhibits microsomal lipid peroxidation. Rifamycin S can be used for tuberculosis and leprosy.
  • HY-136163
    (S,R,S)-AHPC-C2-NH2 dihydrochloride

    E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-C2-NH2 dihydrochloride incorporates a VHL ligand for the E3 ubiquitin ligase, and a PROTAC linker. (S,R,S)-AHPC-OH can be used in the synthesis of a series of PROTACs.
  • HY-18767A
    (R,S)-Ivosidenib

    (R,S)-AG-120

    Isocitrate Dehydrogenase (IDH) Cancer
    (R,S)-Ivosidenib ((R,S)-AG-120) is the less active enantiomer of Ivosidenib (AG-120).
  • HY-14864A
    (S)-Mapracorat

    (S)-ZK-245186; (S)-BOL-303242X

    Glucocorticoid Receptor Endocrinology
    (S)-Mapracorat is a selective and less active glucocorticoid receptor agonist.
  • HY-101030A
    MBM-17S

    Apoptosis Cancer
    MBM-17S is a potent NIMA-related kinase 2 (Nek2) inhibitor, with an IC50 of 3 nM. MBM-17S effectively inhibits the proliferation of cancer cells by inducing cell cycle arrest and apoptosis. MBM-17S shows antitumor activities, and no obvious toxicity to mice.
  • HY-113330
    12S-HHT

    12(S)-HHTrE

    Leukotriene Receptor Inflammation/Immunology
    12S-HHT (12(S)-HHTrE) is an enzymatic product of prostaglandin H 2 (PGH 2) derived from cyclooxygenase (COX)-mediated arachidonic acid metabolism. 12S-HHT is an endogenous ligand for BLT2 that fully activates BLT2 in vivo. 12S-HHT suppresses UV-induced IL-6 synthesis in keratinocytes, exerting an anti-inflammatory activity.
  • HY-13636A
    Fulvestrant (S enantiomer)

    ICI 182780 (S enantiomer); ZD 9238 (S enantiomer); ZM 182780 (S enantiomer)

    Others Cancer
    Fulvestrant S enantiomer (ICI 182780 S enantiomer) is the S enantiomer of Fulvestrant. Fulvestrant is a potent estrogen receptor antagonist with an IC50 of 9.4 nM.
  • HY-138861A
    (S,R,S)-AHPC-C1-NH2 hydrochloride

    E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-C1-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used in PROTAC technology.
  • HY-138861
    (S,R,S)-AHPC-C1-NH2

    E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-C1-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used in PROTAC technology.
  • HY-12044
    Cabozantinib S-malate

    XL184 S-malate; BMS-907351 S-malate

    VEGFR Apoptosis Cancer
    Cabozantinib S-malate (XL184 S-malate) is a potent multiple receptor tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.
  • HY-108597
    TC-S 7005

    Polo-like Kinase (PLK) Inflammation/Immunology Cardiovascular Disease
    TC-S 7005 is a Polo-like kinases (Plks) inhibitor with IC50s of 4 nM, 24 nM and 214 nM for Plk2, Plk3, and Plk1, respectively.
  • HY-15464D
    (S)-Gossypol acetic acid

    (S)-(+)-Gossypol acetic acid

    Bcl-2 Family Cancer
    (S)-Gossypol is the isomer of a natural product Gossypol. (S)-Gossypol binds to the BH3-binding groove of Bcl-xL and Bcl-2 proteins with high affinity.
  • HY-106992
    S 3304

    MMP Cancer
    S 3304 is a novel matrix metalloproteinases (MMP) inhibitor specific for MMP-2 and MMP-9.
  • HY-101029A
    MBM-55S

    Ribosomal S6 Kinase (RSK) DYRK Apoptosis Cancer
    MBM-55S is a potent NIMA-related kinase 2 (Nek2) inhibitor with an IC50 of 1 nM. MBM-55S shows a 20-fold or greater selectivity in most kinases with the exception of RSK1 (IC50=5.4 nM) and DYRK1a (IC50=6.5 nM). MBM-55S effectively inhibits the proliferation of cancer cells by inducing cell cycle arrest and apoptosis. MBM-55S shows antitumor activities, and no obvious toxicity to mice.
  • HY-19212
    S-2474

    COX Lipoxygenase Inflammation/Immunology
    S-2474 is an inhibitor of COX-2 and 5-lipoxygenase (5-LO), with IC50s of 11 nM and 27 μM for COX-2 and COX-1 in human intact cells, and used as a nonsteroidal anti-inflammatory drug.
  • HY-Y0017
    L-Norleucine

    (S)-2-Aminohexanoic acid; (S)-Norleucine

    Influenza Virus Endogenous Metabolite Infection Cancer
    L-Norleucine ((S)-2-Aminohexanoic acid) is an isomer of leucine, specifically affects protein synthesis in skeletal muscle, and has antivirus activity.
  • HY-B0392
    (S)-(+)-Rolipram

    (+)-Rolipram; (S)-Rolipram

    Phosphodiesterase (PDE) Apoptosis Cancer Inflammation/Immunology Neurological Disease
    (S)-(+)-Rolipram ((+)-Rolipram) is a cyclic AMP(cAMP)-specific phosphodiesterase 4 (PDE4) inhibitor, with an IC50 of 1100 nM. (S)-(+)-Rolipram can suppresse tumor necrosis factor-alpha (TNFα) production by human mononuclear cells.
  • HY-112929B
    (1S,2S,3R)-DT-061

    Others Cancer
    (1S,2S,3R)-DT-061 is an enantiomer of DT-061. DT-061 is an orally bioavailable activator of protein phosphatase 2A (PP2A) and could be applied in the therapy of KRAS-mutant and MYC-driven tumorigenesis.
  • HY-13528
    Clinofibrate

    S-8527

    HMG-CoA Reductase (HMGCR) Autophagy Metabolic Disease
    Clinofibrate (S-8527) is a hypelipidemic agent and a HMG-CoA reductase inhibitor.
  • HY-12515B
    (S)-Nicardipine

    (S)-YC-93 free bASe

    Others Neurological Disease Cardiovascular Disease
    (S)-Nicardipine ((S)-YC-93 free base) is the less active S enantiomer of Nicardipine. Nicardipine is a calcium channel blocker with an IC50 of 1 μM for blocking cardiac calcium channels. Nicardipine acts as an agent for chronic stable angina and for controlling blood pressure.
  • HY-130849
    (S,R,S)-AHPC-Me-C5-COOH

    E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-Me-C5-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the a VHL ligand and a linker. (S,R,S)-AHPC-Me-C5-COOH can be used in PROTAC DT2216 (HY-130604).
  • HY-78093A
    (S)-(-)-Phenylethanol

    Endogenous Metabolite Metabolic Disease
    (S)-(-)-Phenylethanol is an endogenous metabolite.
  • HY-30215
    (S)-Leucic acid

    Endogenous Metabolite Others
    (S)-Leucic acid is an amino acid metabolite.
  • HY-101445B
    (S)-Trolox

    Others Neurological Disease
    (S)-Trolox is an analogue of vitamin E, in which the phytyl chain is replaced with a carboxyl group. (S)-Trolox is frequently used as a model compound for studies of structural features, as well as a standard for evaluation of antioxidant activity. (S)-Trolox has potent and specific neuroprotective and antioxidant effects.
  • HY-130642
    (S,R,S)-AHPC-Me-C10-Br

    E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-Me-C10-Br is a synthesized E3 ligase ligand-linker conjugate. (S,R,S)-AHPC-Me-C10-Br incorporates a VHL E3 ligase linker and MS432 based on the MEK1/2 inhibitor PD0325901.
  • HY-110277
    S2101

    Histone Demethylase Cancer
    S2101 is a lysine-specific demethylase 1 (LSD1) inhibitor with an IC50 of 0.99 μM, Ki of 0.61 μM and Kinact/Ki of 4560 M/s.
  • HY-112143
    STOCK2S-26016

    Others Cardiovascular Disease
    STOCK2S-26016 is a WNK signalling inhibitors. STOCK2S-26016 inhibits WNK4 and WNK1 with IC50s of 16 μM and 34.4 μM, respectively. STOCK2S-26016 has potential for antihypertensive research.
  • HY-130640
    (S,R,S)-AHPC-Me-C7 ester

    E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-Me-C7 ester is a E3 ligase ligand-linker conjugate used to synthesise BCL-XL PROTAC degraders.
  • HY-108625
    SHA 68

    Neuropeptide Y Receptor Neurological Disease
    SHA 68 is a potent and selective non-peptide neuropeptide S receptor (NPSR) antagonist with IC50s of 22.0 and 23.8 nM for NPSR Asn 107 and NPSR Ile 107, respectively. SHA 68 has limited the blood-brain barrier (BBB) penetration and the activity in neuralgia.
  • HY-14423
    Velneperit

    S2367

    Neuropeptide Y Receptor Metabolic Disease Endocrinology
    Velneperit (S-2367) is a novel neuropeptide Y (NPY) Y5 receptor antagonist.
  • HY-17628
    Cefiderocol

    S-649266

    Bacterial Antibiotic Infection
    Cefiderocol (S-649266) is a siderophore cephalosporin which has a potent activity against a broad range of aerobic Gram-negative bacterial species with MIC50s of 2 μg/mL or less.
  • HY-19822D
    Elacestrant (S enantiomer)

    RAD1901 S enantiomer

    Estrogen Receptor/ERR Cancer
    Elacestrant S enantiomer (RAD1901 S enantiomer) is an low activity enantiomer of elacestrant. Elacestrant (RAD1901) is a selective and orally available estrogen receptor (ERR) degrader with IC50 values of 48 and 870 nM for ERα and ERβ, respectively.
  • HY-119366
    S18-000003

    ROR Inflammation/Immunology
    S18-000003 is a potent, selective and orally active inhibitor of retinoic acid receptor-related orphan receptor-gamma-t (RORγt), with an IC50 of <30 nM towards human RORγt in competitive binding assays. S18-000003 shows selectivity for RORγt over other ROR family members (IC50>10 μM). S18-000003 can be used for the research of psoriasis with low risk of thymic aberrations.
  • HY-12995A
    (S)-BI 665915

    FLAP Inflammation/Immunology
    (S)-BI 665915 is an orally active oxadiazole-containing 5-lipoxygenase-activating protein (FLAP) inhibitor with an IC50 of 1.7 nM for FLAP binding. (S)-BI 665915 inhibits FLAP functional in human whole blood with an IC50 of 45 nM. (S)-BI 665915 demonstrates an excellent cross-species drug metabolism and pharmacokinetics (DMPK) profile and a dose-dependent inhibition of LTB4 production.
  • HY-112818
    S130

    Cathepsin Autophagy Apoptosis Cancer
    S130 is a high affinity, selective inhibitor of ATG4B (a major cysteine protease) with an IC50 of 3.24 µM. S130 suppresses autophagy flux.
  • HY-B0196B
    (S)-Venlafaxine

    Serotonin Transporter Cancer
    (S)-Venlafaxine is the (S)-configuration of Venlafaxine. Venlafaxine is an orally active, potent serotonin (5-HT)/norepinephrine (NE) reuptake dual inhibitor. Venlafaxine is an antidepressant agent.
  • HY-U00222
    S3337

    Proton Pump Inflammation/Immunology
    S3337 is an H +, K +-ATPase inhibitor.
  • HY-N2176
    S-(+)-Marmesin

    (+)-Marmesin; (S)-Marmesin

    COX Lipoxygenase Others
    S-(+)-Marmesin is a natural coumarin, exhibiting COX-2/5-LOX dual inhibitory activity.
  • HY-14258
    Escitalopram

    (S)-Citalopram; (S)-(+)-Citalopram

    Serotonin Transporter Neurological Disease
    Escitalopram ((S)-Citalopram), the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a Ki of 0.89 nM. Escitalopram has ∼30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram is an antidepressant for the research of major depression.
  • HY-130233
    S516

    Microtubule/Tubulin Cancer
    S516 (Compound 22) is an active metabolite of CKD-516 and a potent tubulin polymerization inhibitor with an IC50 of 4.29 μM. S516 has marked antitumor activity.
  • HY-103641A
    (2S)-Octyl-α-hydroxyglutarate

    (2S)-Octyl-2-HG

    Others Cancer
    (2S)-Octyl-α-hydroxyglutarate ((2S)-Octyl-2-HG) is a modified form of S-isomer 2-Hydroxyglutarate.
  • HY-117279
    (S)-Metolachor

    Others Others
    (S)-Metolachor, a derivative of aniline, is a major pesticide in use.
  • HY-N5019
    Notoginsenoside S

    Others Others
    Notoginsenoside S is a compound isolated from Panax notoginseng.
  • HY-B0371D
    (S)-Terazosin

    Adrenergic Receptor Endocrinology
    (S)-Terazosin is an active S-enantiomer of Terazosin. (S)-Terazosin is a potent and high-affinity α-adrenoceptor antagonist with Ki values of 3.91 nM, 0.79 nM and 1.16 nM for α1a, α1b and α1d-adrenoceptor, respectively. (S)-Terazosin also has high-affinity for α2a, α2B and α2c-adrenoceptor with Ki values of 729 nM, 3.5 nM and 46.4 nM, respectively.
  • HY-136522
    S2116

    Histone Demethylase Apoptosis Cancer
    S2116, a N-alkylated tranylcypromine (TCP) derivative, is a potent lysine-specific demethylase 1 (LSD1) inhibitor. S2116 increases H3K9 methylation and reciprocal H3K27 deacetylation at super-enhancer regions. S2116 induces apoptosis in TCP-resistant T-cell acute lymphoblastic leukemia (T-ALL) cells by repressing transcription of the NOTCH3 and TAL1 genes. S2116 significantly retardes the growth of T-ALL cells in xenotransplanted mice.
  • HY-15427B
    GDC-0834 S-enantiomer

    Btk Others
    GDC-0834 (S-enantiomer) is the S-enantiomer of GDC-0834. GDC-0834 is a potent and selective BTK inhibitor.
  • HY-B0573A
    (S)-(-)-Propranolol hydrochloride

    Adrenergic Receptor Inflammation/Immunology Cardiovascular Disease
    (S)-(-)-Propranolol hydrochloride is a β-adrenergic receptor antagonist with log Kd values of -8.16, -9.08, and -6.93 for β1, β2, and β3, respectively. (S)-(-)-Propranolol hydrochloride the active enantiomer of propranolol and can be s used for study of hypertension, pheochromocytoma, myocardial infarction, cardiac arrhythmias, angina pectoris, and hypertrophic cardiomyopathy.
  • HY-113126
    (S)-3-Hydroxyisobutyric acid

    Endogenous Metabolite Others
    (S)-3-Hydroxyisobutyric acid is an important interorgan metabolite, an intermediate in the pathways of l-valine and thymine and a good gluconeogenic substrate.
  • HY-141159A
    (S)-TCO-PEG4-acid

    PROTAC Linker Cancer
    (S)-TCO-PEG4-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
  • HY-130847
    (S,R,S)-AHPC-Me-C10-NH2

    E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-Me-C10-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the a VHL ligand and a linker. (S,R,S)-AHPC-Me-C10-NH2 can be used in PROTAC MS432 (HY-130602).
  • HY-79334
    (S)-(+)-1,2-Propanediol

    Endogenous Metabolite Others
    (S)-(+)-1,2-Propanediol is an endogenous metabolite.
  • HY-15532B
    SCH900776 S-isomer

    MK-8776 S-isomer

    Others Cancer
    SCH900776 S-isomer is the S-isomer of SCH900776. SCH900776 is a potent, selective and orally bioavailable inhibitor of checkpoint kinase1 (Chk1) with IC50 of 3 nM.
  • HY-107004A
    Amotosalen hydrochloride

    S-59

    Others Inflammation/Immunology
    Amotosalen hydrochloride (S-59) is a light-activated, DNA-, RNA-crosslinking psoralen compound, which is used to neutralise pathogens.
  • HY-12422C
    (2S,3R)-Voruciclib

    CDK Cancer
    (2S,3R)-Voruciclib is the (2S,3R)-enantiomer of Voruciclib. (2S,3R)-Voruciclib is an orally active CDK inhibitor.
  • HY-122136
    S26131

    Melatonin Receptor Neurological Disease
    S26131 (compound 5) is a potent and selective MT1 melatoninergic ligand, and the Ki values are 0.5 and 112 nM for MT1 and MT2, respectively. S26131 behaves as an MT1 and MT2 antagonist.
  • HY-12210
    (S)-BI-1001

    HIV Integrase Infection
    (S)-BI-1001 (Compound 11) is an active S-enantiomer of BI-1001. (S)-BI-1001 exhibits antiviral potency against HIV-1 integrase with an IC50 of 28 nM, an EC50 of 450 nM and a Kd of 4.7 μM.
  • HY-B1190A
    Cefadroxil hydrate

    BL-S 578 hydrate

    Bacterial Antibiotic Infection
    Cefadroxil hydrate (BL-S 578 hydrate) is an orally active and first-generation cephalosporin with a broad spectrum antibacterial activity. Cefadroxil hydrate (BL-S 578 hydrate) also acts as a substrate of the peptide transporter PEPT1 and PEPT2.
  • HY-107198
    (2S)-6-Prenylnaringenin

    GABA Receptor Neurological Disease
    (2S)-6-Prenylnaringenin is the most efficient compound in forebrain. (2S)-6-Prenylnaringenin acts as a GABAA positive allosteric modulator at α+β- binding interface.
  • HY-N0603
    20(S)-Ginsenoside Rg3

    20(S)-Propanaxadiol; S-ginsenoside Rg3

    Sodium Channel Potassium Channel NF-κB COX Amyloid-β Endogenous Metabolite Cancer Inflammation/Immunology Neurological Disease
    20(S)-Ginsenoside Rg3 is the main component of Red ginseng. Ginsenoside Rg3 inhibits Na + and hKv1.4 channel with IC50s of 32.2±4.5 and 32.6±2.2 μM, respectively. 20(S)-Ginsenoside Rg3 also inhibits levels, NF-κB activity, and COX-2 expression.
  • HY-B0580A
    (S)-Ketorolac

    (-)-Ketorolac

    COX Inflammation/Immunology
    (S)-Ketorolac is a nonsteroidal anti-inflammatory agent. (S)-ketorolac exhibits potent COX1 and COX2 enzyme inhibition.
  • HY-107367
    Epertinib

    S-22611

    EGFR Cancer
    Epertinib (S-22611) is a potent, oral, reversible, and selective tyrosine kinase inhibitor of EGFR, HER2 and HER4, with IC50s of 1.48 nM, 7.15 nM and 2.49 nM, respectively. Epertinib shows potent antitumor activity.
  • HY-N0725
    Cucurbitacin S

    Others Inflammation/Immunology
    Cucurbitacin S is isolated from cucurbitaceae with anticancer and anti-inflammatory activities.
  • HY-136523
    S2157

    Histone Demethylase Apoptosis Cancer
    S2157, a N-alkylated tranylcypromine (TCP) derivative, is a potent lysine-specific demethylase 1 (LSD1) inhibitor. S2157 increases H3K9 methylation and reciprocal H3K27 deacetylation at super-enhancer regions. S2157 induces apoptosis in TCP-resistant T-cell acute lymphoblastic leukemia (T-ALL) cells by repressing transcription of the NOTCH3 and TAL1 genes. S2157 efficiently pass through the blood-brain barrier and can almost completely eradicate CNS leukemia in mice transplanted with T-ALL cells.
  • HY-107367A
    Epertinib hydrochloride

    S-22611 hydrochloride

    EGFR Cancer
    Epertinib hydrochloride (S-22611 hydrochloride) is a potent, orally active, reversible, and selective tyrosine kinase inhibitor of EGFR, HER2 and HER4, with IC50s of 1.48 nM, 7.15 nM and 2.49 nM, respectively. Epertinib hydrochloride shows potent antitumor activity.
  • HY-114177A
    (S)-PF-06873600

    Others Cancer
    (S)-PF-06873600 it the S enantiomer of PF-06873600. PF-06873600 is a selective and orally bioavailable inhibitor of cyclin-dependent kinase (CDK).
  • HY-110282
    S3QEL-2

    Mitochondrial Metabolism Metabolic Disease
    S3QEL-2, a suppressor of superoxide production from mitochondrial complex III, potently and selectively suppresses site IIIQo superoxide production (IC50=1.7 μM). S3QEL-2 does not affect oxidative phosphorylation, and normal electron flux. S3QEL-2 inhibits HIF-1α accumulation.
  • HY-100583
    (-)-(S)-Equol

    Estrogen Receptor/ERR Endogenous Metabolite Cancer Metabolic Disease Neurological Disease
    (-)-(S)-Equol is a high affinity ligand for estrogen receptor β with a Ki of 0.73 nM.
  • HY-U00432
    S-MTC

    NO Synthase Neurological Disease
    S-MTC is a selective type I nitric oxide synthase (NOS) inhibitor.
  • HY-15529
    S0859

    Na+/HCO3- Cotransporter Cardiovascular Disease
    S0859 is a selective, high-affinity generic Na +/HCO3 - transporter (NBC) inhibitor. S0859 reversibly inhibits NBC-mediated intracellular pH (pHi) recovery (Ki=1.7 μM, full inhibition at approximately 30 μM).
  • HY-B0130
    Perindopril

    S-9490

    Angiotensin-converting Enzyme (ACE) Cancer Cardiovascular Disease
    Perindopril (S-9490) is a long-acting ACE inhibitor of which is used to treat high blood pressure, heart failure or stable coronary artery disease.
  • HY-104003
    S 38093

    Histamine Receptor Neurological Disease Endocrinology
    S 38093 is a brain-penetrant, orally active antagonist of H3 receptor, with Kis of 8.8, 1.44 and 1.2 µM for rat, mouse and human H3 receptors, respectively.
  • HY-B1122
    L-Cycloserine

    (S)-Cycloserine; (S)-4-Amino-3-isoxazolidone

    GABA Receptor HIV Neurological Disease Cancer
    L-Cycloserine ((S)-4-Amino-3-isoxazolidone) irreversibly inhibits GABA pyridoxal 5′-phosphate-dependent aminitransferase in E.
  • HY-12422B
    (2S,3R)-Voruciclib hydrochloride

    CDK Cancer
    (2S,3R)-Voruciclib hydrochloride is the enantiomer of Voruciclib hydrochloride. (2S,3R)-Voruciclib is an orally active CDK inhibitor.
  • HY-12023
    GTx-007

    S-4

    Androgen Receptor Cancer
    GTx-007 (S-4) is an orally active and selective nonsteroidal androgen receptor (AR) modulator (SARM) and a partial agonist, with Ki of 4 nM. GTx-007 (S-4) is identified as SARMs with potent and tissue-selective in vivo pharmacological activity.
  • HY-W050145
    (1R,2S,3S,4R,5S)-6,8-Dioxabicyclo[3.2.1]octane-2,3,4-triol

    Endogenous Metabolite Metabolic Disease
    (1R,2S,3S,4R,5S)-6,8-Dioxabicyclo[3.2.1]octane-2,3,4-triol is an endogenous metabolite.
  • HY-101332
    EGLU

    (2S)-α-Ethylglutamic acid; (2S)-α-EGLU

    mGluR Neurological Disease
    EGLU ((2S)-α-Ethylglutamic acid; (2S)-α-EGLU) is a potent and competitive mGluR-2 receptor antagonist. EGLU interacts with (lS,3S)-ACPD-sensitive site with a Kd value of 66 μM. EGLU is an antidepressant agent.
  • HY-141349
    S-Acetyl-PEG3-C2-acid

    PROTAC Linker Cancer
    S-Acetyl-PEG3-C2-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
  • HY-P2093
    S961

    Insulin Receptor Metabolic Disease
    S961 is an high-affinity and selective insulin receptor (IR) antagonist with IC50s of 0.048, 0.027, and 630 nM for HIR-A, HIR-B, and human insulin-like growth factor I receptor (HIGF-IR) in SPA-assay, respectively.
  • HY-P2093B
    S961 acetate

    Insulin Receptor Metabolic Disease
    S961 acetate is an high-affinity and selective insulin receptor (IR) antagonist with IC50s of 0.048, 0.027, and 630 nM for HIR-A, HIR-B, and human insulin-like growth factor I receptor (HIGF-IR) in SPA-assay, respectively.
  • HY-19627
    Naldemedine

    S-297995

    Opioid Receptor Neurological Disease
    Naldemedine (S-297995) is an orally active, peripherally acting µ-opioid receptor antagonist. Naldemedine shows potent binding affinities (IC50s = 1.15, 1.11, and 1.5 nM, repectively) and antagonist activities (IC50s= 25.57, 7.09, 16.1 nM, repectively) for recombinant human μ-, δ-, and κ- opioid receptors. Naldemedine tempers opioid-induced constipation (OIC) without compromising opioid analgesia.
  • HY-N0707
    (S)-Indoximod

    1-Methyl-L-tryptophan; (S)-NLG-8189

    Indoleamine 2,3-Dioxygenase (IDO) Cancer
    (S)-Indoximod (1-Methyl-L-tryptophan) is an inhibitor of indoleamine 2,3-dioxygenase (IDO). (S)-Indoximod can be used for the research of cancer.
  • HY-14622B
    Necrostatin 2 S enantiomer

    RIP kinase Cancer
    Necrostatin 2 S enantiomer is the S enantiomer of Necrostatin 2.
  • HY-B0617A
    S-Adenosyl-L-methionine tosylate

    S-Adenosyl methionine tosylate; Ademetionine tosylate; AdoMet tosylate

    Endogenous Metabolite Cancer Inflammation/Immunology Neurological Disease
    S-Adenosyl-L-methionine tosylate (S-Adenosyl methionine tosylate) is produced endogenously from methionine and ATP by action of the enzyme methionine adenosyltransferase and is an important orally active methyl group donor. S-Adenosyl-L-methionine tosylate is a dietary supplement with potent antidepressant and analgesic effects, and has the potential for liver disease and osteoarthritis research.
  • HY-136593
    (S)-3-(4-Hydroxyphenyl)-2-hydroxypropionic acid

    (S)-3-(4-Hydroxyphenyl)lactic acid

    Others Others
    (S)-3-(4-Hydroxyphenyl)-2-hydroxypropionic acid (compound 1) is a metabolite isolated from the culture medium of Leuconostoc mesenteroides. (S)-3-(4-Hydroxyphenyl)-2-hydroxypropionic acid has high DPPH radical-scavenging activities and antioxidative activities.
  • HY-79457
    S-Methylisothiourea sulfate

    NO Synthase HSV Infection Inflammation/Immunology
    S-Methylisothiourea sulfate is a potent, selective and competitive inhibitor of inducible nitric oxide synthase (iNOS). S-Methylisothiourea sulfate exerts beneficial effects in rodent models of septic shock.
  • HY-15267B
    (24S)-MC 976

    VD/VDR Metabolic Disease
    (24S)-MC 976 is a Vitamin D3 derivative.
  • HY-14664C
    (3S,5R)-Fluvastatin sodium

    (3S,5R)-XU 62-320

    HMG-CoA Reductase (HMGCR) Cancer Cardiovascular Disease
    (3S,5R)-Fluvastatin sodium ((3S,5R)-XU 62-320) is the (3S,5R)-enantiomer of Fluvastatin. Fluvastatin is a first fully synthetic, competitive HMG-CoA reductase inhibitor with an IC50 of 8 nM. Fluvastatin protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway.
  • HY-13950
    S186

    Others Others
    S186 is a kind of sodium salts of calcium-acetylpropylamine phosphonate(APA); a new strontium-specific chelating agent.
  • HY-B0612ES
    (S)-Lercanidipine D3 hydrochloride

    Others Cardiovascular Disease
    (S)-Lercanidipine D3 (hydrochloride) is a deuterium labeled Lercanidipine D3 hydrochloride. (S)-Lercanidipine hydrochloride is an antihypertensive agent.
  • HY-100815A
    (S)-AMPA

    L-AMPA

    iGluR Neurological Disease
    (S)-AMPA (L-AMPA), an active S-enantiomer of AMPA, is a potent and selective AMPA receptor agonist.
  • HY-12598
    (S)-3,5-DHPG

    mGluR Neurological Disease
    (S)-3,5-DHPG is a weak, but selective group I metabotropic glutamate receptors (mGluRs) agonist with Ki values of 0.9 µM and 3.9 µM for mGluR1a and mGluR5a, respectively. (S)-3,5-DHPG exhibits anxiolytic activity in rats subjected to hypoxia.
  • HY-15439
    (24S)-24,25-Dihydroxyvitamin D3

    (24S)-24,25-Dihydroxycholecalciferol

    VD/VDR Others
    (24S)-24,25-Dihydroxyvitamin D3 ((24S)-24,25-Dihydroxycholecalciferol) is an inactive form of vitamin D3 which undergoes various levels of hydroxylation to form active vitamin D3 analogs.
  • HY-136163A
    (S,R,S)-AHPC-C2-NH2

    E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-C2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology.
  • HY-N0835
    (20S)-Protopanaxatriol

    20(S)-APPT; g-PPT

    Glucocorticoid Receptor Estrogen Receptor/ERR LXR Apoptosis Cardiovascular Disease Endocrinology
    (20S)-Protopanaxatriol is a metabolite of ginsenoside, works through the glucocorticoid receptor (GR) and oestrogen receptor (ER), and is also a LXRα inhibitor. (20S)-Protopanaxatriol shows a broad spectrum of antitumor effects.
  • HY-103225
    S-8510 phosphate

    SB-737552 phosphate

    GABA Receptor Neurological Disease
    S-8510 (phosphate) is an inverse Benzodiazepine (BDZ) receptor agonist, with Kis of 34.6 nM, 36.2 nM for –GABA and +GABA respectively.
  • HY-P1437
    Neuropeptide S(Mouse)

    Neuropeptide Y Receptor Neurological Disease
    Neuropeptide S (Mouse) is a bioactive peptide. Neuropeptide S (Mouse), as a neurotransmitter/neuromodulator of 20 amino acids, can be used for the research of arousal, anxiety, locomotion, feeding behaviors, memory and drug addiction.
  • HY-P1438
    Neuropeptide S(Rat)

    Neuropeptide Y Receptor Neurological Disease
    Neuropeptide S (Rat) is an endogenous ligand of a previously orphan G-protein-coupled receptor now named NPS receptor. Neuropeptide S (Rat) can be used for the research of nervous system disease.
  • HY-16106A
    (8R,9S)-Talazoparib

    (8R,9S)-BMN-673; (8R,9S)-LT-673

    PARP Cancer
    (8R,9S)-Talazoparib ((8R,9S)-BMN-673) is an enantiomer of Talazoparib. (8R,9S)-Talazoparib is an PARP1 inhibitor, with an IC50 of 144 nM.
  • HY-138697
    S65487

    VOB560

    Bcl-2 Family Cancer
    S65487 (VOB560) is a potent and selective Bcl-2 inhibitor. S65487 has poor affinity with MCL-1, BFL-1 and BCL-XL. S65487 has anticaner activities.
  • HY-131284
    (S)-Dehydro Venlafaxine

    Others Others
    (S)-Dehydro Venlafaxine is an inactive S-enantiomer of Dehydro Venlafaxine. Dehydro Venlafaxine is an impurity of Venlafaxine hydrochloride. Venlafaxine hydrochloride (Wy 45030 hydrochloride) is a potent serotonin (5-HT) / norepinephrine (NE) reuptake dual inhibitor.
  • HY-W040240
    (3S,4R,5S)-1,3,4,5,6-Pentahydroxyhexan-2-one

    Endogenous Metabolite Metabolic Disease
    (3S,4R,5S)-1,3,4,5,6-Pentahydroxyhexan-2-one is an endogenous metabolite.
  • HY-13818
    Stattic

    STAT Apoptosis Cancer Inflammation/Immunology
    Stattic is a potent STAT3 inhibitor and inhibits STAT3 phosphorylation (at Y705 and S727). Stattic inhibits the binding of a high affinity phosphopeptide for the SH2 domain of STAT3. Stattic ameliorates the renal dysfunction in Alport syndrome (AS) mice.
  • HY-100549
    (S)-Crizotinib

    DNA/RNA Synthesis Apoptosis Cancer
    (S)-Crizotinib is a potent and selective MTH1 (mutT homologue) inhibitor with an IC50 of 330 nM. (S)-Crizotinib disrupts nucleotide pool homeostasis via MTH1 inhibition, induces an increase in DNA single strand breaks, activates DNA repair in human colon carcinoma cells, and effectively suppresses tumour growth in animal models.
  • HY-125770
    5(S)​-​HPETE

    Others Inflammation/Immunology
    5(S)-HpETE is a monohydroperoxy polyunsaturated fatty acid (PUFA) produced by the action of 5-LO on arachidonic acid. 5(S)-HpETE is metabolized to leukotriene A4 (LTA4), a key intermediate in the formation of LTs.
  • HY-122614
    S29434

    NMDPEF

    Autophagy Neurological Disease
    S29434 (NMDPEF) is a potent, competitive, selective and cell-permeable inhibitor of quinone reductase 2 (QR2), with IC50s ranging from 5 to 16 nM for human QR2 at different organizational levels, and has good selectivity for QR2 over QR1. S29434 (NMDPEF) induces autophagy and inhibits QR2-mediated ROS production.
  • HY-15193B
    EMD638683 S-Form

    SGK Metabolic Disease
    EMD638683 S-Form is the S-form of EMD638683. EMD638683 is a highly selective SGK1 inhibitor with IC50 of 3 μM.
  • HY-100233
    IQ-1S free acid

    JNK Cancer Inflammation/Immunology
    IQ-1S free acid is a prospective inhibitor of NF-κB/activating protein 1 (AP-1) activity with an IC50 of 2.3±0.41 μM. IQ-1S free acid has binding affinity (Kd values) in the nanomolar range for all three JNKs with Kds of 100 nM, 240 nM, and 360 nM for JNK3, JNK1, and JNK2, respectively.
  • HY-134661
    (S)-CVN424

    Others Neurological Disease
    (S)-CVN424 is a potent G-Protein-Coupled Receptor 6 (GPR6) modulator. (S)-CVN424 has the potential for a variety of neurological and psychiatric disorders research, including Parkinson's disease.
  • HY-100504
    S-methyl DM1

    Microtubule/Tubulin ADC Cytotoxin Cancer
    S-methyl DM1 is a thiomethyl derivative of Maytansine. S-methyl DM1 binds to tubulin with a Kd of 0.93 μM and inhibts microtubule polymerization. S-methyl DM1 potently suppresses microtubule dynamic instability and has anticancer effects.
  • HY-N9413
    γ-Glutamyl-S-allylcysteine

    L-γ-Glutamyl-(S)-Allyl-Cysteine

    Others Metabolic Disease
    γ-Glutamyl-S-allylcysteine (L-γ-Glutamyl-(S)-Allyl-Cysteine) is a naturally occurring organosulfur compound found in garlic. γ-Glutamyl-S-allylcysteine has antiglycative effect and shows radical-scavenging and metal-chelating capacities.
  • HY-137231B
    (S)-UFR2709 hydrochloride

    nAChR Neurological Disease
    (S)-UFR2709 (hydrochloride) is a competitive nAChR antagonist and displays higher affinity for α4β2 nAChRs than for α7 nAChRs. (S)-UFR2709 (hydrochloride) decreases anxiety and reduces ethanol consumption and ethanol preference in alcohol-preferring rats. (S)-UFR2709 (hydrochloride) acts as an anxiolytic agent and can be used for the study of nicotine addiction.
  • HY-137231A
    (S)-UFR2709

    nAChR Neurological Disease
    (S)-UFR2709 is a competitive nAChR antagonist and displays higher affinity for α4β2 nAChRs than for α7 nAChRs. (S)-UFR2709 decreases anxiety and reduces ethanol consumption and ethanol preference in alcohol-preferring rats. (S)-UFR2709 acts as an anxiolytic agent and can be used for the study of nicotine addiction.
  • HY-113304
    (S)-3,4-Dihydroxybutyric acid

    Endogenous Metabolite Metabolic Disease
    (S)-3,4-Dihydroxybutyric acid is a normal human urinary metabolite that is excreted in increased concentration in patients with succinic semialdehyde dehydrogenase (SSADH) deficiency.
  • HY-111827
    S-1-Propenyl-L-cysteine

    Others Inflammation/Immunology Cardiovascular Disease
    S-1-Propenyl-L-cysteine is a stereoisomer of S-allyl-l-cysteine, extracted from garlic, with immunomodulatory effects and reduces blood pressure in a hypertensive animal model.
  • HY-141411A
    (S)-MRI-1867

    Cannabinoid Receptor NO Synthase Metabolic Disease
    (S)-MRI-1867 is a peripherally restricted, orally bioavailable dual cannabinoid CB1 receptor and inducible NOS (iNOS) antagonist. (S)-MRI-1867 ameliorates obesity-induced chronic kidney disease (CKD).
  • HY-103504
    (S)-SNAP5114

    GABA Receptor Neurological Disease
    (S)-SNAP5114 is a selective GABA transport inhibitor, with IC50 values of 5 μM and 21 μM for hGAT-3 and rGAT-2, respectively. (S)-SNAP5114 is an anticonvulsant drug.
  • HY-135125
    DC4

    ADC Cytotoxin Cancer
    DC4, a ADC cytotoxin, can be used in the synthesis of Antibody-drug Conjugate (ADC). DC4 can be used for the targeted treatment of cancer.
  • HY-78828A
    (S)-Dolaphenine hydrochloride

    Others Others
    (S)-Dolaphenine hydrochloride is a component of Dolastatin 10 (HY-15580). Dolastatin 10, an antineoplastic agent, inhibits tubulin polymerization.
  • HY-12965
    S49076

    FGFR c-Met/HGFR Cancer
    S49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3 with IC50 values below 20 nM.
  • HY-101533B
    AZD-5991 (S-enantiomer)

    Bcl-2 Family Cancer
    AZD-5991 S-enantiomer is the less active enantiomer of AZD-5991. AZD-5991 S-enantiomer is a Mcl-1 inhibitor with an IC50 of 6.3 μM in FRET assay and a Kd of 0.98 μM in surface plasmon resonance (SPR) assay.
  • HY-100406
    (S)-MCPG

    (+)-MCPG

    mGluR Neurological Disease
    (S)-MCPG ((+)-MCPG) is a potent group I/II metabotropic glutamate receptor (mGluRs) antagonist and the active isomer of (RS)-MCPG (HY-100371). (S)-MCPG can be used for the study of the function of mGluRs in spatial learning.
  • HY-12885C
    ADU-S100 enantiomer ammonium salt

    MIW815 enantiomer ammonium salt; ML RR-S2 CDA enantiomer ammonium salt

    Others Inflammation/Immunology
    ADU-S100 enantiomer ammonium salt (MIW815 enantiomer ammonium salt) is the less active enantiomer of ADU-S100. ADU-S100 is an activator of stimulator of interferon genes (STING).
  • HY-112543
    S119-8

    Influenza Virus Infection
    S119-8 is a broad spectrum inhibitor of influenza A and B viruses, showing activity against multiple influenza B viruses and an oseltamivir-resistant influenza A virus, but does not inhibit a non-influenza virus, vesicular stomatitis nirus (VSV).
  • HY-15319B
    AMG 487 (S-enantiomer)

    CXCR Others
    AMG 487 S-enantiomer is the S enantiomer of AMG 487. AMG 487 is an antagonist of the chemokine receptor CXCR3.
  • HY-10450A
    Dapagliflozin ((2S)-1,2-propanediol, hydrate)

    BMS-512148 (2S)-1,2-propanediol, hydrate

    SGLT Cancer Metabolic Disease
    Dapagliflozin ((2S)-1,2-propanediol, hydrate) is the S-enantiomer of Dapagliflozin 1,2-propanediol, hydrate. Dapagliflozin ((2S)-1,2-propanediol, hydrate), a new type of drug used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine. Dapagliflozin ((2S)-1,2-propanediol, hydrate) induces HIF1 expression and attenuates renal IR injury.
  • HY-100741
    S63845

    Bcl-2 Family Cancer
    S63845 is a potent and selective myeloid cell leukemia 1 (MCL1) inhibitor with a Kd of 0.19 nM for human MCL1.
  • HY-129995
    TSHR antagonist S37b

    TSH Receptor Endocrinology
    TSHR antagonist S37b is the less effective enantiomer of TSHR antagonist S37a (HY-129995A). TSHR antagonist S37b shows only a minor effect for thyrotropin receptor (TSHR) inhibition. TSHR antagonist S37b can be used for the research of thyroid function.
  • HY-N6680
    Virginiamycin S1

    Bacterial Antibiotic Infection
    Virginiamycin S1 is a cyclic hexadepsipeptide antibiotic, inhibits bacterial protein synthesis at the level of aminoacyl-tRNA binding and peptide bond formation. Virginiamycin S1 belongs to the type B compounds in the streptogramin family and is produced by Streptomyces virginiae, shows a strong bactericidal activity against a wide range of Gram-positive bacteria. Virginiamycin S1 together with virginiamycin M1 is more effective in treat multidrug-resistant bacterial infections[1][2].
  • HY-N6262
    20(S),24(R)-Ocotillol

    Others Others
    20(S),24(R)-Ocotillol is isolated from Panax ginseng.
  • HY-U00228
    Rilmazafone hydrochloride

    450191S

    GABA Receptor Neurological Disease
    Rilmazafone hydrochloride (450191S) is a benzodiazepine ω ligand with sedative and hypnotic effects.
  • HY-113380
    (S)-b-aminoisobutyric acid

    Endogenous Metabolite Metabolic Disease
    (S)-b-aminoisobutyric acid is a non-protein amino acid originating from the catabolism of thymine and valine.
  • HY-12499
    (S)-Willardiine

    (-)-Willardiine

    iGluR Neurological Disease
    (S)-Willardiine is a potent agonist of AMPA/kainate receptors with EC50 of 44.8 uM.
  • HY-B2188
    S-Methyl-L-cysteine

    L-S-Methylcysteine

    Reactive Oxygen Species Metabolic Disease Neurological Disease
    S-Methyl-L-cysteine is a natural product that acts as a substrate in the catalytic antioxidant system mediated by methionine sulfoxide reductase A (MSRA), with antioxidative, neuroprotective, and anti-obesity activities.
  • HY-W021425
    (2S,3R,4S,5R)-2-Amino-3,4,5,6-tetrahydroxyhexanal hydrochloride

    Endogenous Metabolite Metabolic Disease
    (2S,3R,4S,5R)-2-Amino-3,4,5,6-tetrahydroxyhexanal hydrochloride is an endogenous metabolite.
  • HY-P2093A
    S961 TFA

    Insulin Receptor Metabolic Disease
    S961 TFA is an high-affinity and selective insulin receptor (IR) antagonist with IC50s of 0.048, 0.027, and 630 nM for HIR-A, HIR-B, and human insulin-like growth factor I receptor (HIGF-IR) in SPA-assay, respectively.
  • HY-109025
    Baloxavir marboxil

    S-033188

    Influenza Virus Infection
    Baloxavir marboxil (S-033188) is a selective inhibitor of influenza cap-dependent endonuclease. Baloxavir marboxil, a potent antiviral agent, shows activity against influenza A and B virus.
  • HY-111652
    S-Gboxin

    Others Cancer
    S-Gboxin, a functional analogue of Gboxin, inhibits growth of mouse and human glioblastoma (GBM) with an IC50 of 470 nM. Antitumour activity.
  • HY-N2584
    (2S)-Isoxanthohumol

    Others Cancer
    (2S)-Isoxanthohumol is a microbial biotransformed metabolite of the hop prenylflavanone Isoxanthohumol.
  • HY-115682
    (S)-ZINC-3573

    Others Others
    (S)-ZINC-3573 is an inactive enantiomer of ZINC-3573. (R)-ZINC-3573 is a selective MRGPRX2 agonist. (S)-ZINC-3573 and (R)-ZINC3573 are effective and internally controlled probe-pairs for investigating the biology of primate-exclusive receptor.
  • HY-15124
    (S)-(-)-Bay-K-8644

    Calcium Channel Cardiovascular Disease
    (S)-(-)-Bay-K-8644 is an agonist of L-type Ca 2+ channel. (S)-(-)-Bay-K-8644 activates Ba 2+ currents (IBa) (EC50=32 nM).
  • HY-N0797
    (20S)-Protopanaxadiol

    20-Epiprotopanaxadiol; 20(S)-APPD

    P-glycoprotein Reactive Oxygen Species Apoptosis Cancer
    (20S)-Protopanaxadiol (20-Epiprotopanaxadiol) is an aglycon metabolic derivative of the protopanaxadiol-type ginseng saponin; apoptosis inducer.
  • HY-14258A
    Escitalopram oxalate

    (S)-Citalopram oxalate; (S)-(+)-Citalopram oxalate

    Serotonin Transporter Neurological Disease
    Escitalopram ((S)-Citalopram) oxalate, the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a Ki of 0.89 nM. Escitalopram oxalate has ∼30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram oxalate is an antidepressant for the research of major depression.
  • HY-N4130
    25S-Inokosterone

    Others Inflammation/Immunology
    25S-Inokosterone is a phytoecdysone in the roots of two same species of A. bidentata Blume and A. japonica Nakai, and two different species of C. capitata Moq and C. officinalis Kuan. 25S-Inokosterone has the potential for the LPS-induced acute kidney injury research.
  • HY-12835
    S1P1 Agonist III

    LPL Receptor Inflammation/Immunology
    S1P1 Agonist III is a potent and orally active S1P1 agonist with EC50 of 18 nM; no activity on S1P3.
  • HY-13788A
    LY 344864 S-enantiomer

    5-HT Receptor Others
    LY 344864 S-enantiomer is the S-enantiomer of LY344864. LY344864 is a 5-HT1F receptor agonist.
  • HY-40354B
    (3S,4R)-Tofacitinib

    JAK Inflammation/Immunology
    (3S,4R)-Tofacitinib is an less active enantiomer of Tofacitinib. Tofacitinib inhibits JAK3 with IC50 of 1 nM.
  • HY-18408
    5S rRNA modificator

    Others Others
    5S rRNA modificator is a suitable electrophile for 2’-hydroxyl acylation on structured RNA molecules, yielding accurate structural information comparable to that obtained with existing probes; 5S rRNA RNA modification.
  • HY-112217A
    PSEM 89S TFA

    nAChR Neurological Disease
    PSEM 89S TFA is a selective and brain penetrant agonists for the resulting ion channels. PSEM 89S TFA is orthogonally selective for Q79G and L141F, respectively.
  • HY-112218
    MIK665

    S-64315

    Bcl-2 Family Cancer
    MIK665 (S-64315) is a special Mcl-1 inhibitor extracted from patent WO2016207225A1, compound Preparation 13, has an IC50 of 1.81 nM.
  • HY-117288A
    S55746 hydrochloride

    BCL201 hydrochloride

    Bcl-2 Family Cancer
    S55746 hydrochloride (BCL201 hydrochloride) is a potent, orally active and selective BCL-2 inhibitor, with a Ki of 1.3 nM and a Kd of 3.9 nM. S55746 hydrochloride (BCL201 hydrochloride) has antitumor activity with low toxicity.
  • HY-117288
    S55746

    BCL201

    Bcl-2 Family Cancer
    S55746 (BCL201) is a potent, orally active and selective BCL-2 inhibitor, with a Ki of 1.3 nM and a Kd of 3.9 nM. S55746 (BCL201) has antitumor activity with low toxicity.
  • HY-114272A
    T4-ATA (S-isomer)

    Thyroid Hormone Receptor Endocrinology
    T4-ATA S-isomer is the S-isomer of T4-ATA, which is the active form of the thyroid hormone.
  • HY-114271A
    T3-ATA (S-isomer)

    Thyroid Hormone Receptor Endocrinology
    T3-ATA S-isomer is the S-isomer of T3-ATA, which is the active form of the thyroid hormone.
  • HY-128736
    (S)-3-Hydroxy-2-(Phosphonooxy)Propanoic Acid

    Endogenous Metabolite Metabolic Disease
    (S)-3-Hydroxy-2-(Phosphonooxy)Propanoic Acid is an endogenous metabolite.
  • HY-126456
    (S,R,S)-AHPC-propargyl

    VH032-propargyl; VHL ligand 7

    Ligand for E3 Ligase Cancer
    (S,R,S)-AHPC-propargyl (VH032-propargyl) is a VHL ligand which is used in “click reaction” for PROTACs.
  • HY-100742B
    (S)-GNE-140

    Lactate Dehydrogenase Cancer
    (S)-GNE-140 is the less active enantiomer of GNE-140 which can inhibit Lactate dehydrogenase A (LDHA).
  • HY-111664A
    (S)​-​(-​)​-​Citronellal

    (-​)​-​Citronellal

    Endogenous Metabolite Metabolic Disease
    (S)-(-)-Citronellal ((-)-Citronellal) is a monoterpenoid compound found in Corymbia citriodora and Cymbopogon nardus essential oils.
  • HY-30220
    (S)-2-Hydroxy-3-phenylpropanoic acid

    Endogenous Metabolite Metabolic Disease
    (S)-2-Hydroxy-3-phenylpropanoic acid is a product of phenylalanine catabolism. An elevated level of phenyllactic acid is found in body fluids of patients with or phenylketonuria.
  • HY-100740C
    (1α,1'S,4β)-Lanabecestat

    (1α,1'S,4β)-AZD3293; (1α,1'S,4β)-LY3314814

    Beta-secretase Neurological Disease
    (1α,1'S,4β)-Lanabecestat ((1α,1'S,4β)-AZD3293) is a Beta site APP Cleaving Enzymel (BACE1) inhibitor extracted from patent WO2012087237A1, compound 20a, has IC50s of 2.2 nM (TR-FRET assay) and 0.28 nM (sAPPp release assay), respectively.
  • HY-100822A
    (S)-(-)-HA 966

    (-)-HA 966

    iGluR Neurological Disease
    (S)-(-)-HA 966 ((-)-HA 966), a γ-Hydroxybutyrate-like agent, is weakly active as an NMDA-receptor antagonist. (S)-(-)-HA 966 possesses muscle relaxant action and prevents enhanced mesocorticolimbic dopamine metabolism and behavioral correlates of restraint stress, conditioned fear.
  • HY-103603B
    (S,R,S)-AHPC-PEG2-NH2 dihydrochloride

    VH032-PEG2-NH2 dihydrochloride

    E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-PEG2-NH2 dihydrochloride (VH032-PEG2-NH2 dihydrochloride) is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 2-unit PEG linker used in the synthesis of PROTACs.
  • HY-Z0081
    2S,4R-Sacubitril

    Others Cardiovascular Disease
    2S,4R-Sacubitril is the impurity of Sacubitril. Sacubitril is approved by the Food and Drug Administration for use in combination with valsartan for the treatment of patients with heart failure.
  • HY-N0095
    (S)-10-Hydroxycamptothecin

    10-HCPT; 10-Hydroxycamptothecin

    Topoisomerase Apoptosis Cancer
    (S)-10-Hydroxycamptothecin (10-HCPT;10-Hydroxycamptothecin) is a DNA topoisomerase I inhibitor of isolated from the Chinese plant Camptotheca accuminata. (S)-10-Hydroxycamptothecin exhibits a remarkable apoptosis-inducing effect. (S)-10-Hydroxycamptothecin has the potential for hepatoma, gastric carcinoma, colon cancer and leukaemia treatment.
  • HY-136008A
    (S,R,S)-AHPC-PEG1-NH2 dihydrochloride

    VH032-PEG1-NH2 dihydrochloride

    E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-PEG1-NH2 (VH032-PEG1-NH2) dihydrochloride incorporates a VHL ligand for the E3 ubiquitin ligase and a PROTAC linker. (S,R,S)-AHPC-PEG1-NH2 dihydrochloride can be used to design PROTACs.
  • HY-100390
    (S)-ML753286

    BCRP Cancer
    (S)-ML753286 is a breast cancer resistance protein (BCRP) inhibitor with an IC50 of 0.6 μM on BCRP efflux transporter.
  • HY-15853A
    MK-7246 S enantiomer

    Prostaglandin Receptor Inflammation/Immunology Endocrinology
    MK-7246 S enantiomer is the less active enantiomer of MK-7246. MK-7246 is a potent and selective CRTH2 antagonist.
  • HY-42680
    (3S,4S,5R)-1,3,4,5,6-Pentahydroxyhexan-2-one

    Tagatose, D- (8CI)

    Endogenous Metabolite Metabolic Disease
    (3S,4S,5R)-1,3,4,5,6-Pentahydroxyhexan-2-one is an endogenous metabolite.
  • HY-13238A
    Dolutegravir sodium

    S/GSK1349572 sodium

    HIV Integrase HIV Infection
    Dolutegravir sodium (S/GSK1349572 sodium) is a highly potent and orally bioavailable HIV integrase strand transfer inhibitor with an IC50 of 2.7 nM for HIV-1 integrase-catalyzed strand transfer. Dolutegravir sodium (S/GSK1349572 sodium) inhibits HIV-1 viral replication with an IC50 of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir sodium (S/GSK1349572 sodium) retains a high potency against the HIV-1 Y143R, N155H, and G140S/Q148H mutants (EC50=3.6-5.8 nM).
  • HY-123023
    12(S)-HETE D8

    Others Cancer
    12(S)-HETE D8 contains eight deuterium atoms at the 5, 6, 8, 9, 11, 12, 14 and 15 positions. 12(S)-HETE D8 is intended for use as an internal standard for the quantification of 12(S)-HETE by GC- or LC-mass spectrometry (MS). 12(S)-HETE D8 is the predominant lipoxygenase product of mammalian platelets. It enhances tumor cell adhesion to endothelial cells, fibronectin, and the subendothelial matrix at 0.1 µM.
  • HY-Z0478
    (-)-Limonene

    (S)-(-)-Limonene

    Others Cardiovascular Disease
    (-)-Limonene ((S)-(-)-Limonene) is a monoterpene found in many pine-needle oils and in turpentine. (-)-Limonene can induce a mild bronchoconstrictive effect.
  • HY-17368
    Rivastigmine

    S-Rivastigmine

    AChE Neurological Disease
    Rivastigmine (S-Rivastigmine) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC50s of 0.037 μM , 4.15 μM, respectively. Rivastigmine can pass the blood brain barrier (BBB). Rivastigmine is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease.
  • HY-101763A
    (S,R,S)-AHPC hydrochloride

    VH032-NH2 hydrochloride; VHL ligand 1 hydrochloride

    Ligand for E3 Ligase Cancer
    (S,R,S)-AHPC hydrochloride is the VH032-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. (S,R,S)-AHPC hydrochloride can be connected to the ligand for protein (e.g., BCR-ABL1) by a linker to form PROTACs (e.g., GMB-475). GMB-475 induces the degradation of BCR-ABL1 with an IC50 of 1.11 μM in Ba/F3 cells.
  • HY-112078
    (S,R,S)-AHPC-Me

    VHL ligand 2; E3 ligASe Ligand 1A

    Ligand for E3 Ligase Cancer
    (S,R,S)-AHPC-Me (VHL ligand 2) is the (S,R,S)-AHPC-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. (S,R,S)-AHPC-Me can be used to synthesize ARV-771, a von Hippel-Landau (VHL) E3 ligase-based BET PROTAC degrader. ARV-771 potently degrades BET protein in castration-resistant prostate cancer (CRPC) cells with a DC50 <1 nM.
  • HY-N1746
    (2S)-2'-Methoxykurarinone

    2'-O-Methylkurarinone

    Others Cancer Metabolic Disease Inflammation/Immunology
    (2S)-2'-Methoxykurarinone, a compound isolated from the roots of Sophora flavescens, has anti-inflammatory, antipyretic, antidiabetic, and antineoplastic effects. (2S)-2'-Methoxykurarinone (MK) inhibits osteoclastogenesis and bone resorption through down-regulation of RANKL signaling. (2S)-2'-Methoxykurarinone (MK) displays cytotoxic activity against human myeloid leukemia HL-60 cells.
  • HY-135383A
    (3S,5R)-Pitavastatin calcium

    Others Metabolic Disease
    (3S,5R)-Pitavastatin cacium is the enantiomer of Pitavastatin. Pitavastatin is a potent HMG-CoA reductase inhibitor.
  • HY-131387
    (S,R,S)-AHPC-Me-CO-CH2-PEG3-NH2

    E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-Me-CO-CH2-PEG3-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the a VHL ligand and a linker. (S,R,S)-AHPC-Me-CO-CH2-PEG3-NH2 can be used in PROTAC BRD4 Degrader-5 (HY-133737) and PROTAC BRD4 Degrader-5-CO-PEG3-N3 (HY-133736).
  • HY-15030
    Naproxen

    (S)-Naproxen

    COX Autophagy Inflammation/Immunology Cancer
    Naproxen is a COX-1 and COX-2 inhibitor with IC50s of 8.72 and 5.15 μM, respectively in cell assay.
  • HY-126047A
    (R,S)-Anatabine

    Others Inflammation/Immunology
    (R,S)-Anatabine is a a minor tobacco alkaloid found in the Solanaceae family of plants that can be used as a specific marker for the detection of tobacco use.
  • HY-108496
    Sphingosine-1-phosphate

    S1P

    Endogenous Metabolite LPL Receptor Endocrinology
    Sphingosine-1-phosphate (S1P) is an agonist of S1P1-5 receptors and a ligand of GPR3, GPR6 and GPR12. Sphingosine-1-phosphate is an intracellular second messenger and mobilizes Ca 2+ as an extracellular ligand for G protein-coupled receptors. Sphingosine-1-phosphate is an important lipid mediator generated from Sphingomyelin (HY-113498) or other membrane phospholipids.
  • HY-12560D
    PNU-282987 S enantiomer free base

    nAChR Others
    PNU-282987 S enantiomer free base is the S-enantiomer of PNU-282987 free base. PNU-282987 is an α7 nicotinic acetylcholine receptor (α7 nAChR) agonist.
  • HY-125845
    (S,R,S)-AHPC

    VH032-NH2; VHL ligand 1

    Ligand for E3 Ligase Cancer
    (S,R,S)-AHPC (VH032-NH2) is the VH032-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. (S,R,S)-AHPC can be connected to the ligand for protein (e.g., BCR-ABL1) by a linker to form PROTACs (e.g., GMB-475). GMB-475 induces the degradation of BCR-ABL1 with an IC50 of 1.11 μM in Ba/F3 cells.
  • HY-115688A
    (S)-TXNIP-IN-1

    Others Others
    (S)-TXNIP-IN-1 is the less active S-enantiomer of TXNIP-IN-1 (HY-115688). TXNIP-IN-1 is a TXNIP-TRX complex inhibitor which can be used in the research of TXNIP-TRX complex associated metabolic disorder (diabetes), cardiovascular disease, or inflammatory disease
  • HY-100754B
    (2R,5S)-Ritlecitinib

    (2R,5S)-PF-06651600

    JAK Inflammation/Immunology
    (2R,5S)-Ritlecitinib ((2R,5S)-PF-06651600) is a potent and selective JAK3 inhibitor (IC50=144.8 nM) extracted from patent US20150158864A1, example 68.
  • HY-114415
    AWZ1066S

    Parasite Infection
    AWZ1066S is a highly specific anti-Wolbachia drug candidate for a short-course treatment of filariasis, with an EC50 of 2.5 nM in cell assay.
  • HY-U00366
    S1PR1-MO-1

    LPL Receptor Inflammation/Immunology
    S1PR-MO-1 is the modulator of sphingosine-1-phosphate receptor, used for research of hyperproliferative, inflammatory diseases.
  • HY-126145
    S1PR1 modulator 1

    LPL Receptor Inflammation/Immunology
    S1PR1 modulator 1 is a selective S1PR1 inhibitor, with a pIC50 of 7.6, with >40- and >80-fold selectivity, over the other S1PR isoforms S1PR2/3/4.
  • HY-15652
    Freselestat

    ONO-6818; ONO-PO-736

    Elastase Inflammation/Immunology
    Freselestat (ONO-6818) is a potent and orally active neutrophil elastase inhibitor with a Ki of 12.2 nM. Freselestat is >100-fold less-active against other proteases such as trypsin, protein-ase 3, pancreatic elastase, plasmin, thrombin, collagenase, cathepsin G, and murine macrophage elastase. Freselestat has a potent anti-inflammatory activity.
  • HY-P1112
    Sarafotoxin S6a

    Endothelin Receptor Neurological Disease Cardiovascular Disease
    Sarafotoxin S6a, a sarafotoxin analogue, is a endothelin receptor agonist and has an ETA/ETB selectivity profile similar to that of Endothelin-3 (HY-P0204). Sarafotoxin S6a elicits the pig coronary artery with an EC50 value of 7.5 nM.
  • HY-15123
    (S)-Flurbiprofen

    Esflurbiprofen

    COX PGE synthase Inflammation/Immunology
    (S)-Flurbiprofen is an active enantiomer of Flurbiprofen, with IC50 values of 0.48 μM and 0.47 μM for COX-1 and COX-2, respectively.
  • HY-42424
    (S,R,S)-AHPC-Me hydrochloride

    VHL ligand 2 hydrochloride; E3 ligASe Ligand 1

    Ligand for E3 Ligase Cancer
    (S,R,S)-AHPC-Me hydrochloride (VHL ligand 2 hydrochloride) is the (S,R,S)-AHPC-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. (S,R,S)-AHPC-Me hydrochloride can be used to synthesize ARV-771, a von Hippel-Landau (VHL) E3 ligase-based BET PROTAC degrader. ARV-771 potently degrades BET protein in castration-resistant prostate cancer (CRPC) cells with a DC50 <1 nM.
  • HY-42424A
    (S,R,S)-AHPC-Me dihydrochloride

    VHL ligand 2 dihydrochloride; E3 ligASe Ligand 1 dihydrochloride

    Ligand for E3 Ligase Cancer
    (S,R,S)-AHPC-Me dihydrochloride (VHL ligand 2 dihydrochloride) is the (S,R,S)-AHPC-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. (S,R,S)-AHPC-Me dihydrochloride can be used to synthesize ARV-771, a von Hippel-Landau (VHL) E3 ligase-based BET PROTAC degrader. ARV-771 potently degrades BET protein in castration-resistant prostate cancer (CRPC) cells with a DC50 <1 nM.
  • HY-136184
    (S,R,S)-AHPC-phenol-C4-NH2 dihydrochloride

    VH032-phenol-C4-NH2 dihydrochloride

    E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-phenol-C4-NH2 (VH032-phenol-C4-NH2) dihydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and a linker used in PROTAC technology.
  • HY-116514
    (S)-(−)-Perillyl alcohol

    Apoptosis Endogenous Metabolite Cancer
    (S)-(−)-Perillyl alcohol is a monoterpene found in lavender, inhibits farnesylation of Ras, upregulates the mannose-6-phosphate receptor and induces apoptosis. Anti-cancer activity.
  • HY-W050031
    (S)-3-Hydroxybutanoic acid

    (S)-β-Hydroxybutanoic acid; L-(+)-3-Hydroxybutyric acid; L-β-Hydroxybutyric acid

    Endogenous Metabolite Others
    (S)-3-Hydroxybutanoic acid is a normal human metabolite, that has been found elevated in geriatric patients remitting from depression. In humans, 3-Hydroxybutyric acid is synthesized in the liver from acetyl-CoA, and can be used as an energy source by the brain when blood glucose is low.
  • HY-17504D
    (3S,5R)-Rosuvastatin

    HMG-CoA Reductase (HMGCR) Potassium Channel Autophagy Metabolic Disease Cardiovascular Disease
    (3S,5R)-Rosuvastatin is the (3S,5R)-enantiomer of Rosuvastatin. Rosuvastatin is a competitive HMG-CoA reductase inhibitor with an IC50 of 11 nM. Rosuvastatin potently blocks human ether-a-go-go related gene (hERG) current with an IC50 of 195 nM. Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin is very effective in lowering low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels.
  • HY-W016798
    (S)-2-acetamido-4-amino-4-oxobutanoic acid

    Endogenous Metabolite Metabolic Disease
    (S)-2-acetamido-4-amino-4-oxobutanoic acid is an endogenous metabolite.
  • HY-W096147
    S-acetyl-PEG6

    PROTAC Linker Cancer
    S-acetyl-PEG6 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
  • HY-10319
    ROCK-IN-2

    Azaindole 1; TC-S 7001

    ROCK Cardiovascular Disease
    ROCK-IN-2 (Azaindole 1; TC-S 7001) is an orally active and ATP-competitive ROCK inhibitor with IC50s of 0.6 and 1.1 nM for human ROCK-1 and ROCK-2, respectively.
  • HY-12885
    ADU-S100

    MIW815; ML RR-S2 CDA

    STING Inflammation/Immunology
    ADU-S100 (MIW815), an activator of stimulator of interferon genes (STING), leads to potent and systemic tumor regression and immunity.
  • HY-N2738
    (2S)-7,4'-Dihydroxy-3'-prenylflavan

    Others Others
    (2S)-7,4'-Dihydroxy-3'-prenylflavan is a natural product.
  • HY-126126
    S-Adenosyl-DL-methionine

    Others Others
    S-Adenosyl-DL-methionine is a derivative of Ademetionine (HY-B0617). Ademetionine is an intermediate metabolite of methionine.
  • HY-14664CS
    (3S,5R)-Fluvastatin D6 sodium

    (3S,5R)-XU 62-320 D6

    HMG-CoA Reductase (HMGCR) Cancer Cardiovascular Disease
    (3S,5R)-Fluvastatin D6 sodium is the deuterium labeled (3S,5R)-Fluvastatin sodium. Fluvastatin is a first fully synthetic, competitive HMG-CoA reductase inhibitor with an IC50 of 8 nM. Fluvastatin protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway.
  • HY-Z0075
    (Z)2S,4R-Sacubitril

    Others Cardiovascular Disease
    (Z)2S,4R-Sacubitril is the impurity of Sacubitril. Sacubitril is approved by the Food and Drug Administration for use in combination with valsartan for the treatment of patients with heart failure.
  • HY-128910
    MC-VC(S)-PABQ-Tubulysin M

    Drug-Linker Conjugates for ADC Cancer
    MC-VC(S)-PABQ-Tubulysin M is a drug-linker conjugate for ADC with potent antitumor activity by using Tubulysin M (a tubulin inhibitor), linked via the ADC linker MC-VC(S)-PABQ. MC-VC(S)-PABQ-Tubulysin M is effective against multidrug-resistant lymphoma cell lines and tumors.
  • HY-136006
    (S,R,S)-AHPC-C6-NH2 dihydrochloride

    VH032-C6-NH2 dihydrochloride

    E3 Ligase Ligand-Linker Conjugate Cancer Inflammation/Immunology
    (S,R,S)-AHPC-C6-NH2 dihydrochloride (VH032-C6-NH2 dihydrochloride) is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used for AKT PROTAC degrader. (S,R,S)-AHPC-C6-NH2 dihydrochloride is XF038-161A, example 6, extracted from patent WO2019173516A1.
  • HY-133487B
    (S,R,S)-AHPC-C8-NH2

    VH032-C8-NH2

    E3 Ligase Ligand-Linker Conjugate Cancer Inflammation/Immunology
    (S,R,S)-AHPC-C8-NH2 (VH032-C8-NH2) is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used for AKT PROTAC degrader. (S,R,S)-AHPC-C8-NH2 is XF038-164A, example 8, extracted from patent WO2019173516A1.
  • HY-136006A
    (S,R,S)-AHPC-C6-NH2 hydrochloride

    VH032-C6-NH2 hydrochloride

    E3 Ligase Ligand-Linker Conjugate Cancer Inflammation/Immunology
    (S,R,S)-AHPC-C6-NH2 hydrochloride (VH032-C6-NH2 hydrochloride) is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used for AKT PROTAC degrader. (S,R,S)-AHPC-C6-NH2 hydrochloride is XF038-161A, example 6, extracted from patent WO2019173516A1.
  • HY-133487
    (S,R,S)-AHPC-C8-NH2 dihydrochloride

    VH032-C8-NH2 dihydrochloride

    E3 Ligase Ligand-Linker Conjugate Cancer Inflammation/Immunology
    (S,R,S)-AHPC-C8-NH2 dihydrochloride (VH032-C8-NH2 dihydrochloride) is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used for AKT PROTAC degrader. (S,R,S)-AHPC-C8-NH2 is XF038-164A, example 8, extracted from patent WO2019173516A1.
  • HY-N0363A
    (+)-Columbianetin acetate

    (S)-Columbianetin acetate

    Others Infection Inflammation/Immunology
    (S)-Columbianetin acetate is an isomer of Columbianetin. Columbianetin is a phytoalexin associated with celery (Apium graveolens) resistance to pathogens during storage. Columbianetin exhibits excellent anti-fungal and anti-inflammatory activity.
  • HY-W013579
    (S)-(+)-Carvone

    D-​Carvone

    Others Others
    (S)-(+)-Carvone (D Carvone) is a naturally occuring conmpound found in several food items and can be used in flavouring foods.
  • HY-129356A
    (S)-Seco-Duocarmycin SA

    ADC Cytotoxin DNA Alkylator/Crosslinker Cancer
    (S)-Seco-Duocarmycin SA is a DNA alkylator, cytotoxic to cancer cells, and acts as a ADC cytotoxin for antibody-drug conjugates.
  • HY-14744
    Levamlodipine

    (S)-Amlodipine; Levoamlodipine

    Calcium Channel Others
    Levamlodipine ((S)-Amlodipine) is a powerful dihydropyridine calcium channel blocker, possessing vasodilation properties and used in the treatment of hypertension and angina.
  • HY-N0455A
    L-Arginine hydrochloride

    (S)-(+)-Arginine hydrochloride

    NO Synthase Endogenous Metabolite Others
    L-Arginine hydrochloride ((S)-(+)-Arginine hydrochloride) is the nitrogen donor for synthesis of nitric oxide, a potent vasodilator that is deficient during times of sickle cell crisis.
  • HY-120601
    Alizarin Red S sodium

    ARS sodium

    Others Others
    Alizarin Red S sodium (ARS sodium) is an anthraquinone dye that has been widely used to evaluate calcium deposits in cell culture.
  • HY-U00459A
    GSK2850163 (S enantiomer)

    Others Others
    GSK2850163 S enantiomer is the inactive enantiomer of GSK2850163. GSK2850163 is an inositol-requiring enzyme-1 alpha (IRE1a) inhibitor.
  • HY-12201
    TAK-901

    Aurora Kinase Cancer
    TAK-901 is a multi-targeted aurora inhibitor with IC50s of 21 and 15 nM for aurora A and B, respectively.
  • HY-10338
    Foretinib

    XL880; GSK1363089; GSK089; EXEL-2880

    VEGFR c-Met/HGFR Cancer
    Foretinib is a multi-target tyrosine kinase inhibitor with IC50s of 0.4 nM and 0.9 nM for Met and KDR.
  • HY-13238
    Dolutegravir

    S/GSK1349572

    HIV Integrase HIV Infection
    Dolutegravir (S/GSK1349572) is a highly potent and orally bioavailable HIV integrase strand transfer inhibitor with an IC50 of 2.7 nM for HIV-1 integrase-catalyzed strand transfer. Dolutegravir (S/GSK1349572) inhibits HIV-1 viral replication with an IC50 of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir retains a high potency against the HIV-1 Y143R, N155H, and G140S/Q148H mutants (EC50=3.6-5.8 nM).
  • HY-18099
    S1RA

    E-52862

    Sigma Receptor Neurological Disease
    S1RA(E-52862) is a potent and selective sigma-1 receptor(σ1R, Ki=17 nM) antagonist, showed good selectivity against σ2R (Ki > 1000 nM).
  • HY-12421B
    BET-BAY 002 (S enantiomer)

    Epigenetic Reader Domain Cancer
    BET-BAY 002 S enantiomer is the S-enantiomer of BET-BAY 002. BET-BAY 002 is a BET inhibitor.
  • HY-136186
    (S,R,S)-AHPC-C7-amine

    VH032-C7-amine

    E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-C7-amine (VH032-C7-amine) is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used for estrogen-related receptor α (ERRα) PROTAC degrader.
  • HY-14664DS
    (3S,5R)-Fluvastatin D6

    (3S,5R)-XU 62-320 free acid D6

    Autophagy Cancer Cardiovascular Disease
    (3S,5R)-Fluvastatin D6 is the deuterium labeled (3S,5R)-Fluvastatin sodium. Fluvastatin is a first fully synthetic, competitive HMG-CoA reductase inhibitor with an IC50 of 8 nM. Fluvastatin protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway.
  • HY-136183
    (S,R,S)-AHPC-phenol-alkylC6-amine dihydrochloride

    VH032 phenol-alkylC6-amine dihydrochloride

    E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-phenol-alkylC6-amine dihydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and an alkyl linker used for PROTAC degrader.
  • HY-118557
    Iferanserin

    S-MPEC

    5-HT Receptor Inflammation/Immunology
    Iferanserin (S-MPEC) is a selective 5-HT receptor (serotonin receptor) antagonist with an affinity for 5-HT2A receptor. Iferanserin has the potential for internal hemorrhoid disease treatment.
  • HY-B0311A
    Carbidopa monohydrate

    (S)-(-)-Carbidopa monohydrate

    Aryl Hydrocarbon Receptor Cancer Neurological Disease
    Carbidopa ((S)-(-)-Carbidopa) monohydrate, a peripheral decarboxylase inhibitor, can be used for the research of Parkinson's disease. Carbidopa monohydrate is a selective aryl hydrocarbon receptor (AhR) modulator. Carbidopa monohydrate inhibits pancreatic cancer cell and tumor growth.
  • HY-B0311
    Carbidopa

    (S)-(-)-Carbidopa

    Aryl Hydrocarbon Receptor Cancer Neurological Disease
    Carbidopa ((S)-(-)-Carbidopa), a peripheral decarboxylase inhibitor, can be used for the research of Parkinson's disease. Carbidopa is a selective aryl hydrocarbon receptor (AhR) modulator. Carbidopa inhibits pancreatic cancer cell and tumor growth.
  • HY-17038A
    Agomelatine hydrochloride

    S-20098 hydrochloride

    Melatonin Receptor 5-HT Receptor Neurological Disease
    Agomelatine hydrochloride (S-20098 hydrochloride) is a specific agonist of MT1 and MT2 receptors with Kis of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively. Agomelatine hydrochloride is a selective 5-HT2C receptor antagonist with pKis of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively.
  • HY-17038
    Agomelatine

    S-20098

    Melatonin Receptor 5-HT Receptor Neurological Disease
    Agomelatine (S-20098) is a specific agonist of MT1 and MT2 receptors with Kis of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively. Agomelatine is a selective 5-HT2C receptor antagonist with pKis of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively.
  • HY-12885A
    ADU-S100 disodium salt

    MIW815 disodium salt; ML RR-S2 CDA disodium salt

    STING Inflammation/Immunology
    ADU-S100 disodium salt (MIW815 disodium salt) is an activator of stimulator of interferon genes (STING).
  • HY-17038S
    Agomelatine D6

    S-20098 D6

    Melatonin Receptor 5-HT Receptor Neurological Disease
    Agomelatine D6 (S-20098 D6) is deuterium labeled Agomelatine. Agomelatine is a specific agonist of MT1 and MT2 receptors .
  • HY-101265
    S1p receptor agonist 1

    LPL Receptor Inflammation/Immunology
    S1p receptor agonist 1 is a potent and orally active S1P receptor agonist, exhibits an activity of inducing S1P1 internalization (EC50=9.83 nM). S1p receptor agonist 1 has the potential for the study of arthritis and EAE (experimental autoimmune encephalitis). S1p receptor agonist 1 is extracted from patent WO2015039587A1, Compound 2.
  • HY-114269
    (-)-(S)-B-973B

    nAChR Neurological Disease
    (-)-(S)-B-973B is a potent allosteric agonist and positive allosteric modulator of α7 nAChR, with antinociceptive activity.
  • HY-128732
    rel-(2R,3S)-2,3-Dihydroxysuccinic acid hydrate

    Endogenous Metabolite Metabolic Disease
    rel-(2R,3S)-2,3-Dihydroxysuccinic acid (hydrate) is an endogenous metabolite.
  • HY-P1112A
    Sarafotoxin S6a TFA

    Endothelin Receptor Neurological Disease Cardiovascular Disease
    Sarafotoxin S6a TFA , a sarafotoxin analogue, is a endothelin receptor agonist and has an ETA/ETB selectivity profile similar to that of Endothelin-3 (HY-P0204). Sarafotoxin S6a TFA elicits the pig coronary artery with an EC50 value of 7.5 nM.
  • HY-15652A
    Freselestat quarterhydrate

    ONO-6818 quarterhydrate; ONO-PO-736 quarterhydrate

    Elastase Inflammation/Immunology
    Freselestat quarterhydrate (ONO-6818 quarterhydrate) is a potent and orally active neutrophil elastase inhibitor with a Ki of 12.2 nM. Freselestat quarterhydrate is >100-fold less-active against other proteases such as trypsin, protein-ase 3, pancreatic elastase, plasmin, thrombin, collagenase, cathepsin G, and murine macrophage elastase. Freselestat quarterhydrate has a potent anti-inflammatory activity.
  • HY-W013573
    S-Allyl-L-cysteine

    Apoptosis Cancer Metabolic Disease Inflammation/Immunology Neurological Disease
    S-Allyl-L-cysteine, one of the organosulfur compounds found in AGE, possess various biological effects including neurotrophic activity, anti-cancer activity, anti-inflammatory activity.
  • HY-111540B
    (S)-IDO1-IN-5

    Indoleamine 2,3-Dioxygenase (IDO) Cancer
    (S)-IDO1-IN-5 (Example 1B) is an active S-isomer of IDO1-IN-5. (S)-IDO1-IN-5 binds to IDOL with an IC50 value less than 1.5 µΜ. IDO1-IN-5 is a potent, selective and brain penetrated inhibitor of Indoleamine 2,3-Dioxygenase 1 (IDO1) activity, binds to apo-IDO1 lacking heme rather than mature heme-bound IDO1.
  • HY-13259C
    (R)-MG-132

    (S,R,S)-(-)-MG-132; Z-Leu-D-Leu-Leu-al

    Proteasome Cancer
    (R)-MG-132 ((S,R,S)-(-)-MG-132) is the enantiomer of MG-132. (R)-MG-132 is a proteasome inhibitor with weaker cell cytotoxicity than MG-132. (R)-MG-132 stereoisomer is a more potent proteasome inhibitor than MG-132.
  • HY-135374
    (3R,5S)-Atorvastatin sodium

    Others Metabolic Disease Inflammation/Immunology
    (3R,5S)-Atorvastatin sodium is an impurity of Atorvastatin. Atorvastatin is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin inhibits human SV-SMC proliferation and invasion with IC50s of 0.39 μM and 2.39 μM, respectively.
  • HY-15146
    NSC 74859

    S3I-201

    STAT Cancer
    NSC 74859 (S3I-201) is a selective Stat3 inhibitor with an IC50 of 86 μM.
  • HY-110402
    (S,R,S)-AHPC TFA

    VH032-NH2 TFA; VHL ligand 1 TFA

    Ligand for E3 Ligase Cancer
    (S,R,S)-AHPC TFA (VH032-NH2 TFA) is the VH032-based VHL ligand used in the recruitment of the von Hippel-Lindau (VHL) protein. (S,R,S)-AHPC TFA can be connected to the ligand for protein (e.g., BCR-ABL1) by a linker to form PROTACs (e.g., GMB-475). GMB-475 induces the degradation of BCR-ABL1 with an IC50 of 1.11 μM in Ba/F3 cells.
  • HY-129995A
    TSHR antagonist S37a

    TSH Receptor Endocrinology
    TSHR antagonist S37a is a highly selective thyrotropin receptor (TSHR) antagonist, with potential for the treatment of Graves' orbitopathy.
  • HY-B1059
    Levosulpiride

    RV-12309; S-(-)-Sulpiride

    Dopamine Receptor Neurological Disease
    Levosulpiride (RV-12309) is the (S)-enantiomer of sulpiride, which is a D2 receptor a antagonist, an atypical antipsychotic drug of the benzamide class.
  • HY-129942
    S-(1-Hydroxy-2-methylpropan-2-yl) methanesulfonothioate

    ADC Linker Cancer
    S-(1-Hydroxy-2-methylpropan-2-yl) methanesulfonothioate is a glutathione cleavable ADC linker used for the antibody-drug conjugates (ADCs) and refers to the Alkyl-Chain composition. S-(1-Hydroxy-2-methylpropan-2-yl) methanesulfonothioate is the linker portions of the molecules employed for mAb attachment purposes.
  • HY-131254
    (S)-O-Desmethyl Venlafaxine N-Oxide

    Drug Metabolite Neurological Disease
    (S)-O-Desmethyl Venlafaxine N-Oxide is a N-oxyde of (S)-O-Desmethyl Venlafaxine. O-Desmethyl Venlafaxine is an active metabolite of Venlafaxine. Venlafaxine (HY-B0196) is an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI) class.
  • HY-141340
    S-acetyl-PEG3-alcohol

    PROTAC Linker Cancer
    S-acetyl-PEG3-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
  • HY-138497
    F-PEG2-S-COOH

    PROTAC Linker Cancer
    F-PEG2-S-COOH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
  • HY-141350
    S-acetyl-PEG4-propargyl

    PROTAC Linker Cancer
    S-acetyl-PEG4-propargyl is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
  • HY-141347
    S-acetyl-PEG4-Boc

    PROTAC Linker Cancer
    S-acetyl-PEG4-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
  • HY-141343
    S-acetyl-PEG16-alcohol

    PROTAC Linker Cancer
    S-acetyl-PEG16-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
  • HY-130209
    S-Acetyl-PEG8-OH

    PROTAC Linker Cancer
    S-Acetyl-PEG8-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
  • HY-133473
    S-acetyl-PEG6-Tos

    PROTAC Linker Cancer
    S-acetyl-PEG6-Tos is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
  • HY-141341
    S-acetyl-PEG4-alcohol

    PROTAC Linker Cancer
    S-acetyl-PEG4-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
  • HY-141346
    S-acetyl-PEG3-Boc

    PROTAC Linker Cancer
    S-acetyl-PEG3-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
  • HY-138758
    S-acetyl-PEG4-Thiol

    PROTAC Linker Cancer
    S-acetyl-PEG4-Thiol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
  • HY-138752
    S-acetyl-PEG4-amine

    PROTAC Linker Cancer
    S-acetyl-PEG4-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
  • HY-141178A
    (S)-TCO-PEG3-amine

    PROTAC Linker Cancer
    (S)-TCO-PEG3-amine is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
  • HY-140859
    S-Acetyl-PEG3-azide

    PROTAC Linker Cancer
    S-Acetyl-PEG3-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
  • HY-141348
    S-acetyl-PEG6-Boc

    PROTAC Linker Cancer
    S-acetyl-PEG6-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
  • HY-138755
    S-acetyl-PEG4-NHBoc

    PROTAC Linker Cancer
    S-acetyl-PEG4-NHBoc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
  • HY-141342
    S-acetyl-PEG12-alcohol

    PROTAC Linker Cancer
    S-acetyl-PEG12-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
  • HY-N0650
    L-Serine

    (-)-Serine; (S)-Serine

    Endogenous Metabolite Cancer
    L-Serine ((-)-Serine; (S)-Serine), one of the so-called non-essential amino acids, plays a central role in cellular proliferation.
  • HY-138493
    F-PEG2-S-Boc

    PROTAC Linker Cancer
    F-PEG2-S-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
  • HY-140600
    S-Bis-(PEG4-Boc)

    PROTAC Linker Cancer
    S-Bis-(PEG4-Boc) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
  • HY-141344
    S-acetyl-PEG20-alcohol

    PROTAC Linker Cancer
    S-acetyl-PEG20-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
  • HY-141345
    S-acetyl-PEG2-Boc

    PROTAC Linker Cancer
    S-acetyl-PEG2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
  • HY-138748
    S-acetyl-PEG5-alcohol

    PROTAC Linker Cancer
    S-acetyl-PEG5-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
  • HY-141351
    m-PEG3-S-Acetyl

    PROTAC Linker Cancer
    m-PEG3-S-Acetyl is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
  • HY-40354D
    (3R,4S)-Tofacitinib

    JAK Inflammation/Immunology
    (3R,4S)-Tofacitinib is an less active enantiomer of Tofacitinib. Tofacitinib inhibits JAK3 with IC50 of 1 nM.
  • HY-W017770
    S-Adenosyl-L-methionine disulfate tosylate

    Ademetionine disulfate tosylate; S-Adenosyl methionine disulfate tosylate; AdoMet disulfate tosylate

    Others Neurological Disease
    S-Adenosyl-L-methionine disulfate tosylate (Ademetionine disulfate tosylate) is the principal biological methyl donor synthesized in all mammalian cells but most abundantly in the liver.
  • HY-D0205
    (RS)-Carbocisteine

    S-(Carboxymethyl)-DL-cysteine

    Others Others
    (RS)-Carbocisteine is the S-carboxymethyl cysteine with no detectable inhibitory effect. (RS)-Carbocisteine is the inactive enantiomer of Carbocisteine.
  • HY-130654
    (S,R,S)-AHPC-C2-PEG4-N3

    VH032-C2-PEG4-N3

    E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-C2-PEG4-N3 (VH032-C2-PEG4-N3) is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 4-unit PEG linker used in PROTAC technology. (S,R,S)-AHPC-C2-PEG4-N3 can be used in the synthesis of vRucaparib-TP4 (HY-130647). vRucaparib-TP4 a highly potent PARP1 degrader with a half-maximal degrading concentration (DC50) of 82 nM.
  • HY-136006B
    (S,R,S)-AHPC-C6-NH2

    VH032-C6-NH2

    E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-C6-NH2 (VH032-C6-NH2) is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology.
  • HY-130711B
    (S,R,S)-AHPC-C3-NH2 hydrochloride

    VH032-C3-NH2 hydrochloride

    E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-C3-NH2 (VH032-C3-NH2) hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology.
  • HY-136008
    (S,R,S)-AHPC-PEG1-NH2

    VH032-PEG1-NH2

    E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-PEG1-NH2 (VH032-PEG1-NH2) is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology.
  • HY-133487A
    (S,R,S)-AHPC-C8-NH2 hydrochloride

    VH032-C8-NH2 hydrochloride

    E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-C8-NH2 (VH032-C8-NH2) hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology.
  • HY-101780
    EDO-S101

    Tinostamustine

    HDAC Cancer
    EDO-S101 (Tinostamustine) is a pan HDAC inhibitor; inhibits HDAC6, HDAC1, HDAC2 and HDAC3 with IC50 values of 6 nM, 9 nM, 9 nM and 25 nM, respectively.
  • HY-136055
    (S,R,S)-AHPC-C5-COOH

    VH032-C5-COOH

    E3 Ligase Ligand-Linker Conjugate HIF/HIF Prolyl-Hydroxylase Cancer
    (S,R,S)-AHPC-C5-COOH (VH032-C5-COOH) is a synthesized E3 ligase ligand-linker conjugate, contains the VH032 VHL-based ligand and a linker to form PROTACs. VH-032 is a selective and potent inhibitor of VHL/HIF-1α interaction with a Kd of 185 nM, has the potential for the study of anemia and ischemic diseases.
  • HY-117286
    (S)-JQ-35

    TEN-010

    Epigenetic Reader Domain Cancer
    (S)-JQ-35 (TEN-010) is an inhibitor of the Bromodomain and Extra-Terminal (BET) family bromodomain-containing proteins with potential antineoplastic activity.
  • HY-B0753
    Gliclazide

    S1702; SE1702

    Potassium Channel Cardiovascular Disease
    Gliclazide (S1702) is a whole-cell beta-cell ATP-sensitive potassium currents blocker with an IC50 of 184 nM. Gliclazide is used as an antidiabetic.
  • HY-14664B
    (3R,5S)-Fluvastatin

    (3R,5S)-XU 62-320 free acid

    HMG-CoA Reductase (HMGCR) Autophagy Cancer Cardiovascular Disease
    (3R,5S)-Fluvastatin is the 3R,5S-isomer Fluvastatin. Fluvastatin (XU 62-320 free acid) is a first fully synthetic, competitive HMG-CoA reductase inhibitor with an IC50 of 8 nM. Fluvastatin protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway.
  • HY-136187
    (S,R,S)-AHPC-C5-NH2

    VH032-C5-NH2

    E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-C5-NH2 (VH032-C5-NH2) is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used for estrogen-related receptor α (ERRα) PROTAC degrader.
  • HY-115681
    (2R/S)-6-PNG

    6-Prenylnaringenin

    Calcium Channel Neurological Disease
    (2R/S)-6-PNG (6-Prenylnaringenin) is a potent and reversible Cav3.2 T-type Ca 2+ channels (T-channels) blocker. (2R/S)-6-PNG can penetrate the blood-brain barrier (BBB). (2R/S)-6-PNG suppresses neuropathic and visceral pain in mice.
  • HY-12885B
    ADU-S100 ammonium salt

    MIW815 ammonium salt; ML RR-S2 CDA ammonium salt

    STING Inflammation/Immunology
    ADU-S100 ammonium salt (MIW815 ammonium salt), an activator of stimulator of interferon genes (STING), leads to potent and systemic tumor regression and immunity.
  • HY-78131
    Ibuprofen

    (±)-Ibuprofen

    COX Inflammation/Immunology Cancer
    Ibuprofen is an anti-inflammatory agent targeting COX-1 and COX-2 with IC50s of 13 μM and 370 μM, respectively.
  • HY-113025A
    L-hydroxylysine dihydrochloride

    (2S,5R)-5-Hydroxylysine dihydrochloride

    Endogenous Metabolite Others
    L-hydroxylysine dihydrochloride ((2S,5R)-5-Hydroxylysine dihydrochloride), an amino acid, is exclusive to collagen protein, which is formed by posttranslational hydroxylation of some lysine residues.
  • HY-B2246A
    D-Carnitine hydrochloride

    (S)-Carnitine hydrochloride

    Endogenous Metabolite Metabolic Disease
    D-Carnitine hydrochloride ((S)-Carnitine Hydrochloride) has been used to study sulfur factor transporter SLC22A4 and carnitine transporter SLC22A5 in ergot. D-Carnitine hydrochloride is also used to get palmitic acid into mitochondria.
  • HY-B0161A
    Duloxetine hydrochloride

    (S)-Duloxetine hydrochloride; LY-248686 hydrochloride

    Serotonin Transporter Neurological Disease
    Duloxetine hydrochloride ((S)-Duloxetine hydrochloride) is a serotonin-norepinephrine reuptake inhibitor (SNRI) with a Ki of 4.6 nM, used for treatment of major depressive disorder and generalized anxiety disorder (GAD).
  • HY-78847
    2R,4S-Sacubitril

    Others Cardiovascular Disease
    2R,4S-Sacubitril is the impurity of Sacubitril. Sacubitril is approved by the Food and Drug Administration for use in combination with valsartan for the treatment of patients with heart failure.
  • HY-N1467
    (-​)​-​α-​Terpineol

    (S​)​-​α-​Terpineol

    Others Others
    (-)-α-Terpineol ((S)-α-Terpineol), a monoterpene compound, is one of important aroma compounds in white wines.
  • HY-N2380
    N-Benzoyl-(2R,3S)-3-phenylisoserine

    Others Cancer
    N-Benzoyl-(2R,3S)-3-phenylisoserine is a Taxol C-13 Side Chain and crucial for the strong antitumor activity of Taxol.
  • HY-17021B
    Esomeprazole potassium salt

    (S)-Omeprazole potassium salt; (-)-Omeprazole potassium salt

    Proton Pump Cancer Endocrinology Inflammation/Immunology
    Esomeprazole potassium salt ((S)-Omeprazole potassium salt) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H +, K +-ATPase in gastric parietal cells. Esomeprazole potassium salt has the potential for symptomatic gastroesophageal reflux disease research.
  • HY-17380
    (S)-Timolol Maleate

    L-714,465 Maleate; MK 950

    Adrenergic Receptor Neurological Disease Cardiovascular Disease
    (S)-Timolol Maleate (L-714,465 Maleate) is a non-cardioselective hydrophilic β-adrenoceptor blocker. (S)-Timolol Maleate is widely used as standard medication for intraocular pressure (glaucoma) by preventing the production of aqueous humor. (S)-Timolol Maleate can be used for hypertension, angina pectoris and myocardial infarction.
  • HY-N0455
    L-Arginine

    (S)-(+)-Arginine

    NO Synthase Endogenous Metabolite Cardiovascular Disease
    L-Arginine ((S)-(+)-Arginine) is the substrate for the endothelial nitric oxide synthase (eNOS) to generate NO. L-Arginine is transported into vascular smooth muscle cells by the cationic amino acid transporter family of proteins where it is metabolized to nitric oxide (NO), polyamines, or L-proline.
  • HY-141317
    S-acetyl-PEG3-phosphonic acid ethyl ester

    PROTAC Linker Cancer
    S-acetyl-PEG3-phosphonic acid ethyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
  • HY-132094
    Azido-PEG9-S-methyl ethanethioate

    PROTAC Linker Cancer
    Azido-PEG9-S-methyl ethanethioate is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
  • HY-132093
    Azido-PEG5-S-methyl ethanethioate

    PROTAC Linker Cancer
    Azido-PEG5-S-methyl ethanethioate is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
  • HY-G0014
    Quetiapine sulfoxide

    Quetiapine S-oxide

    Drug Metabolite Neurological Disease
    Quetiapine sulfoxide (Quetiapine S-oxide) is a main metabolite of Quetiapinem. Quetiapine is a second-generation antipsychotic. Quetiapine is a 5-HT receptors agonist and a dopamine receptor antagonist.
  • HY-G0014B
    Quetiapine sulfoxide hydrochloride

    Quetiapine S-oxide hydrochloride

    Drug Metabolite Neurological Disease
    Quetiapine sulfoxide hydrochloride (Quetiapine S-oxide hydrochloride) is a main metabolite of Quetiapinem. Quetiapine is a second-generation antipsychotic. Quetiapine is a 5-HT receptors agonist and a dopamine receptor antagonist.
  • HY-G0014A
    Quetiapine sulfoxide dihydrochloride

    Quetiapine S-oxide dihydrochloride

    Drug Metabolite Neurological Disease
    Quetiapine sulfoxide dihydrochloride (Quetiapine S-oxide dihydrochloride) is a main metabolite of Quetiapinem. Quetiapine is a second-generation antipsychotic. Quetiapine is a 5-HT receptors agonist and a dopamine receptor antagonist.
  • HY-131345A
    (S)-PI3Kα-IN-4

    PI3K Cancer
    (S)-PI3Kα-IN-4 is a potent inhibitor of PI3Kα, with an IC50 of 2.3 nM. (S)-PI3Kα-IN-4 shows 38.3-, 4.25-, and 4.93-fold selectivity for PI3Kα over PI3Kβ, PI3Kδ, and PI3Kγ, respectively. (S)-PI3Kα-IN-4 can be used for the research of cancer.
  • HY-19322C
    (1S,3R,5R)-PIM447 dihydrochloride

    (1S,3R,5R)-LGH447 dihydrochloride

    Pim Cancer
    (1S,3R,5R)-PIM447 (dihydrochloride) an PIM inhibitor extracted from patent US 20100056576 A1, compound example 72, has IC50 values of 0.095 μM for Pim1, 0.522 μM for Pim2 and 0.369 μM for Pim3.
  • HY-19487A
    Ribocil B

    Ribocil S enantiomer; ent-Ribocil A

    Bacterial Infection
    Ribocil-B is the active S-isomer of ribocil which can inhibit flavin mononucleotide (FMN) with a KD of 6.6 nM.
  • HY-106376
    DL-Buthionine-(S,R)-sulfoximine

    Buthionine sulfoximine; BSO

    Ferroptosis Cancer
    DL-Buthionine-(S,R)-sulfoximine is a potent inhibitor of glutamylcysteine synthetase biosynthesis.
  • HY-19528
    SAH

    SAH (S-Adenosylhomocysteine)

    Endogenous Metabolite Metabolic Disease
    SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine. SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC50 of 0.9 µM.
  • HY-103608
    (S,R,S)-AHPC-(C3-​PEG)​2-​C6-​Cl

    VHL Ligand-Linker Conjugates 11; E3 ligASe Ligand-Linker Conjugates 11

    E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-(C3-​PEG)​2-​C6-​Cl is a small molecule HaloPROTAC that incorporates the (S,R,S)-AHPC based VHL ligand and 2-unit PEG linker. (S,R,S)-AHPC-(C3-​PEG)​2-​C6-​Cl is capable of inducing the degradation of GFP-HaloTag7 in cell-based assays.
  • HY-13650
    Indisulam

    E 7070

    Carbonic Anhydrase Cancer
    Indisulam (E 7070) is a carbonic anhydrase inhibitor with anticancer activity. Indisulam (E 7070) is a sulfonamide agent that targets the G1 phase of the cell cycle. Indisulam (E 7070) causes a blockade in the G1/S transition through inhibition of the activation of both CDK2 and cyclin E. Indisulam (E 7070) targets splicing by inducing RBM39 degradation via recruitment to DCAF15.
  • HY-111826
    γ-Glutamyl-S-1-propenyl cysteine

    Others Others
    γ-Glutamyl-S-1-propenyl cysteine is a compound isolated from garlic.
  • HY-106376B
    DL-Buthionine-(S,R)-sulfoximine hydrochloride

    Buthionine sulfoximine hydrochloride; BSO hydrochloride

    Ferroptosis Cancer
    DL-Buthionine-(S,R)-sulfoximine hydrochloride (Buthionine sulfoximine hydrochloride) is a potent inhibitor of glutamylcysteine synthetase biosynthesis.
  • HY-14417A
    (1R,2S)-VU0155041

    mGluR Neurological Disease
    (1R,2S)-VU0155041, Cis regioisomer of VU0155041, is a partial mGluR4 agonist with an EC50 of 2.35 μM.
  • HY-W008437
    (S)-2-Amino-3-(4-hydroxy-3,5-diiodophenyl)propanoic acid dihydrate

    Endogenous Metabolite Metabolic Disease
    (S)-2-Amino-3-(4-hydroxy-3,5-diiodophenyl)propanoic acid dihydrate is an endogenous metabolite.
  • HY-10372
    PP121

    mTOR PDGFR VEGFR Src Apoptosis Cancer
    PP121 is a multi-targeted kinase inhibitor with IC50s of 10, 60, 12, 14, 2 nM for mTOR, DNK-PK, VEGFR2, Src, PDGFR, respectively.
  • HY-10501
    SU14813

    PDGFR VEGFR c-Kit Cancer
    SU14813 is a multi-targeted receptor tyrosine kinases inhibitor with IC50s of 50, 2, 4, 15 nM for VEGFR2, VEGFR1, PDGFRβ and KIT.
  • HY-10501A
    SU14813 maleate

    PDGFR VEGFR c-Kit Cancer
    SU14813 maleate is a multi-targeted receptor tyrosine kinases inhibitor with IC50s of 50, 2, 4, 15 nM for VEGFR2, VEGFR1, PDGFRβ and KIT.
  • HY-B1532
    Anabasine

    (S)-Anabasine; (+)-Anabasine

    nAChR Neurological Disease
    Anabasine ((S)-Anabasine) is an alkaloid that found as a minor component in tobacco (Nicotiana). Anabasine is a botanical pesticide nicotine, acts as a full agonist of nicotinic acetylcholine receptors (nAChRs). Anabasine induces depolarization of TE671 cells endogenously expressing human fetal muscle-type nAChRs (EC50=0.7 µM).
  • HY-W014928
    Anabasine hydrochloride

    (S)-Anabasine hydrochloride; (+)-Anabasine hydrochloride

    nAChR Neurological Disease
    Anabasine ((S)-Anabasine) hydrochloride is an alkaloid that found as a minor component in tobacco (Nicotiana). Anabasine is a botanical pesticide nicotine, acts as a full agonist of nicotinic acetylcholine receptors (nAChRs). Anabasine induces depolarization of TE671 cells endogenously expressing human fetal muscle-type nAChRs (EC50=0.7 µM).
  • HY-116463A
    (2R,3S)-E1R

    Sigma Receptor Neurological Disease
    (2R,3S)-E1R (Compound 2c) is an enantiomer of E1R. (2R,3S)-E1R is a sigma-1 receptor positive allosteric modulator (Sig1R PAM) for the treatment of cognition/memory disorders.
  • HY-44688
    S.pombe lumazine synthase-IN-1

    Bacterial Fungal Infection
    S.pombe lumazine synthase-IN-1 is an inhibitor of lumazine synthases with Ki values of 243 μM and 9.6 μM for Schizosaccharomyces pombe and Mycobacterium tuberculosis lumazine synthases, respectively.
  • HY-103599
    (S,R,S)-AHPC-PEG2-N3

    VH032-PEG2-N3; VHL Ligand-Linker Conjugates 6; E3 ligASe Ligand-Linker Conjugates 13

    E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-PEG2-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 2-unit PEG linker used in PROTAC technology.
  • HY-103604
    (S,R,S)-AHPC-PEG4-NH2 hydrochloride

    VH032-PEG4-NH2 hydrochloride; VHL Ligand-Linker Conjugates 4 hydrochloride; E3 ligASe Ligand-Linker Conjugates 7

    E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-PEG4-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 4-unit PEG linker used in PROTAC technology.
  • HY-103601
    (S,R,S)-AHPC-PEG4-N3

    VH032-PEG4-N3; VHL Ligand-Linker Conjugates 5; E3 ligASe Ligand-Linker Conjugates 4

    E3 Ligase Ligand-Linker Conjugate Others
    (S,R,S)-AHPC-PEG4-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 4-unit PEG linker used in PROTAC technology.
  • HY-103600
    (S,R,S)-AHPC-PEG1-N3

    VH032-PEG1-N3; VHL Ligand-Linker Conjugates 9; E3 ligASe Ligand-Linker Conjugates 3

    E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-PEG1-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 1-unit PEG linker used in PROTAC technology.
  • HY-103598
    (S,R,S)-AHPC-PEG3-N3

    VH032-PEG3-N3; VHL Ligand-Linker Conjugates 8; E3 ligASe Ligand-Linker Conjugates 12

    E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-PEG3-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 3-unit PEG linker used in PROTAC technology.
  • HY-103602
    (S,R,S)-AHPC-PEG3-NH2 hydrochloride

    VH032-PEG3-NH2 hydrochloride; VHL Ligand-Linker Conjugates 1 hydrochloride; E3 ligASe Ligand-Linker Conjugates 5

    E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-PEG3-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 3-unit PEG linker used in PROTAC technology.
  • HY-B0168B
    Milnacipran ((1S-cis) hydrochloride)

    Levomilnacipran hydrochloride; F-2695 hydrochloride

    Serotonin Transporter Neurological Disease
    Milnacipran (1S-cis) hydrochloride is a serotonin-norepinephrine reuptake inhibitor (SNRI), used in the clinical treatment of fibromyalgia.
  • HY-130271
    (S,R,S)-AHPC-PEG5-COOH

    VH032-PEG5-COOH; VHL Ligand-Linker Conjugates 16; E3 LigASe Ligand-Linker Conjugates 58

    E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-PEG5-COOH (VH032-PEG5-COOH) is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 5-unit PEG linker used in PROTAC technology.
  • HY-18099A
    S1RA hydrochloride

    E-52862 hydrochloride

    Sigma Receptor Neurological Disease
    S1RA hydrochloride (E-52862 hydrochloride) is a potent and selective sigma-1 receptor(σ1R, Ki=17 nM) antagonist, showed good selectivity against σ2R (Ki > 1000 nM).
  • HY-132103
    NHS ester-PEG3-S-methyl ethanethioate

    PROTAC Linker Cancer
    NHS ester-PEG3-S-methyl ethanethioate is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
  • HY-14744A
    Levamlodipine besylate

    (S)-Amlodipine besylate; Levoamlodipine besylate

    Calcium Channel Cardiovascular Disease
    Levamlodipine besylate ((S)-Amlodipine besylate) is a powerful dihydropyridine calcium channel blocker, possessing vasodilation properties and used in the treatment of hypertension and angina.
  • HY-17374
    Benfotiamine

    S-Benzoylthiamine O-monophosphate

    Others Neurological Disease
    Benfotiamine (S-Benzoylthiamine O-monophosphate) is an analog of vitamin B1 with higher absorption and bioavailability than vitamin B1, and is commonly used as a food supplement for diabetic complications. Benfotiamine exhibits direct antioxidative capacity and prevents induction of DNA damage.
  • HY-101671
    S-methyl-KE-298

    M-2

    MMP Drug Metabolite Inflammation/Immunology
    S-methyl-KE-298 is an active metabolite of KE-298. KE-298 inhibits matrix metalloproteinase (MMP-1) production from rheumatoid arthritis (RA) synovial cells.
  • HY-17023
    Esomeprazole sodium

    (S)-Omeprazole sodium; (-)-Omeprazole sodium

    Proton Pump Endocrinology
    Esomeprazole sodium ((S)-Omeprazole sodium) is a potent and orally active proton pump inhibitor. Esomeprazole reduces acid secretion through inhibition of the H +, K +-ATPase in gastric parietal cells. Esomeprazole acts as an exosome inhibitor by blocking the exosome release via the inhibition of V-H +-ATPases. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research.
  • HY-121526
    S-Nitroso-N-acetyl-DL-penicillamine

    SNAP

    NO Synthase Cardiovascular Disease
    S-Nitroso-N-acetyl-DL-penicillamine (SNAP) is a nitric oxide donor and acts as a stable inhibitor of platelet aggregation.
  • HY-103606
    (S,R,S)-AHPC-PEG6-C4-Cl

    VH032-PEG6-C4-Cl; VHL Ligand-Linker Conjugates 10; E3 ligASe Ligand-Linker Conjugates 9

    PROTAC Cancer
    (S,R,S)-AHPC-PEG6-C4-Cl is a small molecule HaloPROTAC that incorporates the (S,R,S)-AHPC based VHL ligand and 6-unit PEG linker. (S,R,S)-AHPC-PEG6-C4-Cl is capable of inducing the degradation of GFP-HaloTag7 in cell-based assays.
  • HY-103607
    (S,R,S)-AHPC-PEG2-C4-Cl

    VH032-PEG2-C4-Cl; VHL Ligand-Linker Conjugates 7; E3 ligASe Ligand-Linker Conjugates 10

    PROTAC Cancer
    (S,R,S)-AHPC-PEG2-C4-Cl is a small molecule HaloPROTAC that incorporates the (S,R,S)-AHPC based VHL ligand and 2-unit PEG linker. (S,R,S)-AHPC-PEG2-C4-Cl is capable of inducing the degradation of GFP-HaloTag7 in cell-based assays.
  • HY-114668
    Camptothecin-20(S)-O-propionate

    Camptothecin-20-O-propionate

    Topoisomerase Cancer
    Camptothecin-20(S)-O-propionate (CZ48), the C20-propionate ester of CPT, is a highly effective anticancer agent. Camptothecin-20(S)-O-propionate (CZ48) is a topoisomerase-Ι inhibitor.
  • HY-13716
    Noscapine

    (S,R)-Noscapine

    Opioid Receptor Apoptosis Cancer Inflammation/Immunology Neurological Disease
    Noscapine ((S,R)-Noscapine) is an orally active phthalideisoquinoline alkaloid with potent antitussive. Noscapine exerts its antitussive effects by activating sigma opioid receptors and is a non-competitive Bradykinin inhibitor. Noscapine disrupts microtubule dynamics, induces mitotic arrest and apoptosis. Noscapine possesses anticancer, neuroprotective, anti-inflammatory activities, and can cross the blood-brain barrier.
  • HY-13716A
    Noscapine hydrochloride

    (S,R)-Noscapine hydrochloride

    Opioid Receptor Apoptosis Cancer Inflammation/Immunology Neurological Disease
    Noscapine hydrochloride ((S,R)-Noscapine hydrochloride) is an orally active phthalideisoquinoline alkaloid with potent antitussive. Noscapine hydrochloride exerts its antitussive effects by activating sigma opioid receptors and is a non-competitive Bradykinin inhibitor. Noscapine hydrochloride disrupts microtubule dynamics, induces mitotic arrest and apoptosis. Noscapine hydrochloride possesses anticancer, neuroprotective, anti-inflammatory activities, and can crosse the blood-brain barrier.
  • HY-140593
    m-PEG3-S-PEG2-OH

    PROTAC Linker Cancer
    m-PEG3-S-PEG2-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
  • HY-140591
    Azido-PEG3-S-PEG4-propargyl

    PROTAC Linker Cancer
    Azido-PEG3-S-PEG4-propargyl is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
  • HY-140594
    m-PEG3-S-PEG4-propargyl

    PROTAC Linker Cancer
    m-PEG3-S-PEG4-propargyl is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.
  • HY-140599
    Propargyl-PEG4-S-PEG4-Boc

    PROTAC Linker Cancer
    Propargyl-PEG4-S-PEG4-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
  • HY-140598
    Propargyl-PEG4-S-PEG4-propargyl

    PROTAC Linker Cancer
    Propargyl-PEG4-S-PEG4-propargyl is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
  • HY-140590
    Azido-PEG3-S-PEG3-azide

    PROTAC Linker Cancer
    Azido-PEG3-S-PEG3-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
  • HY-103602A
    (S,R,S)-AHPC-PEG3-NH2

    VH032-PEG3-NH2; VHL Ligand-Linker Conjugates 1; E3 ligASe Ligand-Linker Conjugates 5 Free BASe

    E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-PEG3-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 3-unit PEG linker used in PROTAC technology.
  • HY-103604A
    (S,R,S)-AHPC-PEG4-NH2

    VH032-PEG4-NH2; VHL Ligand-Linker Conjugates 4 ; E3 ligASe Ligand-Linker Conjugates 7 Free BASe

    E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-PEG4-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 4-unit PEG linker used in PROTAC technology.
  • HY-13263
    CHIR-124

    Checkpoint Kinase (Chk) FLT3 PDGFR Apoptosis Cancer
    CHIR-124 is a potent and selective Chk1 inhibitor with IC50 of 0.3 nM, and also potently targets PDGFR and FLT3 with IC50s of 6.6 nM and 5.8 nM.
  • HY-12423A
    TAS-115 mesylate

    TAS-115 methanesulfonate

    VEGFR c-Met/HGFR Cancer
    TAS-115 mesylate is a potent VEGFRand hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase inhibitor, with IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectively.
  • HY-12423
    TAS-115

    VEGFR c-Met/HGFR Cancer
    TAS-115 is a potent VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase inhibitor with IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectively.
  • HY-112900
    DC41SMe

    ADC Cytotoxin Cancer
    DC41SMe, a DC1 derivative, shows cytotoxicity in Ramos, Namalwa, and HL60/s cells with IC50s ranging from 18-25 pM. DC1, a simplified analogue of CC-1065, is an antibody conjugate of cytotoxic DNA alkylators for the targeted treatment of cancer.
  • HY-136592
    1-Hydroxy-ibuprofen

    COX Cancer Inflammation/Immunology
    1-Hydroxy Ibuprofen is a metabolite of Ibuprofen in P. australis. Ibuprofen is an anti-inflammatory inhibitor targeting COX-1 and COX-2 with IC50s of 13 μM and 370 μM, respectively.
  • HY-140596
    m-PEG3-S-PEG3-Boc

    PROTAC Linker Cancer
    m-PEG3-S-PEG3-Boc is a PEG- and Alkyl/ether -based PROTAC linker can be used in the synthesis of PROTACs.
  • HY-137430
    Aldumastat

    GLPG1972; S201086

    MMP Metabolic Disease
    Aldumastat (GLPG1972; S201086) is a potent, seletive and orally active ADAMTS-5 (IC50=19 nM) inhibitor, and has 8-fold seletivity over ADAMTS-4 (IC50=156 nM). Aldumastat has anticatabolic activity and is used for osteoarthritis research.
  • HY-100309
    9-amino-CPT

    9-amino-20(S)-camptothecin

    Topoisomerase Cancer
    9-amino-CPT (9-amino-20(S)-camptothecin) is a topoisomerase I inhibitor with potent anticancer activity.
  • HY-19717
    DCVC

    S-[(1E)-1,2-dichloroethenyl]--L-cysteine

    TNF Receptor Inflammation/Immunology
    DCVC (S-[(1E)-1,2-dichloroethenyl]--L-cysteine) is a bioactive metabolite of trichloroethylene (TCE). DCVC inhibits pathogen-stimulated pro-inflammatory cytokines IL-1β, IL-8, and TNF-α release from tissue cultures.
  • HY-103603
    (S,R,S)-AHPC-PEG2-NH2 hydrochloride

    VH032-PEG2-NH2 hydrochloride; VHL Ligand-Linker Conjugates 3 hydrochloride; E3 ligASe Ligand-Linker Conjugates 6

    E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-PEG2-NH2 hydrochloride (VH032-PEG2-NH2 hydrochloride) is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 2-unit PEG linker used in the synthesis of PROTACs.
  • HY-N0215
    L-Phenylalanine

    (S)-2-Amino-3-phenylpropionic acid

    Calcium Channel iGluR Endogenous Metabolite Metabolic Disease
    L-Phenylalanine ((S)-2-Amino-3-phenylpropionic acid) is an essential amino acid isolated from Escherichia coli. L-Phenylalanine is a α2δ subunit of voltage-dependent Ca + channels antagonist with a Ki of 980 nM. L-phenylalanine is a competitive antagonist for the glycine- and glutamate-binding sites of N-methyl-D-aspartate receptors (NMDARs) (KB of 573 μM ) and non-NMDARs, respectively. L-Phenylalanine is widely used in the production of food flavors and pharmaceuticals.
  • HY-10339
    KW-2449

    FLT3 FGFR Bcr-Abl Aurora Kinase Apoptosis Cancer
    KW-2449 is a multi-targeted kinase inhibitor of FLT3, ABL, ABL T315I and Aurora kinase with IC50s of 6.6, 14, 4 and 48 nM, respectively.
  • HY-126121
    2-Hydroxy Ibuprofen

    (±)-2-Hydroxy Ibuprofen

    COX Cancer Inflammation/Immunology
    2-Hydroxy Ibuprofen is a metabolite of Ibuprofen. Ibuprofen is an anti-inflammatory inhibitor targeting COX-1 and COX-2 with IC50s of 13 μM and 370 μM, respectively.
  • HY-100315
    Tyrosine kinase-IN-1

    VEGFR PDGFR FGFR Cardiovascular Disease
    Tyrosine kinase-IN-1 is a multi-targeted tyrosine kinase inhibitor with IC50s of 4, 20, 4, 2 nM for KDR, Flt-1, FGFR1 and PDGFRα, respectively.
  • HY-100096
    Emtricitabine S-oxide

    Emtricitabine sulfoxide; Emtricitabine Degradant-III

    HIV Reverse Transcriptase Infection
    Emtricitabine S-oxide (Emtricitabine sulfoxide) is a major degradation product of Emtricitabine. Emtricitabine is a potent nucleoside reverse transcriptase inhibitor used for the treatment of HIV infection.
  • HY-133152S
    Brexpiprazole S-oxide D8

    DM-3411 D8

    5-HT Receptor Dopamine Receptor Neurological Disease
    Brexpiprazole S-oxide D8 (DM-3411 D8) is a deuterium labeled Brexpiprazole S-oxide. Brexpiprazole S-oxide is a main metabolite of Brexpiprazole and is metabolized by cytochrome P450 3A4 (CYP3A4). Brexpiprazole is an atypical antipsychotic agent and a partial agonist of human 5-HT1A and dopamine receptor with Kis of 0.12 nM and 0.3 nM, respectively. Brexpiprazole is also a 5-HT2A receptor antagonist with a Ki of 0.47 nM.
  • HY-100218A
    RSL3

    (1S,3R)-RSL3

    Glutathione Peroxidase Ferroptosis Cancer
    RSL3 ((1S,3R)-RSL3) is an inhibitor of glutathione peroxidase 4 (GPX4) (ferroptosis activator), reduces the expression of GPX4 protein, and induces ferroptotic death of head and neck cancer cell. RSL3 increases the expression of p62 and Nrf2 and inactivates Keap1 in HN3-rslR cells.
  • HY-100560
    Abscisic acid

    (S)​-​(+)​-​Abscisic acid; ABA

    Endogenous Metabolite Proton Pump Metabolic Disease
    Abscisic acid ((S)-(+)-Abscisic acid), an orally active phytohormone in fruits and vegetables, is an endogenously produced mammalian hormone. Abscisic acid is a growth inhibitor and can regulate many aspects of plant growth and development. Abscisic acid inhibits proton pump (H +-ATPase) and leads to the plasma membrane depolarization in a Ca 2+-dependent manner. Abscisic acid, a LANCL2 natural ligand, is a potent insulin-sensitizing compound and has the potential for pre-diabetes, type 2 diabetes and metabolic syndrome.
  • HY-N5152
    (2′S)-4′-O-β-D-apiofuranosyl-(1→6)-O-β-D-glucopyranosylvisamminol

    Others Cancer
    (2′S)-4′-O-β-D-apiofuranosyl-(1→6)-O-β-D-glucopyranosylvisamminol is a chromone Glycoside that could be isolated from Roots of Saposhnikovia divaricate. (2′S)-4′-O-β-D-apiofuranosyl-(1→6)-O-β-D-glucopyranosylvisamminol exhibits weak anti-cancer activity in human cancer cell lines.
  • HY-120051
    Afizagabar

    S44819; Egis-13529

    GABA Receptor Neurological Disease
    Afizagabar (S44819) is a first-in-class, competitive, and selective antagonist at the GABA-binding site of the α5-GABAAR, with an IC50 of 585 nM for α5β2γ2 and a Ki of 66 nM for α5β3γ2. Afizagabar enhances hippocampal synaptic plasticity and exhibits pro-cognitive efficacy.
  • HY-12316
    20(S)-Hydroxycholesterol

    20α-Hydroxycholesterol

    Smo Endogenous Metabolite Cancer
    20(S)-hydroxyCholesterol (20α-Hydroxycholesterol) is an allosteric activator of the oncoprotein smoothened (Smo) that activates the hedgehog (Hh) signaling pathway with an EC50 of 3 μM in a gene transcription reporter assay using NIH3T3 cells.
  • HY-123275A
    H-D-Phe-Pip-Arg-pNA hydrochloride

    S-2238 hydrochloride

    Others Others
    H-D-Phe-Pip-Arg-pNA (S-2238) hydrochloride, a chromogenic substrate, is patterned after the N-terminal portion of the A alpha chain of fibrinogen, which is the natural substrate of thrombin. H-D-Phe-Pip-Arg-pNA hydrochloride is specific for thrombin and is used to measure antithrombin-heparin cofactor (AT-III). The AT-III assay using H-D-Phe-Pip-Arg-pNA hydrochloride is sensitive, accurate, and easy to perform.
  • HY-123275C
    H-D-Phe-Pip-Arg-pNA dihydrochloride

    S-2238 dihydrochloride

    Others Others
    H-D-Phe-Pip-Arg-pNA (S-2238) dihydrochloride, a chromogenic substrate, is patterned after the N-terminal portion of the A alpha chain of fibrinogen, which is the natural substrate of thrombin. H-D-Phe-Pip-Arg-pNA dihydrochloride is specific for thrombin and is used to measure antithrombin-heparin cofactor (AT-III). The AT-III assay using H-D-Phe-Pip-Arg-pNA dihydrochloride is sensitive, accurate, and easy to perform.
  • HY-131259
    Ibuprofen Impurity F

    COX Inflammation/Immunology
    Ibuprofen Impurity F is an Ibuprofen impurity. Ibuprofen is an anti-inflammatory inhibitor targeting COX-1 and COX-2 with IC50s of 13 μM and 370 μM, respectively.
  • HY-131258
    Ibuprofen impurity 1

    COX Inflammation/Immunology
    Ibuprofen impurity 1 is an Ibuprofen impurity. Ibuprofen is an anti-inflammatory inhibitor targeting COX-1 and COX-2 with IC50s of 13 μM and 370 μM, respectively.
  • HY-131260
    Ibuprofen Impurity K

    COX Inflammation/Immunology
    Ibuprofen Impurity K is an Ibuprofen impurity. Ibuprofen is an anti-inflammatory inhibitor targeting COX-1 and COX-2 with IC50s of 13 μM and 370 μM, respectively.
  • HY-18179
    AZD2932

    PDGFR VEGFR FLT3 c-Kit Cancer
    AZD2932 is a potent and multi-targeted kinase inhibitor VEGFR2, PDGFβ, Flt-3 and c-Kit with IC50s of 8, 4, 7 and 9 nM in cell assay, respectively.
  • HY-103603A
    (S,R,S)-AHPC-PEG2-NH2

    VH032-PEG2-NH2 ; VHL Ligand-Linker Conjugates 3 ; E3 ligASe Ligand-Linker Conjugates 6 Free BASe

    E3 Ligase Ligand-Linker Conjugate Cancer
    (S,R,S)-AHPC-PEG2-NH2 (VH032-PEG2-NH2) is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 2-unit PEG linker used in the synthesis of PROTACs.
  • HY-140592
    Azido-PEG3-S-PEG4-t-butyl ester

    PROTAC Linker Cancer
    Azido-PEG3-S-PEG4-t-butyl ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
  • HY-103605
    (S,R,S)-AHPC-C6-PEG3-C4-Cl

    VH032-C6-PEG3-C4-Cl; VHL Ligand-Linker Conjugates 12; E3 ligASe Ligand-Linker Conjugates 8

    PROTAC Cancer
    (S,R,S)-AHPC-C6-PEG3-C4-Cl is a small molecule HaloPROTAC that incorporates the (S,R,S)-AHPC based VHL ligand and 3-unit PEG linker. (S,R,S)-AHPC-C6-PEG3-C4-Cl is capable of inducing the degradation of GFP-HaloTag7 in cell-based assays.
  • HY-106376A
    L-Buthionine-(S,R)-sulfoximine

    L-Buthionine sulfoximine; L-BSO

    Ferroptosis Cancer
    L-Buthionine-(S,R)-sulfoximine is a cell-permeable, potent, fast acting and irreversible inhibitor of g-glutamylcysteine synthetase and depletes cellular glutathione levels. The IC50 value of L-Buthionine-(S,R)-sulfoximine on melanoma, breast and ovarian tumor specimens are 1.9 μM, 8.6 μM, and 29 μM, respectively.
  • HY-101354
    R-IMPP

    PF-00932239

    Ser/Thr Protease Cancer Cardiovascular Disease
    R-IMPP (PF-00932239) is an anti-secretagogue of PCSK9 (IC50=4.8 μM), which targets the 80S ribosome to inhibit PCSK9 protein translation.
  • HY-121765
    Dacisteine

    N,S-Diacetyl-L-cysteine

    Endogenous Metabolite Metabolic Disease
    Dacisteine (N,S-Diacetyl-L-cysteine) is a cysteine derivative and displays a less New Delhi metallo-beta-lactamase-1 (NDM-1) inhibitor with an IC50 value of 1000 μM. Dacisteine can be used for the treatment of cardiovascular and cerebrovascular diseases caused by platelet aggregation.
  • HY-133021
    Arazine

    N-Acetyl-S-farnesyl-L-cysteine

    Others Inflammation/Immunology
    Arazine (N-Acetyl-S-farnesyl-L-cysteine) is a cell-permeable modulator of G protein and G-protein coupled receptor signaling. Arazine can be a a substrate for isoprenylcysteine methyltransferase by competing with prenylated G protein or its receptors site.
  • HY-41094
    cis-Isolimonenol

    (1S,4R)-p-Mentha-2,8-dien-1-ol

    Others Others
    cis-Isolimonenol ((1S,4R)-p-Mentha-2,8-dien-1-ol) is a chemical composition of essential oil.
  • HY-106376C
    L-Buthionine-(S,R)-sulfoximine hydrochloride

    L-Buthionine sulfoximine hydrochloride; L-BSO hydrochloride

    Ferroptosis Cancer Metabolic Disease
    L-Buthionine-(S,R)-sulfoximine hydrochloride is a cell-permeable, potent, fast acting, orally active and irreversible inhibitor of g-glutamylcysteine synthetase and depletes cellular glutathione levels. The IC50 value of L-Buthionine-(S,R)-sulfoximine on melanoma, breast and ovarian tumor specimens are 1.9 μM, 8.6 μM, and 29 μM, respectively.
  • HY-13017
    Ivacaftor

    VX-770

    CFTR Autophagy Endocrinology
    Ivacaftor (VX-770) is a potent and orally bioavailable CFTR potentiator, targeting G551D-CFTR and F508del-CFTR with EC50s of 100 nM and 25 nM, respectively.
  • HY-10065
    Axitinib

    AG-013736

    VEGFR PDGFR Cancer
    Axitinib is a multi-targeted tyrosine kinase inhibitor with IC50s of 0.1, 0.2, 0.1-0.3, 1.6 nM for VEGFR1, VEGFR2, VEGFR3 and PDGFRβ, respectively.
  • HY-19567
    PK 11195

    RP 52028

    Parasite Infection
    PK 11195 (RP 52028) is a ligand of translocator protein (TSPO), which targets Leishmania chemotherapy, with IC50s of 14.2 μM, 8.2 μM, 3.5 μM for L. amazonensis, L. major and L. braziliensis, respectively.
  • HY-80002
    BMX-IN-1

    BMX kinASe inhibitor

    Btk BMX Kinase Cancer
    BMX-IN-1 is a selective, irreversible inhibitor of bone marrow tyrosine kinase on chromosome X (BMX) that targets Cys 496 in the BMX ATP binding domain with an IC50 of 8 nM, also targets the related Bruton’s tyrosine kinase (BTK) with an IC50 value of 10.4 nM, but is more than 47-656-fold less potent against Blk, JAK3, EGFR, Itk, or Tec activity.
  • HY-17021A
    Esomeprazole magnesium salt

    (S)-Omeprazole magnesium salt; (-)-Omeprazole magnesium salt

    Proton Pump Cancer Endocrinology Inflammation/Immunology
    Esomeprazole magnesium salt ((S)-Omeprazole magnesium salt) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H +, K +-ATPase in gastric parietal cells. Esomeprazole magnesium salt has the potential for symptomatic gastroesophageal reflux disease research.
  • HY-133152
    Brexpiprazole S-oxide

    DM-3411

    5-HT Receptor Dopamine Receptor Neurological Disease
    Brexpiprazole S-oxide (DM-3411) is a main metabolite of Brexpiprazole and is metabolized by cytochrome P450 3A4 (CYP3A4). Brexpiprazole is an atypical antipsychotic agent and a partial agonist of human 5-HT1A and dopamine receptor with Kis of 0.12 nM and 0.3 nM, respectively. Brexpiprazole is also a 5-HT2A receptor antagonist with a Ki of 0.47 nM.
  • HY-127146
    Platensimycin

    Antibiotic Bacterial
    Platensimycin is an antibiotic produced by S. platensis that inhibits gram-positive bacteria by selectively inhibiting cellular lipid biosynthesis (IC50=0.1 μM). Platensimycin targets the β-ketoacyl-acyl-carrier-protein synthase I/II, FabF/B, an enzyme that participates in the biosynthesis of fatty acids (IC50s=48 nM and 160 nM for S.aureus and E.coli enzymes, respectively). Platensimycin is a promising agent for overcoming antibiotic resistance.
  • HY-133537
    Hygrolidin

    Antibiotic Fungal ADC Cytotoxin Cancer Infection
    Hygrolidin is a 16-membered macrolide antibiotic produced by Streptomyces hygroscopicus D-1166. Hygrolidin has anti-fungus activity against Valsa ceratosperma. Hygrolidin induces p21 expression and abrogates cell cycle progression at G1 and S phases. Hygrolidin has antitumor activity.
  • HY-N1374
    Magnolin

    ERK Inflammation/Immunology
    Magnolin, a major component of Magnolia flos (Shin-Yi), inhibits the Ras/ERKs/RSK2 signaling axis by targeting the active pocket of ERK1 and ERK2 with IC50s of 87 nM and 16.5 nM, respectively.
  • HY-15749
    XL228

    Aurora Kinase Bcr-Abl IGF-1R Src Cancer Endocrinology
    XL228 is a multi-targeted tyrosine kinase inhibitor with IC50s of 5, 3.1, 1.6, 6.1, 2 nM for Bcr-Abl, Aurora A, IGF-1R, Src and Lyn, respectively.
  • HY-101877
    Statine

    (3S,4S)-Statine; (S,S)-Statine

    Others Endocrinology
    Statine is an unusual amino acid that occurs twice in the sequence of pepstatin, a protease inhibitor that is active against pepsin and other acid proteases.
  • HY-P0109A
    Z-FA-FMK

    (1S)-Z-FA-FMK

    SARS-CoV Infection
    Z-FA-FMK ((1S)-Z-FA-FMK; Compound 6) is a broad-spectrum halomethyl ketone inhibitor sgainst Coronavirus (SARS-CoV) main protease 3CL with a Ki of 25.7 μM.
  • HY-17397
    Strontium Ranelate

    Distrontium renelate; S12911

    CaSR Metabolic Disease
    Strontium Ranelate (S12911) is an antiosteoporotic agent that acts by reducing bone resorption and promoting bone formation, thereby inducing a positive bone balance. Strontium Ranelate also can activate the calcium-sensing receptor (CaSR) in non skeletal cells, resulting in the activation of inositol 1, 4, 5-triphosphate production and mitogen-activated protein kinase signaling.
  • HY-W011241
    Cinchonine hydrochloride

    (8R,9S)-Cinchonine hydrochloride; LA40221 hydrochloride

    Apoptosis Parasite Cancer
    Cinchonine hydrochloride ((8R,9S)-Cinchonine hydrochloride) is a natural alkaloid present in Cinchona bark, with antimalarial activity. Cinchonine hydrochloride activates endoplasmic reticulum (ER) stress-induced apoptosis in human liver cancer cells.
  • HY-136557
    PAD2-IN-1

    Protein Arginine Deiminase Cancer Inflammation/Immunology
    PAD2-IN-1, a benzimidazole-based derivative, is a potent and selective protein arginine deiminase 2 (PAD2) inhibitor. PAD2-IN-1 shows superior selectivity for PAD2 over PAD4 (95-fold) and PAD3 (79-fold).
  • HY-131704
    FGFR4-IN-5

    FGFR Cancer
    FGFR4-IN-5 is a potent and selective covalent FGFR4 inhibitor with an IC50 of 6.5 nM. FGFR4-IN-5 exhibits strong anti-tumor activity in vivo and can be used for hepatocellular carcinoma research.
  • HY-140595
    m-PEG3-S-PEG1-C2-Boc

    PROTAC Linker Cancer
    m-PEG3-S-PEG1-C2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
  • HY-111950
    (-)-Ibuprofenamide

    (R)-Ibuprofenamide

    Others Inflammation/Immunology
    (-)-Ibuprofenamide is an amide prodrug of Ibuprofen with anti-inflammatory activity. Ibuprofen is an anti-inflammatory inhibitor targeting COX-1 and COX-2 with IC50s of 13 μM and 370 μM, respectively.
  • HY-134640
    AUTAC4

    Mitophagy Cancer Neurological Disease
    AUTAC4 is a mitochondria-targeting autophagy-targeting chimera (AUTAC). AUTAC4 downregulates cytosolic proteins and promotes targeted mitochondrial turnover via mitophagy.
  • HY-17038B
    Agomelatine (L(+)-Tartaric acid)

    S-20098 L(+)-Tartaric acid

    Melatonin Receptor 5-HT Receptor Neurological Disease
    Agomelatine L(+)-Tartaric acid (S-20098 L(+)-Tartaric acid) is a specific agonist of MT1 and MT2 receptors with Kis of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively. Agomelatine L(+)-Tartaric acid is a selective 5-HT2C receptor antagonist with pKis of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively.
  • HY-B1446
    Esomeprazole magnesium

    (S)-Omeprazole magnesium; (-)-Omeprazole magnesium

    Proton Pump Endocrinology
    Esomeprazole magnesium ((S)-Omeprazole magnesium) is a potent and orally active H +, K +-ATPase inhibitor. Esomeprazole magnesium has the potential for upper intestinal disorders and gastroesophageal reflux disease research. Esomeprazole magnesium acts as an exosome inhibitor by blocking the exosome release via the inhibition of V-H +-ATPases.
  • HY-12993
    RSV604

    A-60444

    RSV Infection
    RSV604 (A-60444) is an inhibitor of respiratory syncytial virus (RSV) replication. RSV604 targets the nucleocapsid protein, with a Kd of 1.6 μM. RSV604 displays submicromolar activity against numerous clinical isolates of both the A and B subtypes of RSV (average EC50s=0.8 μM).
  • HY-13070
    MK-8245

    Stearoyl-CoA Desaturase (SCD) Metabolic Disease
    MK-8245 is a potent, liver-targeted stearoyl-CoA desaturase (SCD) inhibitor, with IC50s of 1 nM for human SCD1 and 3 nM for both rat SCD1 and mouse SCD1, with antidiabetic and antidyslipidemic efficacy.
  • HY-B1227
    Carprofen

    COX FAAH Autophagy Inflammation/Immunology
    Carprofen is a nonsteroid anti-inflammatory agent, acts as a multi-target FAAH/COX inhibitor, with IC50s of 3.9 μM, 22.3 μM and 78.6 μM for COX-2, COX-1 and FAAH, respectively.
  • HY-124726
    Aumitin

    Autophagy Cancer Neurological Disease
    Aumitin is a diaminopyrimidine-based autophagy inhibitor which inhibits mitochondrial respiration by targeting complex I. Aumitin inhibits starvation- and rapamycin induced autophagy dose dependently with IC50s of 0.12 μM and 0.24 μM, respectively.
  • HY-10208
    Pazopanib

    GW786034

    VEGFR c-Kit PDGFR Autophagy FGFR Cancer
    Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with IC50s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.
  • HY-100550
    MSDC 0160

    Mitoglitazone; CAY10415

    Insulin Receptor Mitochondrial Metabolism Neurological Disease Endocrinology
    MSDC 0160 (Mitoglitazone) is a mitochondrial target of thiazolidinediones (mTOT)-modulating insulin sensitizer and a modulator of mitochondrial pyruvate carrier (MPC). MSDC 0160 is a thiazolidinedione (TZD) with antidiabetic and neuroprotective activities. MSDC 0160 has the potential for Alzheimer′s disease.
  • HY-109172
    Ezeprogind

    AZP-2006

    Amyloid-β Neurological Disease
    Ezeprogind (AZP-2006) is an orally active neurotrophic inducer. Ezeprogind targets all causes of neurodegeneration and is not only aiming at markers such as Abeta protein or tau protein. Ezeprogind is a potent neuroprotectant and can be used for the research of neurological disorders, including progressive supranuclear palsy (PSP), tauopathies, alzheimer’s and parkinson’s diseases, et al.
  • HY-121629
    PS210

    PDK-1 Cancer
    PS210 is a potent and selective PDK1 activator with a Kd of 3 μM and targets the PIF-binding pocket of PDK1. PS210 is inactive against other protein kinases, including PDK1 downstream signaling components such as S6K, PKB/Akt or GSK3. In cells, the prodrug of PS210 (PS423) acts as a substrate-selective inhibitor of PDK1, inhibiting the phosphorylation and activation of S6K.
  • HY-12047
    Ponatinib

    AP24534

    Bcr-Abl PDGFR VEGFR FGFR Src Autophagy Cancer
    Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively.
  • HY-P1268
    α-Conotoxin PIA

    nAChR Neurological Disease
    α-Conotoxin PIA is a nicotinic acetylcholine receptor (nAChR) antagonist that targets nAChR subtypes containing α6 and α3 subunits. α-Conotoxin PIA has the potential for the research of Parkinson’s disease, and schizophrenia。
  • HY-N2207
    rel-(8R,8'R)-Dimethyl-(7S,7'R)-bis(3,4-methylenedioxyphenyl)tetrahydro-furan

    Others Others
    rel-(8R,8'R)-Dimethyl-(7S,7'R)-bis(3,4-methylenedioxyphenyl)tetrahydro-furan is a chemical constituent of the fruit of Myristica fragrans.
  • HY-128428
    Carboprost

    15(S)-15-Methyl Prostaglandin F2α; 15-Methyl-PGF2α

    Others Endocrinology
    Carboprost (15(S)-15-Methyl Prostaglandin F2α) is a metabolically stable synthetic analog of prostaglandin F2α. Carboprost stimulates uterine contractions and induces abortion. Carboprost is used for postpartum hemorrhage due to uterine atony and for the termination of pregnancy in the second trimester.
  • HY-114236
    Ezeprogind disulfate

    AZP-2006 disulfate

    Amyloid-β Neurological Disease
    Ezeprogind (AZP-2006) disulfate is an orally active neurotrophic inducer. Ezeprogind disulfate targets all causes of neurodegeneration and is not only aiming at markers such as Abeta protein or tau protein. Ezeprogind disulfate is a potent neuroprotectant and can be used for the research of neurological disorders, including progressive supranuclear palsy (PSP), tauopathies, alzheimer’s and parkinson’s diseases, et al.
  • HY-P1268A
    α-Conotoxin PIA TFA

    nAChR Neurological Disease
    α-Conotoxin PIA TFA is a nicotinic acetylcholine receptor (nAChR) antagonist that targets nAChR subtypes containing α6 and α3 subunits. α-Conotoxin PIA has the potential for the research of Parkinson’s disease, and schizophrenia。
  • HY-16900
    Rolipram

    (R,S)-Rolipram; SB 95952; ZK 62711

    Phosphodiesterase (PDE) Bacterial HIV Neurological Disease Cancer
    Rolipram is a selective phosphodiesterases PDE4 inhibitor with IC50s of 3 nM, 130 nM and 240 nM for PDE4A, PDE4B, and PDE4D, respectively.
  • HY-16938
    5'-Methylthioadenosine

    5'-(Methylthio)-5'-deoxyadenosine; 5'-Deoxy-5'-(methylthio)adenosine; 5'-S-Methyl-5'-thioadenosine

    Endogenous Metabolite Metabolic Disease
    5'-Methylthioadenosine is produced from S-adenosylmethionine and behaves as a powful inhibitory product.
  • HY-114414
    HDACs/mTOR Inhibitor 1

    HDAC mTOR Apoptosis Cancer
    HDACs/mTOR Inhibitor 1 is a dual Histone Deacetylases (HDACs) and mammalian target of Rapamycin (mTOR) target inhibitor for treating hematologic malignancies, with IC50s of 0.19 nM, 1.8 nM, 1.2 nM and >500 nM for HDAC1, HDAC6, mTOR and PI3Kα, respectively. HDACs/mTOR Inhibitor 1 stimulates cell cycle arrest in G0/G1 phase and induce tumor cell apoptosis with low toxicity in vivo.
  • HY-10423
    OSI-027

    ASP7486

    mTOR Autophagy Cancer
    OSI-027 (ASP7486) is a potent, selective, orally active and ATP-competitive mTOR kinase activity inhibitor with an IC50 of 4 nM. OSI-027 targets both mTORC1 and mTORC2 with IC50s of 22 nM and 65 nM, respectively.
  • HY-13308
    Regorafenib Hydrochloride

    BAY 73-4506 hydrochloride

    VEGFR Autophagy PDGFR Raf RET Cancer
    Regorafenib Hydrochloride (BAY 73-4506 hydrochloride) is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively.
  • HY-10331A
    Regorafenib monohydrate

    BAY 73-4506 monohydrate

    VEGFR Autophagy PDGFR Raf RET Cancer
    Regorafenib monohydrate (BAY 73-4506 monohydrate) is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively.
  • HY-13488
    HG-10-102-01

    LRRK2 Neurological Disease
    HG-10-102-01 is a potent and selective inhibitor of wild-type LRRK2(IC50=23.3 nM) and the G2019S mutant(IC50=3.2 nM) IC50 Value: 23.3 nM (WT LRRK2); 3.2 nM (LRRK2 G2019S) [1] Target: LRRK2 HG-10-102-01 maintains the ability to potently inhibit the biochemical activity of wild-type and G2019S mutant LRRK2.
  • HY-B0187A
    Doripenem monohydrate

    S 4661 monohydrate

    Bacterial Antibiotic Infection
    Doripenem monohydrate is a new member of the carbapenem class of beta-lactam antibiotics with broad-spectrum coverage of Gram-positive, Gram-negative and anaerobic pathogens.
  • HY-B0187
    Doripenem

    S 4661

    Bacterial Antibiotic Infection
    Doripenem is a new member of the carbapenem class of beta-lactam antibiotics with broad-spectrum coverage of Gram-positive, Gram-negative and anaerobic pathogens.
  • HY-32291
    Methyl L-pyroglutamate

    (S)-Methyl 5-oxopyrrolidine-2-carboxylate; L-Pyroglutamic acid methyl ester

    Others Others
    Methyl L-pyroglutamate ((S)-Methyl 5-oxopyrrolidine-2-carboxylate;L-Pyroglutamic acid methyl ester) is isolated from P. oleracea and has anti-inflammatory activity.
  • HY-121899
    1-Oxo Ibuprofen

    Ibuprofen EP impurity J

    Others Others
    1-Oxo Ibuprofen (Ibuprofen EP impurity J) is a degradation product and a potential impurity in preparations of Ibuprofen. Ibuprofen is an anti-inflammatory inhibitor targeting COX-1 and COX-2 with IC50s of 13 μM and 370 μM, respectively.
  • HY-10331
    Regorafenib

    BAY 73-4506

    VEGFR Autophagy PDGFR Raf RET Cancer
    Regorafenib (BAY 73-4506) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively.
  • HY-B0161AS
    Duloxetine D3 hydrochloride

    (S)-Duloxetine D3 hydrochloride; LY248686 D3 hydrochloride

    Serotonin Transporter Neurological Disease
    Duloxetine D3 hydrochloride ((S)-Duloxetine D3 hydrochloride) is a deuterium labeled Duloxetine hydrochloride. Duloxetine hydrochloride is a serotonin-norepinephrine reuptake inhibitor (SNRI) with a Ki of 4.6 nM, used for treatment of major depressive disorder and generalized anxiety disorder (GAD).
  • HY-18596
    SB-215505

    5-HT Receptor Neurological Disease
    SB-215505 is a potent and subtype-selective 5-HT2B receptor antagonist with pKi values of 8.3, 6.77, 7.66 for 5-HT2B, 5-HT2A, 5-HT2C, respectively. SB-215505 increases wakefulness and motor activity in rats.
  • HY-10002A
    (1S)-Calcitriol

    1α,25-Dihydroxy-3-epi-vitamin-D3

    Others Others
    (1S)-Calcitriol (1α,25-Dihydroxy-3-epi-vitamin-D3) is a natural metabolite of 1α,25-dihydroxyvitamin D3 (1α,25(OH)2D3). (1S)-Calcitriol exhibits potent vitamin D receptor (VDR)-mediated actions such as inhibition of keratinocyte growth or suppression of parathyroid hormone secretion.
  • HY-112898
    DC1SMe

    ADC Cytotoxin Cancer
    DC1Sme, a DC1 derivative, exhibits IC50 values of 22 pM, 10 pM, 32 pM and 250 pM for Ramos, Namalwa, HL60/s and COLO 205 cancer cells, respectively. DC1, an analogue of the minor groove-binding DNA alkylator CC-1065, is a ADC Cytotoxin. DC1 can be used in synthesis of antibody-drug conjugates for the targeted treatment of cancer.
  • HY-126124
    AP39

    Others Neurological Disease Cardiovascular Disease
    AP39 is a triphenylphosphonium derivatised anethole dithiolethione and mitochondria-targeting hydrogen sulfide (H2S) donor. AP39 increases intracellular H2S levels. AP39 exerts cytoprotective effects and maintains mitochondrial DNA integrity under oxidative stress conditions. AP39 protects against myocardial reperfusion injury in mice model and has the potential for Alzheimer's disease research.
  • HY-111558A
    Bobcat339 hydrochloride

    DNA Methyltransferase Cancer
    Bobcat339 hydrochloride is a potent and selective cytosine-based inhibitor of TET enzyme, with the IC50s of 33 μM and 73 μM for TET1 and TET2, respectively. Bobcat339 hydrochloride is useful to the field of epigenetics and serves as a starting point for new therapeutics that target DNA methylation and gene transcription.
  • HY-B0791
    Altiratinib

    DCC-2701

    VEGFR c-Met/HGFR FLT3 Trk Receptor Cancer
    Altiratinib (DCC-2701) is a multi-targeted kinase inhibitor with IC50s of 2.7, 8, 9.2, 9.3, 0.85, 4.6, 0.83 nM for MET, TIE2, VEGFR2, FLT3, Trk1, Trk2, and Trk3 respectively.
  • HY-I0678
    Regorafénib N-oxyde (M2)

    Drug Metabolite Cancer
    Regorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively.
  • HY-10255A
    Sunitinib

    SU 11248

    VEGFR PDGFR IRE1 Mitophagy Autophagy Apoptosis Cancer
    Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively. Sunitinib, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation.
  • HY-111558
    Bobcat339

    DNA Methyltransferase Cancer
    Bobcat339 is a potent and selective cytosine-based inhibitor of TET enzyme, with IC50s of 33 μM and 73 μM for TET1 and TET2, respectively. Bobcat339 is useful to the field of epigenetics and serves as a starting point for new therapeutics that target DNA methylation and gene transcription.
  • HY-N0068
    Solasodine

    Purapuridine; Solancarpidine; Solasodin

    MDM-2/p53 Fungal E1/E2/E3 Enzyme Apoptosis Cancer Infection Inflammation/Immunology Neurological Disease Cardiovascular Disease
    Solasodine (Purapuridine) is a steroidal alkaloid that occurs in plants of the Solanaceae family. Solasodine has neuroprotective, antifungal, hypotensive, anticancer, antiatherosclerotic, antiandrogenic and anti-inflammatory activities.
  • HY-13314
    Tesevatinib

    XL-647; EXEL-7647; KD-019

    EGFR VEGFR Ephrin Receptor Cancer
    Tesevatinib (XL-647; EXEL-7647; KD-019) is an orally available, multi-target tyrosine kinase inhibitor; inhibits EGFR, ErbB2, KDR, Flt4 and EphB4 kinase with IC50s of 0.3, 16, 1.5, 8.7, and 1.4 nM.
  • HY-101920
    Autophinib

    Autophagy Cancer Neurological Disease
    Autophinib is a potent, selective autophagy inhibitor with IC50s of 90 nM and 40 nM for starvation- and Rapamycin-induced autophagy, respectively. Autophinib is also an ATP competitive Vacuolar Protein Sorting 34 (VPS34) inhibitor with an IC50 of 19 nM. Autophinib inhibits autophagy induced by starvation or Rapamycin by targeting VPS34.
  • HY-133512
    NCGC00249987

    Phosphatase Cancer
    NCGC00249987 is a highly selective and allosteric Tyr phosphatase activity of Eya2 inhibitor with IC50s of 3 μM and 6.9 μM for Eya2 ED and MBP-Eya2 FL. NCGC00249987 specifically targets migration, invadopodia formation, and invasion of lung cancer cells.
  • HY-17022
    Esomeprazole magnesium trihydrate

    (S)-Omeprazole magnesium trihydrate; (-)-Omeprazole magnesium trihydrate

    Proton Pump Endocrinology
    Esomeprazole magnesium trihydrate ((S)-Omeprazole magnesium trihydrate) is a potent and orally active H +, K +-ATPase inhibitor. Esomeprazole magnesium trihydrate has the potential for upper intestinal disorders and gastroesophageal reflux disease research. Esomeprazole magnesium trihydrate acts as an exosome inhibitor by blocking the exosome release via the inhibition of V-H +-ATPases.
  • HY-138620
    MCU-i4

    Mitochondrial Metabolism Metabolic Disease
    MCU-i4 blocks the IP3-dependent mitochondrial Ca 2+-uptake, maintaining the gatekeeping role of their target.
  • HY-125877
    PROTAC Mcl1 degrader-1

    PROTAC Bcl-2 Family Cancer
    PROTAC Mcl1 degrader-1 (compound C3), a proteolysis targeting chimera (PROTAC), is a potently and selectively Mcl-1 inhibitor with an IC50 of 0.78 μM. PROTAC Mcl1 degrader-1 induces the ubiquitination and proteasomal degradation of Mcl-1 by introducing the E3 ligase cereblon (CRBN)-binding ligand pomalidomide to Mcl-1 inhibitor S1-6 with μM-range affinity.
  • HY-126313
    BnOH-NH-bis-(C2-S)-propane-O-isoprene ester

    PROTAC Linker 29

    PROTAC Linker Cancer
    BnOH-NH-bis-(C2-S)-propane-O-isoprene ester (PROTAC Linker 29) is an alkyl ether-based PROTAC linker can be used in the synthesis of PROTACs.
  • HY-124729
    BL-918

    ULK Autophagy Neurological Disease
    BL-918 is an orally active UNC-51-like kinase 1 (ULK1) activator with an EC50 of 24.14 nM. BL-918 exerts its cytoprotective autophagic effect by targeting ULK complex. BL-918 has the potential for Parkinson’s disease (PD) treatment.
  • HY-10227
    Bortezomib

    PS-341; LDP-341; NSC 681239

    Proteasome NF-κB Apoptosis Autophagy Cancer
    Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Anti-cancer activity.
  • HY-10255
    Sunitinib Malate

    SU 11248 Malate

    PDGFR VEGFR IRE1 Mitophagy Autophagy Apoptosis Cancer
    Sunitinib Malate (SU 11248 Malate) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively. Sunitinib Malate, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation.
  • HY-12047S
    Ponatinib D8

    AP24534 D8

    Bcr-Abl PDGFR VEGFR FGFR Src Autophagy Cancer
    Ponatinib D8 (AP24534 D8) is a deuterium labeled Ponatinib. Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively.
  • HY-128836
    (4R,5S)-Nutlin carboxylic acid

    MDM2 ligand 2; E3 ligASe Ligand 15

    Ligand for E3 Ligase Cancer
    (4R,5S)-Nutlin carboxylic acid (MDM2 ligand 2) is the Nutlin 3-based MDM2 ligand. (4R,5S)-Nutlin carboxylic acid can be connected to the ligand for protein by a linker to form PROTACs.
  • HY-P2213
    GPLGIAGQ

    MMP Apoptosis Cancer
    GPLGIAGQ, a MMP2-cleavable polypeptide, is used as a stimulus-sensitive linker in both liposomal and micellar nanocarriers for MMP2-triggered tumor targeting. GPLGIAGQ can be used to synthesis unique MMP2-targeted photosensitizer in photodynamic therapy (PDT).
  • HY-B1190
    Cefadroxil

    BL-S 578

    Bacterial Antibiotic Infection
    Cefadroxil is a broad-spectrum antibiotic of the cephalosporin type, effective in Gram-positive and Gram-negative bacterial infections.
  • HY-P2213A
    GPLGIAGQ TFA

    MMP Apoptosis Cancer
    GPLGIAGQ TFA, a MMP2-cleavable polypeptide, is used as a stimulus-sensitive linker in both liposomal and micellar nanocarriers for MMP2-triggered tumor targeting. GPLGIAGQ TFA can be used to synthesis unique MMP2-targeted photosensitizer in photodynamic therapy (PDT).
  • HY-141521
    NX-13

    NOD-like Receptor (NLR) Inflammation/Immunology
    NX-13 is a safe, selective, orally active and well-tolerated novel small molecule. NX-13 targets and activates NLRX1 to induce immunometabolic changes resulting in lower inflammation and responses in inflammatory bowel disease. NX-13 is a promising drug for crohn’s disease and ulcerative colitis research.
  • HY-B0062
    Dovitinib lactate hydrate

    TKI258 lactate hydrate; CHIR-258 lactate hydrate

    FLT3 c-Kit FGFR VEGFR PDGFR Cancer
    Dovitinib lactate hydrate (TKI258 lactate hydrate) is a multi-targeted tyrosine kinase inhibitor with IC50s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/3, VEGFR1/2/3 and PDGFRα/β, respectively.
  • HY-10207
    Dovitinib lactate

    CHIR-258 lactate; TKI-258 lactate

    FLT3 c-Kit FGFR VEGFR PDGFR Cancer
    Dovitinib lactate (TKI258 lactate) is a multi-targeted tyrosine kinase inhibitor with IC50s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/3, VEGFR1/2/3 and PDGFRα/β, respectively.
  • HY-50514
    AT9283

    JAK Aurora Kinase Bcr-Abl FLT3 Apoptosis Autophagy Cancer
    AT9283 is a multi-targeted kinase inhibitor with potent activity against Aurora A/B, JAK2/3, Abl (T315I) and Flt3 (IC50s ranging from 1 to 30 nM). AT9283 inhibits growth and survival of multiple solid tumors in vitro and in vivo.
  • HY-Y0152A
    Cinchonine monohydrochloride hydrate

    (8R,9S)-Cinchonine monohydrochloride hydrate; LA40221 monohydrochloride hydrate

    Parasite Apoptosis Cancer Infection Metabolic Disease Cardiovascular Disease
    Cinchonine ((8R,9S)-Cinchonine) monohydrochloride hydrate is a natural compound which has been effectively used as antimalarial agent. Cinchonine monohydrochloride hydrate activates endoplasmic reticulum stress-induced apoptosis in human liver cancer cells. Cinchonine monohydrochloride hydrate is also an inhibitor of human platelet aggregation. Cinchonine monohydrochloride hydrate possesses a suppressive effect on adipogenesis.
  • HY-101544
    ARQ 069

    FGFR Cancer
    ARQ 069, an analog of ARQ 523, inhibits FGFR in an enantiospecific manner. ARQ 069 targets the unphosphorylated, inactive forms of FGFR1/FGFR2 kinases (IC50s of 0.84 μM and 1.23 μM, respectively). ARQ 069 inhibits FGFR1/FGFR2 autophosphorylation (IC50s of 2.8 and 1.9 μM, respectively) through a mechanism in a non-ATP competitive dependent manner.
  • HY-17442
    Azathramycin

    Azaerythromycin A; Desmethyl Azithromycin

    Bacterial Antibiotic Infection
    Azathramycin (Azaerythromycin A) is an antibiotic and targets ribosome.
  • HY-U00361
    Itch-Targeting Compound 1

    Others Infection Inflammation/Immunology
    Itch-Targeting Compound 1 is an anti-itching agent.
  • HY-13631D
    Dxd

    Exatecan derivative for ADC

    Topoisomerase ADC Cytotoxin Cancer
    Dxd (Exatecan derivative for ADC) is a potent DNA topoisomerase I inhibitor, with an IC50 of 0.31 μM, used as a conjugated drug of HER2-targeting ADC (DS-8201a).
  • HY-120944
    BAY-7598

    MMP Inflammation/Immunology
    BAY-7598 is a potent, orally bioavailable, and selective MMP12 inhibitor probe with IC50s of 0.085, 0.67 and 1.1 nM for human MMP12, murine MMP12, and rat MMP12, respectively.
  • HY-10987A
    ENMD-2076

    Aurora Kinase FLT3 VEGFR FGFR PDGFR Src Apoptosis Cancer
    ENMD-2076 is a multi-targeted kinase inhibitor with IC50s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for Aurora A, Flt3, KDR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src, PDGFRα, respectively.
  • HY-133084
    ERK-IN-2

    ERK Cancer
    ERK-IN-2 is a ERK2 inhibitor probe with an IC50 value of 1.8 nM. ERK-IN-2 might lead to off-target toxicity and/or off-target activity at dose >10 μM.
  • HY-15142
    Doxorubicin hydrochloride

    Hydroxydaunorubicin hydrochloride

    ADC Cytotoxin AMPK Autophagy Apoptosis HIV HBV Mitophagy Bacterial Antibiotic Topoisomerase Cancer Infection
    Doxorubicin (Hydroxydaunorubicin) hydrochloride, a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin hydrochloride is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC50s of 0.8 μM and 2.67 μM, respectively. Doxorubicin hydrochloride reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin hydrochloride induces apoptosis and autophagy.
  • HY-10987
    ENMD-2076 Tartrate

    Aurora Kinase FLT3 VEGFR FGFR Src PDGFR Apoptosis Cancer
    ENMD-2076 Tartrate is a multi-targeted kinase inhibitor with IC50s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for Aurora A, Flt3, KDR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src, PDGFRα, respectively.
  • HY-10255AS
    Sunitinib D10

    SU 11248 D10

    VEGFR PDGFR IRE1 Mitophagy Autophagy Apoptosis Cancer
    Sunitinib D10 (SU 11248 D10) is a deuterium labeled Sunitinib. Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively. Sunitinib, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation.
  • HY-101949
    LTX-401 dihydrochloride

    Others Inflammation/Immunology
    LTX-401, an oncolytic amino acid derivative, targets the Golgi apparatus.
  • HY-N6770
    Curvularin

    (S)-Curvularin

    NO Synthase Inflammation/Immunology Infection
    Curvularin, a fungal metabolite and a potent mycotoxin naturally isolated from Curvularia lunata, inhibits cytokine-induced nitric oxide synthase (iNOS), with an IC50 of 9.5 µM.
  • HY-16991
    Terutroban

    S-18886

    Prostaglandin Receptor Cardiovascular Disease Endocrinology
    Terutroban is a thromboxane-prostaglandin receptor antagonist.
  • HY-N0363
    (+)-Columbianetin

    (S)-Columbianetin

    Others Infection Inflammation/Immunology
    (+)-Columbianetin is an isomer of Columbianetin. Columbianetin is a phytoalexin associated with celery (Apium graveolens) resistance to pathogens during storage. Columbianetin exhibits excellent anti-fungal and anti-inflammatory activity.
  • HY-B2031
    Pyriproxyfen

    S-31183

    Autophagy Parasite Infection
    Pyriproxyfen is a juvenile hormone analog, preventing larvae from developing into adulthood and thus rendering them unable to reproduce.
  • HY-N0235
    Bakuchiol

    (S)-(+)-Bakuchiol

    p38 MAPK Autophagy Cancer
    Bakuchiol is a phytoestrogen isolated from the seeds of Psoralea corylifolia L; has anti-tumor effects.
  • HY-13441
    (-)-Blebbistatin

    (S)-(-)-Blebbistatin

    Myosin Cardiovascular Disease Cancer
    (-)-Blebbistatin is a selective inhibitor of the ATPase activity of non-muscle myosin II.
  • HY-16763
    Asapiprant

    S-555739

    Prostaglandin Receptor Inflammation/Immunology Endocrinology
    Asapiprant is a potent and selective DP1 receptor antagonist with a Ki of 0.44 nM.
  • HY-19883
    Lusutrombopag

    S-888711

    Thrombopoietin Receptor Inflammation/Immunology
    Lusutrombopag is an orally bioavailable thrombopoietin (TPO) receptor agonist, used for treatment of chronic liver disease.
  • HY-B1062
    Dexchlorpheniramine maleate

    S-(+)-Chlorpheniramine maleate salt

    Histamine Receptor Inflammation/Immunology Endocrinology
    Dexchlorpheniramine maleate is an antihistamine, with anticholinergic properties, used to treat allergic conditions.
  • HY-W067716
    Spinacine

    (S)-Spinacine

    Endogenous Metabolite Metabolic Disease
    Spinacine is an endogenous metabolite.
  • HY-10844
    Pretomanid

    PA-824; (S)-PA 824

    Bacterial Antibiotic Infection Cancer
    Pretomanid (PA-824) is an antibiotic used for the research of multi-drug-resistant tuberculosis affecting the lungs. Pretomanid exhibits a sub-micromolar MIC against M. tuberculosis (MTB). The MIC values of PA-824 against a panel of MTB pan-sensitive and Rifampin mono-resistant clinical isolates range from 0.015 to 0.25 µg/mL.
  • HY-112878
    CL656

    c-[2’FdAMP(S)-2’FdIMP(S)]

    STING Inflammation/Immunology
    CL656 is an activator of stimulator of interferon genes (STING).
  • HY-100875
    Bisantrene

    CL216942

    Topoisomerase Cancer
    Bisantrene is a highly effective antitumor drug, targets eukaryotic type II topoisomerases.
  • HY-134809
    Cyclotriazadisulfonamide

    CADA

    HIV Infection Inflammation/Immunology
    Cyclotriazadisulfonamide (CADA) is a specific CD4-targeted HIV entry inhibitors. Cyclotriazadisulfonamide (CADA) inhibits the co-translational translocation of human CD4 (huCD4) into the ER lumen in a signal peptide (SP)-dependent way.
  • HY-10230
    Midostaurin

    PKC412; CGP 41251

    PKC Cancer
    Midostaurin (PKC412; CGP 41251) is a multi-targeted protein kinase inhibitor which inhibits PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50s ranging from 22-500 nM.
  • HY-12680
    PRN694

    Itk Inflammation/Immunology
    PRN694 is an irreversible, highly selective and potent covalent interleukin-2-inducible T-cell kinase (ITK) and resting lymphocyte kinase (RLK) dual inhibitor with IC50s of 0.3 nM and 1.4 nM, respectively. PRN694 exhibits extended target residence time on ITK and RLK, enabling durable attenuation of effector cells in vitro and in vivo.
  • HY-134761
    EN4

    c-Myc Cancer
    EN4 is a covalent ligand that targets cysteine 171 (C171) of MYC. EN4 is selective for c-MYC over N-MYC and L-MYC. EN4 inhibits MYC transcriptional activity, downregulates MYC targets, and impairs tumorigenesis.
  • HY-18219
    Walrycin B

    Bacterial Antibiotic Infection
    Walrycin B is a novel antibacterial compound specifically targeting the essential WalR response regulator.
  • HY-13901
    GANT 61

    NSC 136476

    Gli Autophagy Cancer
    GANT 61 is an inhibitor of Gli1 and Gli2 targeting the Hedgehog/GLI pathway.
  • HY-14881A
    Bedaquiline fumarate

    R403323; TMC207 fumarate; R207910 fumarate

    Bacterial Antibiotic Infection
    Bedaquiline fumarate, a diarylquinoline antibiotic that targets ATP synthase, is effective for the treatment of Mycobacterium tuberculosis infections.
  • HY-U00393
    Arrhythmic-Targeting Compound 1

    Others Cardiovascular Disease
    Arrhythmic-Targeting Compound 1 is used for the research of arrhythmic disease, with nitrogen-containing spirocycles.
  • HY-U00357
    Urinary Incontinence-Targeting Compound 1

    Others Neurological Disease
    Urinary Incontinence-Targeting Compound 1 is a sulfonanilide derivative, used in the research of urinary incontinence.
  • HY-135902
    Synucleozid

    NSC 377363

    DNA/RNA Synthesis Neurological Disease
    Synucleozid (NSC 377363) is a potent inhibitor of the SNCA mRNA that encodes α-synuclein protein (IC50=1.5 μM). Synucleozid selectively targets the α-synuclein mRNA 5′ UTR at the designed IRE site, decreases the amount of SNCA mRNA loaded into polysomes and thereby inhibits SNCA translation. Synucleozid has the potential for the investigation of Parkinson’s disease.
  • HY-50905
    Dovitinib

    CHIR-258; TKI258

    FLT3 c-Kit FGFR VEGFR PDGFR Cancer
    Dovitinib (CHIR-258) is a multi-targeted tyrosine kinase inhibitor with IC50s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively.
  • HY-15147
    XAV-939

    β-catenin PARP Cancer
    XAV-939 is a potent tankyrase inhibitor that targets Wnt/β-catenin signaling. XAV-939 stabilizes axin by inhibiting tankyrase 1 and tankyrase 2 (IC50s of 5 and 2 nM, respectively), thereby stimulating β-catenin degradation. XAV939 binds tightly to the catalytic (PARP) domains of TNKS1 and TNKS2 (Kds of 99 and 93 nM, respectively).
  • HY-135902A
    Synucleozid hydrochloride

    NSC 377363 hydrochloride

    DNA/RNA Synthesis Neurological Disease
    Synucleozid hydrochloride (NSC 377363 hydrochloride) is a potent inhibitor of the SNCA mRNA that encodes α-synuclein protein (IC50=1.5 μM). Synucleozid selectively targets the α-synuclein mRNA 5′ UTR at the designed IRE site, decreases the amount of SNCA mRNA loaded into polysomes and thereby inhibits SNCA translation. Synucleozid has the potential for the investigation of Parkinson’s disease.
  • HY-128171
    Diflapolin

    FLAP Epoxide Hydrolase Inflammation/Immunology
    Diflapolin is a highly active dual 5-lipoxygenase-activating protein (FLAP)/soluble epoxide hydrolase (sEH) inhibitor with marked anti-inflammatory efficacy and high target selectivity. Diflapolin inhibits 5-LOX product formation in intact human monocytes and neutrophils with IC50s of  30 and 170 nM, respectively, and suppressed the activity of isolated sEH (IC50=20 nM).
  • HY-10185
    TG 100572 Hydrochloride

    Src VEGFR FGFR PDGFR Inflammation/Immunology
    TG 100572 Hydrochloride is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.
  • HY-10184
    TG 100572

    Src VEGFR PDGFR FGFR Cancer
    TG 100572 is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.
  • HY-17459
    Clopidogrel hydrogen sulfate

    (S)-(+)-Clopidogrel bisulfate; (S)-(+)-Clopidogrel hydrogen sulfate

    P2Y Receptor Cardiovascular Disease
    Clopidogrel hydrogen sulfate is an antiplatelet agent which works by blocking platelets from sticking together and prevents them from forming harmful clots.
  • HY-10259
    PD 123319

    (S)-(+)-PD 123319

    Angiotensin Receptor Cardiovascular Disease Endocrinology
    PD 123319 (ditrifluoroacetate) is a potent, selective AT2 angiotensin II receptor antagonist with IC50 of 34 nM.
  • HY-16366
    Briciclib

    ON 014185

    Eukaryotic Initiation Factor (eIF) Autophagy Cancer
    Briciclib (ON 014185) is a derivative of ON 013100, and has the potential in targeting eIF4E for solid cancers.
  • HY-112879
    Mito-TEMPO

    Mitochondrial Metabolism Inflammation/Immunology
    Mito-TEMPO is a mitochondria-targeted superoxide dismutase mimetic with superoxide and alkyl radical scavenging properties.
  • HY-10990
    Abexinostat

    CRA 024781; PCI-24781

    HDAC Cancer
    Abexinostat (CRA 024781) is a novel pan-HDAC inhibitor mostly targeting HDAC1 with Ki of 7 nM.
  • HY-119970
    Helenalin

    NF-κB Cancer Inflammation/Immunology
    Helenalin is an anti-inflammatory sesquiterpene lactone. Helenalin selectively inhibits transcription factor NF-κB by directly targeting p65. Helenalin has alkylating activity, targets the cysteine sulfhydryl groups in the p65 subunit of NF-κB, thereby inhibits its DNA binding.
  • HY-P1428
    RFRP-1(human)

    Neuropeptide Y Receptor Endocrinology
    RFRP-1(human) is a gonadotropin-inhibitory hormone (GnIH) homolog. RFRP-1(human) targets human gonadotropin-releasing hormone (GnRH) neurons and gonadotropes and potently inhibits gonadotropin. RFRP-1(human) is a potent Neuropeptide FF (NPFF) receptor agonist with EC50s of 0.0011 nM and 29 nM for NPFF2 and NPFF1, respectively.
  • HY-111552
    PIM1-IN-1

    Pim Cancer
    PIM1-IN-1 is a potent and highly selective PIM1/3 inhibitor, with IC50s of 7, 5530 and 70 nM for PIM1, PIM2, and PIM3, respectively, inhibits the phosphorylation of BAD, a downstream target of PIM, with an EC50 of 262 nM. PIM1-IN-1 shows no obvious effect on FLT3 or hERG binding. Antiproliferative and anti-cancer activity.
  • HY-N0352
    Tuberostemonine

    Parasite Infection
    Tuberostemonine, an alkaloid, is an antimalarial agent that targets Plasmodium falciparum ferredoxin-NADP + reductases (pfFNR).
  • HY-N0805A
    Alisol B

    Others Metabolic Disease
    Alisol B is a potentially novel therapeutic compound for bone disorders by targeting the differentiation of osteoclasts as well as their functions.
  • HY-N2146
    Combretastatin A4

    CRC 87-09

    Microtubule/Tubulin Cancer
    Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with Kd of 0.4 μM.
  • HY-P9908
    Adalimumab

    Anti-Human TNF-alpha, Human Antibody

    TNF Receptor Inflammation/Immunology
    Adalimumab is a human monoclonal IgG1 antibody targeting tumour necrosis factor α (TNF-α).
  • HY-100116A
    Mitoquinone mesylate

    MitoQ mesylate; MitoQ10 mesylate

    Reactive Oxygen Species Metabolic Disease Cancer
    Mitoquinone mesylate is a TPP-based, mitochondrially targeted antioxidant in order to protect against oxidative damage.
  • HY-103028
    GSK962

    Others Others
    GSK962 is an inactive enantiomer of GSK963 and can be used to confirm on-target effects.
  • HY-P9921
    Trastuzumab emtansine

    Ado-Trastuzumab emtansine; PRO132365; T-DM 1

    Antibody-drug Conjugate (ADC) EGFR Cancer
    Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine). Trastuzumab emtansine can be used for the research of advanced breast cancer.
  • HY-122009
    Indican

    Indoxyl-β-D-glucoside

    Others Others
    Indican (Indoxyl-β-D-glucoside), a glycoside of indoxyl, is a precursor of the dyesindigo and indirubin. Indican has a major metabolite, indoxyl sulfate (IS). IS, an uremic toxin, is a substrate/inhibitor of organic anion transporter (OAT) 1, OAT 3 and multidrug resistance-associated protein (MRP) 4.
  • HY-100431
    IMR-1

    Notch Cancer
    IMR-1 is a novel class of Notch inhibitors targeting the transcriptional activation with an IC50 of 26 μM. IMR-1 prevents the recruitment of Mastermind-like 1 (Maml1) to the Notch Ternary Complex (NTC) on chromatin, inhibits Notch target gene transcription and dramatically inhibits tumor growth.
  • HY-17034A
    Dexmedetomidine hydrochloride

    (+)-Medetomidine hydrochloride; (S)-Medetomidine hydrochloride

    Adrenergic Receptor Neurological Disease Endocrinology Cancer
    Dexmedetomidine hydrochloride ((+)-Medetomidine hydrochloride) is a potent, selective and orally active agonist of α2-adrenoceptor, with a Ki of 1.08 nM. Dexmedetomidine hydrochloride shows 1620-fold selectivity against α1-adrenoceptor. Dexmedetomidine hydrochloride exhibits anxiolysis, sedation, and modest analgesia effects.
  • HY-109025A
    Baloxavir

    Baloxavir acid; S-033447

    Influenza Virus Infection
    Baloxavir (Baloxavir acid), derived from the prodrug Baloxavir marboxil, is a first-in-class, potent and selective cap-dependent endonuclease (CEN) inhibitor within the polymerase PA subunit of influenza A and B viruses. Baloxavir inhibits viral RNA transcription and replication and has potently antiviral activity.
  • HY-N0553
    Gypenoside XVII

    Gynosaponin S

    Estrogen Receptor/ERR Endogenous Metabolite Cardiovascular Disease
    Gypenoside XVII, a novel phytoestrogen belonging to the gypenosides, can activate estrogen receptors.
  • HY-B0653A
    Levobupivacaine hydrochloride

    (S)-(-)-Bupivacaine monohydrochloride

    Sodium Channel Neurological Disease
    Levobupivacaine hydrochloride is a sodium channel blocker.
  • HY-15677
    INT-777

    S-EMCA

    GPCR19 Endocrinology
    INT-777 is a potent TGR5 agonist with an EC50 of 0.82 μM.
  • HY-N0927
    (-)-Isocorypalmine

    Tetrahydrocolumbamine; (S)-Tetrahydrocolumbamine

    Dopamine Receptor Others
    (-)-Isocorypalmine (Tetrahydrocolumbamine), isolated from the crude base fraction of Corydalis chaerophylla, is a dopamine receptor ligand. Recombinant CYP719A21 displays strict substrate specificity and high affinity (Km=4.63 ± 0.71 μM) for (-)-Isocorypalmine.
  • HY-117025A
    Manzamine A hydrochloride

    GSK-3 CDK Parasite HIV Proton Pump Autophagy Cancer Infection Neurological Disease
    Manzamine A hydrochloride, an orally active beta-carboline alkaloid, inhibits specifically GSK-3β and CDK-5 with IC50s of 10.2 and 1.5μM, respectively. Manzamine A hydrochloride targets vacuolar ATPases and inhibits autophagy in pancreatic cancer cells. Manzamine A hydrochloride has antimalarial and anticancer activities. Manzamine A hydrochloride also shows potent activity against HSV-1.
  • HY-106423
    Mivobulin

    NSC 613862; (S)-(-)-NSC 613862

    Microtubule/Tubulin Cancer
    Mivobulin (NSC 613862) is a tubulin inhibitor, binds to tubulin in the region that overlaps the colchicine site, and inhibits tubulin polymerization. Mivobulin (NSC 613862) promotes the formation of abnormal polymers and a GTPase activity in the tubulin dimer. Anti-cancer activity.
  • HY-100306
    PNU-176798

    Bacterial Infection
    PNU-176798 is an antimicrobial agent, targeting protein synthesis in a wide spectrum of gram-positive and anaerobic bacteria.
  • HY-W039897
    Methyl α-D-mannopyranoside

    Others Inflammation/Immunology
    Methyl α-D-mannopyranoside could target macrophages in anti-tuberculosis inhalation therapy.
  • HY-101750
    Arrhythmias-Targeting Compound 1

    Others Cardiovascular Disease
    Arrhythmias-Targeting Compound 1 is used in the research of arrhythmias, extracted from patent WO 2001028992 A2.
  • HY-69220
    7-Octynoic acid

    PROTAC Linker Cancer
    7-Octynoic acid (compound 42) is a PROTAC linker and can be used in the synthesis of a series of PROTACs. PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.
  • HY-135869
    Mito-apocynin (C11)

    Mitochondrial Metabolism Neurological Disease
    Mito-apocynin (C11), an orally active mitochondria-targeted triphenylphosphonium (TPP)-based compound, is synthesized by conjugating the Apocynin moiety with a TPP + cation. Mito-apocynin (C11) selectively targets mitochondria, and shows neuroprotective effect. Mito-apocynin (C11) prevents hyposmia and corrects deficits in motor function.
  • HY-10864
    URB-597

    KDS-4103

    FAAH Autophagy Mitophagy Neurological Disease
    URB597 is a potent, orally bioavailable FAAH inhibitor with IC50 of 4.6 nM, with no activity on other cannabinoid-related targets.
  • HY-U00314
    Anti-neurodegeneration agent 1

    Others Neurological Disease
    Anti-neurodegeneration agent 1 a neurodegeneration-targeting compound extracted from patent WO2008039514A1, Compound I.
  • HY-U00385
    Neuromuscular Disorder-Targeting Compound 1

    Others Neurological Disease
    Neuromuscular Disorder-Targeting Compound 1 is used in the research of neuromuscular disorders such as symptoms of fibromyalgia syndrome and chronic fatigue syndrome.
  • HY-15614A
    SC144 hydrochloride

    Interleukin Related Apoptosis Cancer
    SC144 hydrochloride is a first-in-class, orally active gp130 (IL6-beta) inhibitor. SC144 hydrochloride binds gp130, induces gp130 phosphorylation (S782) and deglycosylation, abrogates Stat3 phosphorylation and nuclear translocation, and further inhibits the expression of downstream target genes. SC144 hydrochloride shows potent inhibition of gp130 ligand-triggered signaling. SC144 hydrochloride induces apoptosis in human ovarian cancer cells.
  • HY-15614
    SC144

    Interleukin Related Apoptosis Cancer
    SC144 is a first-in-class, orally active gp130 (IL6-beta) inhibitor. SC144 binds gp130, induces gp130 phosphorylation (S782) and deglycosylation, abrogates Stat3 phosphorylation and nuclear translocation, and further inhibits the expression of downstream target genes. SC144 shows potent inhibition of gp130 ligand-triggered signaling. SC144 induces apoptosis in human ovarian cancer cells.
  • HY-12076
    BMS 777607

    BMS 817378

    c-Met/HGFR TAM Receptor Cancer
    BMS 777607 (BMS 817378) is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3 with IC50s of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM, respectively, and 40-fold more selective for Met-related targets than Lck, VEGFR-2, and TrkA/B, with more than 500-fold greater selectivity versus all other receptor and non receptor kinases.
  • HY-16558
    Butein

    2’,3,4,4’-tetrahydroxy Chalcone

    EGFR Autophagy Apoptosis Phosphodiesterase (PDE) Cancer
    Butein is a cAMP-specific PDE inhibitor with an IC50 of 10.4 μM for PDE4. Butein is a specific protein tyrosine kinase inhibitor with IC50s of 16 and 65 μM for EGFR and p60 c-src in HepG2 cells. Butein sensitizes HeLa cells to Cisplatin through AKT and ERK/p38 MAPK pathways by targeting FoxO3a. Butein is a SIRT1 activator (STAC).
  • HY-P9968
    Nimotuzumab

    EGFR Cancer
    Nimotuzumab is a humanized IgG1 monoclonal antibody targeting EGFR with a KD of 0.21 nM. Nimotuzumab is directed against the extracellular domain of the EGFR blocking the binding to its ligands. Nimotuzumab, a strong antitumor drug, is cytolytic on target tumors by its capacity to cause antibody dependent cell mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC).
  • HY-100474
    Visomitin

    SKQ1

    Reactive Oxygen Species Inflammation/Immunology
    Visomitin (SKQ1) is a mitochondrial-targeted antioxidant with the high mitochondrion membrane penetrating ability and potent antioxidant capability.
  • HY-P9911
    Vedolizumab

    Anti-Human lymphocyte α4β7 integrin, Humanized Antibody

    Integrin Inflammation/Immunology
    Vedolizumab is a humanized monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease.
  • HY-131139
    Ganglioside GD3 disodium salt

    Others Cancer
    Ganglioside GD3 disodium salt is a melanoma-associated antigen and has been used as a target for the immune therapy of melanomas.
  • HY-17602
    Amcasertib

    BBI503

    Others Cancer
    Amcasertib is an orally administered investigational agent designed to inhibit cancer stem cell pathways, including Nanog, by targeting stemness kinases.
  • HY-W004697
    Boc-GABA-OH

    PROTAC Linker Cancer
    Boc-GABA-OH is a PROTAC linker which can be used to synthesis UNC6852, an EED-targeted PROTAC.
  • HY-P1034
    DAPTA

    D-Ala-peptide T-amide; Adaptavir

    CCR HIV Infection Endocrinology
    DAPTA is a synthetic peptide, functions as a viral entry inhibitor by targeting selectively CCR5, and shows potent anti-HIV activities.
  • HY-N1423
    Glycocholic acid

    Endogenous Metabolite Cancer
    Glycocholic acid is a bile acid with anticancer activity, targeting against pump resistance-related and non-pump resistance-related pathways.
  • HY-13640
    Rabacfosadine

    GS-9219; VDC-1101

    Others Cancer
    Rabacfosadine (GS-9219), a novel prodrug of the nucleotide analogue PMEG, is designed as a cytotoxic agent that preferentially targets lymphoid cells.
  • HY-U00300
    Cancer-Targeting Compound 1

    Others Cancer
    Cancer-Targeting Compound 1 is used in the research of hormone-​related cancer, extracted from patent WO 2008021331 A2.
  • HY-122866
    ZT-12-037-01

    Ras Cancer
    ZT-12-037-01 is a STK19-targeted inhibitor, has a high-affinity interaction with STK19 protein and inhibits oncogenic NRAS-driven melanocyte malignant transformation. ZT-12-037-01 is an ATP-competitive inhibitor, inhibiting phosphorylation of NRAS (major isoform of Ras family) with an IC50 of 24 nM.
  • HY-N0239
    Bulleyaconitine A

    Sodium Channel Neurological Disease
    Bulleyaconitine A is an analgesic and antiinflammatory drug isolated from Aconitum plants; has several potential targets, including voltage-gated Na+ channels.
  • HY-U00310
    Neuromuscular-targeting compound 1

    Others Neurological Disease
    Neuromuscular-targeting compound 1, extracted from patent WO2009099594 A1, Paragraph 0100, is useful in treatment of neuromuscular diseases.
  • HY-122909
    GSK2593074A

    GSK'074

    RIP kinase Inflammation/Immunology
    GSK2593074A (GSK’074) is a necroptosis inhibitor with dual targeting ability to both RIP1 and RIP3.
  • HY-B2116
    Osalmid

    Oxaphenamide; 4'-Hydroxysalicylanilide

    HBV Infection
    Osalmid is a ribonucleotide reductase small subunit M2 (RRM2) targeting compound; suppresses ribonucleotide reductase activity with an IC50 of 8.23 μM.
  • HY-16596
    CNX-1351

    PI3K Cancer
    CNX-1351 is a potent and isoform-selective targeted covalent PI3Kα inhibitor with IC50 of 6.8 nM.
  • HY-U00362
    Neurodegenerative Disorder-Targeting Compound 1

    Proteasome Neurological Disease
    Neurodegenerative Disorder-Targeting Compound 1 is a calpain inhibitor extracted from patent WO2010128102A1, compound example 63.
  • HY-102007
    Gamitrinib TPP

    HSP Cancer
    Gamitrinib TPP is a Gamitrinib (GA) mitochondrial matrix inhibitor. Gamitrinib TPP is a mitochondrial targeted HSP90 inhibitor with anti-cancer activity.
  • HY-124295
    MPT0E028

    HDAC Akt Apoptosis Cancer
    MPT0E028 is an orally active and selective HDAC inhibitor with IC50s of 53.0 nM, 106.2 nM, 29.5 nM for HDAC1, HDAC2 and HDAC6, respectively. MPT0E028 reduces the viability of B-cell lymphomas by inducing apoptosis and possesses potent direct Akt targeting ability and reduces Akt phosphorylation in B-cell lymphoma. MPT0E028 has good anticancer activity.
  • HY-128206
    I3MT-3

    HMPSNE

    Hippo (MST) Metabolic Disease
    I3MT-3 (HMPSNE) is a potent, selective, and cell-membrane permeable inhibitor of 3-Mercaptopyruvate sulfurtransferase (3MST) (IC50=2.7 μM). I3MT-3 is inactive for other H2S/sulfane sulfur-producing enzymes. I3MT-3 targets a persulfurated cysteine residue located in the active site of 3MST.
  • HY-U00214
    Ibafloxacine

    R835; S25930

    Bacterial Infection
    Ibafloxacine (R835) is a fluoroquinolone antibiotic agent that is developed exclusively for veterinary use.
  • HY-15229
    Guadecitabine sodium

    SGI-110 sodium; S-110 sodium

    DNA Methyltransferase Cancer
    Guadecitabine sodium (SGI-110 sodium) is a second-generation DNA methyltransferases (DNMT) inhibitor for research of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
  • HY-13740
    Resiquimod

    R848; S28463

    Toll-like Receptor (TLR) HCV Inflammation/Immunology Cancer
    Resiquimod is a Toll-like receptor 7 and 8 (TLR7/TLR8) agonist that induces the upregulation of cytokines such as TNF-α, IL-6 and IFN-α.
  • HY-18715
    Ornidazole (Levo-)

    (S)-Ornidazole; Levornidazole

    Bacterial Parasite Infection
    Ornidazole Levo- is the levo-isomer of Ornidazole. Ornidazole is a 5-nitroimidazole derivative with antiprotozoal and antibacterial properties against anaerobic bacteria. Ornidazole Levo- is the less active isomer.
  • HY-B1895
    Levodropropizine

    (S)-(-)-Dropropizine; DF-526

    Histamine Receptor Inflammation/Immunology Endocrinology
    Levodropropizine (DF-526) is a histamine receptor inhibitor, Levodropropizine is an effective and very well tolerated peripheral antitussive drug.
  • HY-B0161
    Duloxetine

    (S)-Duloxetine; LY248686

    Serotonin Transporter Neurological Disease
    Duloxetine is a serotonin-norepinephrine reuptake inhibitor with a Ki of 4.6 nM, used for treatment of major depressive disorder and generalized anxiety disorder (GAD).
  • HY-D0205A
    Carbocisteine

    S-(Carboxymethyl)-L-cysteine

    Enterovirus Infection Inflammation/Immunology
    Carbocisteine, a mucolytic agent, can be used for the research of chronic obstructive pulmonary disease (COPD).
  • HY-U00041
    Pivalopril

    Pivopril; RHC 3659(S)

    Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Pivalopril is a new orally active angiotensin converting enzyme (ACE) inhibitor.
  • HY-105545
    Dexetimide

    (+)-Benzetimide; (S)-(+)-Dexetimide; Dexbenzetimide

    mAChR Neurological Disease
    Dexetimide ((+)-Benzetimide) is a high-affinity muscarinic receptor antagonist and a potent and persistent anticholinergic agent used to treat neuroleptic-induced parkinsonism.
  • HY-16560
    Camptothecin

    Campathecin; (S)-(+)-Camptothecin; CPT

    Topoisomerase ADC Cytotoxin Influenza Virus Fungal Apoptosis Antibiotic Cancer Infection
    Camptothecin (Campathecin) is a potent DNA enzyme topoisomerase I inhibitor, with an IC50 of 679 nM.
  • HY-Y0479
    L-Lactic acid

    (S)-2-Hydroxypropanoic acid

    Bacterial Endogenous Metabolite Antibiotic Infection
    L-Lactic acid is a buildiing block which can be used as a precursor for the production of the bioplastic polymer poly-lactic acid.
  • HY-116702
    Flufiprole

    GABA Receptor Others
    Flufiprole is a nonsystemic phenylpyrazole insecticide targeting the GABA receptor used in the rice field. Flufiprole is excellent in controlling a wide range of pests.
  • HY-14796
    Olesoxime

    TRO 19622; NSC 21311

    Mitochondrial Metabolism Neurological Disease
    Olesoxime (TRO 19622) is a mitochondrial-targeted neuroprotective compound with mean EC50 value for increasing cell survival is 3.2±0.2 µM.
  • HY-19341
    Compound 401

    DNA-PK Cancer
    Compound 401 is a synthetic inhibitor of DNA-PK (IC50 = 0.28 μM) that also targets mTOR but not PI3K in vitro.
  • HY-N7453
    Fengycin

    Fungal Infection
    Fengycin is a cyclic lipopeptide used as an agricultural fungicide. Fengmycin has an anti-fungal infection effect by damaging the target's cell membrane.
  • HY-W077028
    N-(2-Hydroxypropyl)methacrylamide

    Others Others
    N-(2-Hydroxypropyl)methacrylamide is used to synthesize copolymers for the targeted delivery of antileishmanial agents in Visceral leishmaniasis (VL) .
  • HY-U00160
    SP187

    MON-​DNJ; UV4

    Influenza Virus Infection
    SP187 is a host-targeted iminosugar with activity against filovirus infections in vitro and in vivo. SP187 is active against influenza and dengue in vivo.
  • HY-141536
    PSMA-ALB-56

    Drug-Linker Conjugates for ADC Cancer
    PSMA-ALB-56 is a PSMA-targeting radioligand designed by combining the glutamate-urea PSMA-binding entity and an albumin binder.
  • HY-112088
    AZD4573

    CDK Cancer
    AZD4573 is a potent and highly selective CDK9 inhibitor (IC50 of <4 nM) that enables transient target engagement for the treatment of hematologic malignancies.
  • HY-15233
    Letermovir

    AIC246

    CMV Infection
    Letermovir (AIC246) is a potent inhibitor of CMV, which targets the viral terminase complex and remains active against virus resistant to DNA polymerase inhibitors.
  • HY-16307
    MB05032

    Phosphatase Metabolic Disease
    MB05032 is a special and efficacious GNG inhibitor targeted the AMP binding site of fructose 1,6-bisphosphatase (FBPase) with an IC50 value of 16 nM.
  • HY-111758
    PROTAC B-Raf degrader 1

    PROTAC Raf Cancer
    PROTAC B-Raf degrader 1 (compound 2) is a proteolysis targeting chimera (PROTAC) for the degradation of B-Raf. With anti-cancer activity.
  • HY-10340B
    Tirbanibulin Mesylate

    KX2-391 Mesylate; KX01 Mesylate

    Src Microtubule/Tubulin Cancer
    Tirbanibulin Mesylate (KX2-391 Mesylate) is an inhibitor of Src that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines.
  • HY-15359
    Episilvestrol

    Eukaryotic Initiation Factor (eIF) Autophagy Cancer
    Episilvestrol is a derivative of silvestrol, isolated from the fruits and twigs of Aglaia silvestris, and is a specific eIF4A-targeting translation inhibitor, with antitumor activity.
  • HY-10822A
    ONX 0801 trisodium

    BGC 945 trisodium; Idetrexed trisodium; CB 300945 trisodium

    Thymidylate Synthase Cancer
    ONX 0801 (BGC 945) trisodium is a thymidylate synthase (TS) inhibitor, targeted to α-folate receptor–overexpressing tumors.
  • HY-12702
    10058-F4

    c-Myc Autophagy Cancer
    10058-F4 is a c-Myc inhibitor that prevents c-Myc-Max dimerization and transactivation of c-Myc target gene expression.
  • HY-N4139
    Protohypericin

    Others Cancer
    Protohypericin is a naturally occurring naphthodianthrone derived from plant Hypericum perforatum. Radioiodinated protohypericin is used in Tumor necrosis targeted radiotherapy.
  • HY-102007A
    Gamitrinib TPP hexafluorophosphate

    HSP Cancer
    Gamitrinib TPP hexafluorophosphate is a Gamitrinib (GA) mitochondrial matrix inhibitor. Gamitrinib TPP hexafluorophosphate is a mitochondrial targeted HSP90 inhibitor with anti-cancer activity.
  • HY-136269
    A 410099.1, amine-Boc hydrochloride

    E3 Ligase Ligand-Linker Conjugate Cancer
    A 410099.1, amine-Boc hydrochloride is a functionalized IAP ligand and can be used for the synthesis of PROTACs, such as PROTACs targeting BTK (PROTACs 4 and 5).
  • HY-10340
    Tirbanibulin

    KX2-391; KX-01

    Src Microtubule/Tubulin Cancer
    Tirbanibulin (KX2-391) is an inhibitor of Src that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines.
  • HY-126483
    Telomerase-IN-3

    Telomerase Cancer
    Telomerase-IN-3 is a telomerase inhibitor, which directly targets hTERT promoter activity. hTERT is the key component for maintenance of telomerase activity.
  • HY-P2322
    Iturin A

    Fungal
    IturinA exhibits strong antifungal activity against pathogenic yeast and fungi. Iturin A interacts with the cytoplasmic membrane of the target cell forming ion conducting pores.
  • HY-14989
    SQ109

    NSC 722041

    Parasite Bacterial Antibiotic Infection
    SQ109 is a potent inhibitor of the trypomastigote form of the parasite, with IC50 for cell killing of 50±8 nM. SQ109, targets MmpL3, is an antitubercular agent.
  • HY-10340A
    Tirbanibulin dihydrochloride

    KX2-391 dihydrochloride; KX-01 dihydrochloride

    Src Microtubule/Tubulin Cancer
    Tirbanibulin (dihydrochloride) (KX2-391 (dihydrochloride)) is an inhibitor of Src that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines.
  • HY-10187
    TG 100801 Hydrochloride

    VEGFR FGFR PDGFR Src Cancer
    TG 100801 Hydrochloride is a prodrug that generates TG 100572 by de-esterification in development to treat age-related macular degeneration. TG 100572 is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.
  • HY-N2187
    Deoxyshikonin

    Bacterial HIF/HIF Prolyl-Hydroxylase Cancer Infection Cardiovascular Disease
    Deoxyshikonin is isolated from Lithospermum erythrorhizon Sieb with antitumor activity. Deoxyshikonin increases the expression of VEGF-C and VEGF-A mRNA in HMVEC-dLy, promotes HIF-1α and HIF-1β subunit interaction and binds to specific DNA sequences targeted by HIF, indicates a prolymphangiogenesis as well as a proangiogenesis effect in vitro. Deoxyshikonin shows significant synergic antimicrobial activity against S. pneumonia (MIC=17 μg/mL), also shows significantly inhibitory activities against MRSA.
  • HY-50751
    Linifanib

    ABT-869; AL-39324

    PDGFR VEGFR FLT3 c-Fms c-Kit Autophagy Apoptosis Cancer
    Linifanib (ABT-869) is a potent and orally active multi-target inhibitor of VEGFR and PDGFR family with IC50s of 4, 3, 66, and 4 nM for KDR, FLT1, PDGFRβ, and FLT3, respectively. Linifanib shows prominent antitumor activity. Linifanib has much less activity against unrelated RTKs, soluble tyrosine kinases, or serine/threonine kinases. Linifanib is a specific miR-10b inhibitor that blocks miR-10b biogenesis.
  • HY-10186
    TG 100801

    VEGFR FGFR PDGFR Src Cancer
    TG 100801 is a prodrug that generates TG 100572 by de-esterification in development to treat age-related macular degeneration. TG 100572 is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.
  • HY-100419
    BFH772

    VEGFR Cancer
    BFH772 is a potent oral VEGFR2 inhibitor, which is highly effective at targeting VEGFR2 kinase with an IC50 value of 3 nM.
  • HY-G0017A
    N-Desmethyl imatinib mesylate

    Norimatinib mesylate; Imatinib metabolite N-Desmethyl imatinib mesylate

    Drug Metabolite Others
    N-Desmethyl imatinib mesylate (Norimatinib mesylate) is a metabolite of Imatinib (HY-15463). Imatinib is a multi-target inhibitor of v-Abl, c-Kit and PDGFR.
  • HY-111847
    Androstanolone acetate

    Androgen Receptor Ligand for Target Protein for PROTAC Cancer
    Androstanolone acetate is an androgen ligand, which targets androgen receptor (AR). Androstanolone acetate binds to cIAP1 ligand Bestatin via a linker to form PROTACs.
  • HY-15440
    Temsavir

    BMS-626529

    HIV Infection
    Temsavir (BMS-626529) is a novel attachment inhibitor that targets HIV-1 gp120 and prevents its binding to CD4 + T cells.
  • HY-10331S
    Regorafenib D3

    BAY 73-4506 D3

    VEGFR Autophagy PDGFR Raf RET Cancer
    Regorafenib D3 (BAY 73-4506 D3) is a deuterium labeled Regorafenib. Regorafenib is a multi-targeted receptor tyrosine kinase inhibitor.
  • HY-111927
    Pilloin

    Others Cancer Inflammation/Immunology
    Pilloin, a flavonoid isolated from Marrubium cylleneum, exerts a cytotoxic action targeted at the transformed lymphoblasts. Pilloin also possesses anti-inflammatory activity.
  • HY-13442
    Eribulin

    B1939; E7389; ER-086526

    Microtubule/Tubulin Apoptosis Cancer
    Eribulin (E7389) is a microtubule targeting agent that is used for the research of metastatic breast cancer. Eribulin inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules.
  • HY-G0017
    N-Desmethyl imatinib

    Norimatinib; Imatinib metabolite N-Desmethyl imatinib

    Drug Metabolite Others
    N-Desmethyl imatinib (Norimatinib) is a metabolite of Imatinib (HY-15463). Imatinib is a multi-target inhibitor of v-Abl, c-Kit and PDGFR.
  • HY-111651
    Gboxin

    ATP Synthase Mitochondrial Metabolism Cancer
    Gboxin is an oxidative phosphorylation (OXPHOS) inhibitor that targets glioblastoma. Gboxin inhibits the activity of F0F1 ATP synthase. Antitumour activity.
  • HY-111606
    DUPA

    Ligand for Target Protein for PROTAC Cancer
    DUPA, belongs to a class of glutamate ureas, is used as the targeting moiety in drug conjugate to selectively deliver cytotoxic drugs to prostate cancer cells.
  • HY-10407
    SU 5402

    VEGFR FGFR PDGFR Cancer
    SU 5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC50 of 20 nM, 30 nM, and 510 nM for VEGFR2, FGFR1, and PDGFRβ, respectively.
  • HY-P1727
    Super-TDU

    YAP Cancer
    Super-TDU is a specific YAP antagonist targeting YAP-TEADs interaction. Super-TDU suppresses tumor growth in gastric cancer mouse model.
  • HY-14456A
    MAC13243

    Bacterial Infection
    MAC13243, an antibacterial agent, is an inhibitor of bacterial lipoprotein targeting chaperone, LolA. MAC13243 is an antibacterial agent with Gram-negative selectivity.
  • HY-12134
    Poloxin

    Polo-like Kinase (PLK) Cancer
    Poloxin is a non-ATP competitive Polo-like Kinase 1 (PLK1) inhibitor that targets the polo-box domain, with an IC50 of appr 4.8 μM.
  • HY-13442A
    Eribulin mesylate

    B1939 mesylate; E7389 mesylate; ER-086526 mesylate

    Microtubule/Tubulin Apoptosis Cancer
    Eribulin mesylate (E7389 mesylate) is a microtubule targeting agent that is used for the research of metastatic breast cancer. Eribulin mesylate inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules.
  • HY-129774
    Phthalimide-PEG4-MPDM-OH

    PROTAC Linker Cancer
    Phthalimide-PEG4-MPDM-OH is a PROTAC linker, which refers to the PEGs composition. Phthalimide-PEG4-MPDM-OH can be used in the synthesis of a series of PROTACs. PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.
  • HY-130715
    tert-Butyl 11-aminoundecanoate

    PROTAC Linker Cancer
    tert-Butyl 11-aminoundecanoate (compound 6b) is a PROTAC linker, which refers to the PEG composition. tert-Butyl 11-aminoundecanoate can be used in the synthesis of a series of PROTACs. PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.
  • HY-129773
    Phthalimide-PEG4-PDM-OTBS

    PROTAC Linker Cancer
    Phthalimide-PEG4-PDM-OTBS is a PROTAC linker, which refers to the PEGs composition. Phthalimide-PEG4-PDM-OTBS can be used in the synthesis of a series of PROTACs. PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.
  • HY-101238
    Agmatine sulfate

    Imidazoline Receptor NO Synthase Endogenous Metabolite Neurological Disease Cancer
    Agmatine sulfate exerts modulatory action at multiple molecular targets, such as neurotransmitter systems, ion channels and nitric oxide synthesis. It is an endogenous agonist at imidazoline receptor and a NO synthase inhibitor.
  • HY-119433
    Asoprisnil

    J867

    Progesterone Receptor Endocrinology
    Asoprisnil (J867), a selective progesterone receptor modulator, exhibits mixed progesterone agonist and antagonist effects on various progesterone targeted tissues in animal and human.
  • HY-B1408
    Salicylanilide

    2-Hydroxybenzanilide

    HIV Integrase HIV Infection
    Salicylanilide demonstrates a wide range of biological activities including antiviral potency which can inhibit HIV virus by targeting HIV-1 integrase or reverse transcriptase.
  • HY-B1161
    Methoprene

    ZR-515

    Others Others
    Methoprene, an insect juvenile growth hormone mimic, is a growth-regulating insecticide that manifests its toxicity to target organisms by acting as a juvenile hormone agonist.
  • HY-136374
    Haloxyfop-P-methyl

    Others Others
    Haloxyfop-P-methyl is an aryloxyphenoxypropionate herbicide. Haloxyfop-P-methyl can be absorbed by roots or foliage and hampers lipogenesis and increases oxidative stress in target plants.
  • HY-Y1750
    β-Aminopropionitrile

    Monoamine Oxidase Cancer
    β-Aminopropionitrile is a specific and irreversible lysyl oxidase (LOX) inhibitor. β-Aminopropionitrile targets the active site of LOX or LOXL isoenzymes.
  • HY-W010450
    Thymine

    Endogenous Metabolite Cancer Metabolic Disease
    Thymine is one of the four nucleobases in the nucleic acid of DNA and can be a target for actions of 5-fluorouracil (5-FU) in cancer treatment, with a Km of 2.3 μM.
  • HY-131335
    p38α inhibitor 2

    p38 MAPK Inflammation/Immunology
    p38α inhibitor 2 is a highly potent and selective p38α MAPK inhibitor, with a pIC50 of 9.6. p38α inhibitor 2 inhibits the hERG ion channel (IC50=27 μM) and shows a promising selectivity profile when tested in a panel of 51 other protein kinases (<30% inhibition at 10 μM concentration) and a panel of 141 other biological targets.
  • HY-14754
    Salirasib

    S-Farnesylthiosalicylic acid; Farnesyl Thiosalicylic Acid; FTS

    Ras Autophagy Cancer
    Salirasib is a Ras inhibitor that inhibits specifically both oncogenically activated Ras and growth factor receptor-mediated Ras activation, resulting in the inhibition of Ras-dependent tumor growth.
  • HY-17398
    Mitiglinide Calcium

    KAD-1229; S21403

    Potassium Channel Metabolic Disease
    Mitiglinide Calcium (KAD-1229), an insulinotropic agent, is an ATP-sensitive K + (KATP) channel antagonist. Mitiglinide Calcium is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide Calcium can be used for the research of type 2 diabetes.
  • HY-W013886
    Captopril EP Impurity J

    S-Acetylcaptopril

    Others Others
    Captopril EP Impurity J is an impurity of Captopril. Captopril (SQ-14534), antihypertensive agent, is a thiol-containing competitive, orally active angiotensin-converting enzyme (ACE) inhibitor (IC50=0.025 μM).
  • HY-15677A
    INT-777 R-enantiomer

    S-EMCA R enantiomer

    GPCR19 Others
    INT-777 (R-enantiomer) is the R-enantiomer of INT-777, with EC50 of 4.79 μM for TGR5, and less potent than INT-777.
  • HY-113039
    L-2-Hydroxyglutaric acid

    (S)-2-Hydroxyglutaric acid

    Histone Demethylase Mitochondrial Metabolism Endogenous Metabolite Cancer
    L-2-Hydroxyglutaric acid is an epigenetic modifier and putative oncometabolite in renal cancer. L-2-Hydroxyglutaric acid can inhibit histone demethylases and hence promote histone methylation. L-2-Hydroxyglutaric acid inhibits mitochondrial creatine kinase (Mi-CK) activity with Km and Ki of 2.52 mM and 11.13 mM, respectively.
  • HY-B0381B
    Levobetaxolol hydrochloride

    (S)-Betaxolol hydrochloride; AL-1577A

    Adrenergic Receptor Neurological Disease Endocrinology
    Levobetaxolol hydrochloride is a beta-adrenergic receptor inhibitor (beta blocker) that can lower the pressure in the eye.
  • HY-15592
    Cabotegravir

    GSK-1265744; S/GSK1265744

    HIV HIV Integrase Infection
    Cabotegravir is a potent HIV integrase inhibitor as an oral lead-in tablet and long-acting injectable for the treatment and prevention of HIV infection.
  • HY-B1178
    Cotinine

    (-)-Cotinine; (S)-Cotinine; NIH-10498

    Endogenous Metabolite Others
    Cotinine is an alkaloid found in tobacco and is also the predominant metabolite of nicotine, used as a biomarker for exposure to tobacco smoke.
  • HY-B1352
    L-Ornithine

    (S)-2,5-Diaminopentanoic acid

    Endogenous Metabolite Others
    L-ornithine has an antifatigue effect in increasing the efficiency of energy consumption and promoting the excretion of ammonia.
  • HY-N0605
    Ginsenoside Rh2

    20(S)-Ginsenoside Rh2; 20(S)-Rh2; Ginsenoside-Rh2

    Caspase Apoptosis Endogenous Metabolite Cancer
    Ginsenoside Rh2 induces the activation of caspase-8 and caspase-9. Ginsenoside Rh2 induces cancer cell apoptosis in a multi-path manner.
  • HY-131341
    Syk-IN-4

    Syk Cancer Inflammation/Immunology
    Syk-IN-4 is a potent, selective and orally bioavailable SYK inhibitor with an IC50 of 0.31 nM. SYK has emerged as a potential target for autoimmunity and hematological cancers.
  • HY-108708
    GeA-69

    PARP Cancer
    GeA-69 is a selective, allosteric inhibitor of poly-adenosine-diphosphate-ribose polymerase 14 (PARP14) targeting macrodomain 2, with a Kd of 2.1 µM.
  • HY-130637
    Boc-NH-PEG1-Ph-O-CH2COOH

    PROTAC Linker Cancer
    Boc-NH-PEG1-Ph-O-CH2COOH is a PROTAC Linker which is used for the EED-targeted PROTAC.
  • HY-N6046
    Kamebakaurin

    NF-κB Cancer Inflammation/Immunology
    Kamebakaurin is a natural compound isolated from Isodon japonicus. Kamebakaurin is a potent inhibitor of NF-κB activation by directly targeting DNA-binding activity of p50.
  • HY-N0200
    Albaspidin AP

    Fatty Acid Synthase (FASN) Cancer Metabolic Disease
    Albaspidin AP inhibits fatty acid synthase (FAS) with an IC50 value of 71.7 μM. Fatty acid synthase (FAS) is emerging as a potential therapeutic target for cancer and obesity.
  • HY-B0795
    MHY1485

    mTOR Autophagy Cancer
    MHY1485 is a potent cell-permeable mTOR activator that targets the ATP domain of mTOR. MHY1485 inhibits autophagy by suppression of fusion between autophagosomes and lysosomes.
  • HY-103591
    DUPA(OtBu)-OH

    Others Cancer
    DUPA(OtBu)-OH is a DUPA precursor. DUPA is used as the targeting moiety to actively deliver Docetaxel (DTX) for treatment of Prostate-Specific Membrane Antigen (PSMA) expressing prostate cancer.
  • HY-17369
    Tirofiban hydrochloride monohydrate

    Integrin Cardiovascular Disease
    Tirofiban hydrochloride monohydrate is a potent non-peptide, glycoprotein IIb/IIIa (integrins alphaIIbbetaIII) antagonist IC50 value: Target: integrin IIb/IIIa Tirofiban hydrochloride monohydrate blocks platelet aggregation and thrombus formation.
  • HY-15244
    Alpelisib

    BYL-719

    PI3K Cancer
    Alpelisib (BYL-719) is a potent, selective, and orally active PI3Kα inhibitor. Alpelisib (BYL-719) shows efficacy in targeting PIK3CA-mutated cancer. Alpelisib (BYL-719) also inhibits p110α/p110γ/p110δ/p110β with IC50s of 5/250/290/1200 nM, respectively. Antineoplastic activity.
  • HY-111866
    PROTAC RIPK degrader-2

    PROTAC RIP kinase Inflammation/Immunology
    PROTAC RIPK degrader-2 is a nonpeptidic PROTAC which potently targets serine-threonine kinase RIPK2 and has highly selective for RIPK2 degradation.
  • HY-129939
    PROTAC BRD4 ligand-1

    Epigenetic Reader Domain Ligand for Target Protein for PROTAC Cancer
    PROTAC BRD4 ligand-1 is a potent BET inhibitor and a ligand for target BRD4 protein for PROTACT GNE-987 (HY-129937A).
  • HY-102028
    KY1220

    Wnt β-catenin Cancer
    KY1220 is a compound that destabilizes both β-catenin and Ras, via targeting the Wnt/β-catenin pathway; with an IC50 of 2.1 μM in HEK293 reporter cells.
  • HY-112901
    DC41

    ADC Cytotoxin Cancer
    DC41 is a DC1 derivative. DC1, a simplified analogue of CC-1065, is an antibody conjugate of cytotoxic DNA alkylators for the targeted treatment of cancer.
  • HY-112999
    Serelaxin

    RLX-030

    Others Inflammation/Immunology Cardiovascular Disease
    Serelaxin (RLX-030), a recombinant form of human gene-2 relaxin targeting the RLN receptor, is a vasoactive peptide hormone with an antifibrotic activity.
  • HY-B0863
    Glyphosate

    Apoptosis Autophagy Cancer
    Glyphosate is an herbicidal derivative of the amino acid glycine. Glyphosate targets and blocks a plant metabolic pathway not found in animals, the shikimate pathway, required for the synthesis of aromatic amino acids in plants.
  • HY-B0323
    Sulfisoxazole

    Sulfafurazole

    Bacterial Endothelin Receptor Antibiotic Cancer Infection Endocrinology
    Sulfisoxazole (Sulfafurazole), an endothelin receptor antagonist, is a sulfonamide antibacterial with an oxazole substituent. Sulfisoxazole inhibits breast cancer exosome release by targeting endothelin receptor A.
  • HY-101261
    ATPA

    iGluR Neurological Disease
    ATPA is a selective glutamate receptor GluR5 activator with EC50s of 0.66, 9.5, 1.4, 23, 32, 18, and 14 μM for GluR5wt, GluR5(S741M), GluR5(S721T), GluR5(S721T, S741M), GluR5(S741A), GluR5(S741L), and GluR5(S741V), respectively.
  • HY-15533
    LY 3000328

    Cathepsin Inflammation/Immunology
    LY 3000328 is a potent and selective Cathepsin S (Cat S) inhibitor with IC50s of 7.7 and 1.67 nM for hCat S and mCat S, respectively.
  • HY-112899
    DC1

    ADC Cytotoxin DNA Alkylator/Crosslinker Cancer
    DC1, an analogue of the minor groove-binding DNA alkylator CC-1065, is a ADC Cytotoxin. DC1 can be used in synthesis of antibody-drug conjugates for the targeted treatment of cancer.
  • HY-109084
    Conteltinib

    CT-707

    FAK Cancer
    Conteltinib (CT-707) is a multi-kinase inhibitor targeting FAK, ALK, and Pyk2. Conteltinib exerts significant inhibitory effect on FAK with an IC50 of 1.6 nM.
  • HY-W028047
    JFD01307SC

    Bacterial Infection Inflammation/Immunology
    JFD01307SC is a glutamine synthetase inhibitor and anti-tuberculosis agent. JFD01307SC acts as a mimic of L-Glutamate and thus target enzymes involved in glutamine biosynthesis.
  • HY-N0135
    Tanshinone IIA

    Dan Shen ketone

    VEGFR Cardiovascular Disease Cancer
    Tanshinone IIA (Tan IIA) is one of the main compositions in the root of red-rooted salvia. Tanshinone IIA may suppress angiogenesis by targeting the protein kinase domains of VEGF/VEGFR2.
  • HY-139149
    NiCur

    Histone Acetyltransferase Cancer
    NiCur is a potent and selective CBP HAT inhibitor with an IC50 value of 0.35 μΜ. NiCur can be used for performing mechanistic studies without affecting the expression of target proteins.
  • HY-W004546
    Abametapir

    MMP Parasite Infection
    Abametapir is a metalloproteinase (MMP) inhibitor which is able to target metalloproteinases critical to egg hatching and louse development. Abametapir can inhibit hatching of both head and body louse.
  • HY-13030A
    (R)-(-)-JQ1 Enantiomer

    Epigenetic Reader Domain Cancer
    (R)-(-)-JQ1 Enantiomer is the stereoisomer of (+)-JQ1. (+)-JQ1 potently decreases expression of both BRD4 target genes, whereas (R)-(-)-JQ1 Enantiomer has no effect.
  • HY-136373
    Metazachlor

    Others Others
    Metazachlor is a herbicide of the chloroacetamide class. Metazachlor is an inhibitor of the synthesis of long chain fatty acids and has an effect on cell division or tissue differentiation in the germinating and emerging weed target species.
  • HY-119165
    GSM-1

    γ-secretase Neurological Disease
    GSM-1 is a potent γ-secretase modulator. GSM-1 directly targets the transmembrane domain (TMD) 1 of presenilin 1 (PS1).
  • HY-N1455
    Falcarinol

    Panaxynol; Carotatoxin

    HSP Cancer
    Falcarinol (Panaxynol) is a natural, orally active Hsp90 inhibitor targeting both the N-terminal and C-terminal of Hsp90 with limited toxicities. Falcarinol (Panaxynol) induces apoptosis.
  • HY-15283
    Clopidogrel

    P2Y Receptor Cardiovascular Disease
    Clopidogrel is an orally active platelet inhibitor that targets P2Y12 receptor. Clopidogrel is used to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.
  • HY-111870
    PROTAC RIPK degrader-6

    PROTAC RIP kinase Cancer
    PROTAC RIPK degrader-6 (example 1) is a PROTAC targeting RIP Kinase degradation wherein the RIP2 kinase inhibitor is linked via a linker to a cereblon binder.
  • HY-114406
    TD-106

    Ligand for E3 Ligase Cancer
    TD-106 is a cereblon (CRBN) modulator, which can be used for targeted protein degradation. BRD4 PROTACs with TD-106 induce BRD4 degradation.
  • HY-B1100
    Estradiol (cypionate)

    Estrogen Receptor/ERR Endocrinology Cancer
    Estradiol cypionate is a 17 β-cyclopentylpropinate ester of estradiol, inhibits ET-1 synthesis via estrogen receptor IC50 value: Target: estrogen receptor Estradiol cypionate is a synthetic ester, is a estrogen.
  • HY-111605
    Macropa-NCS

    Others Cancer
    Macropa-NCS is conjugated to trastuzumab as well as to the prostate-specific membrane antigen-targeting compound RPS-070. A promising therapeutic radionuclide applied in the treatment of soft-tissue metastases.
  • HY-13943
    CNX-774

    Btk Cancer
    CNX-774 is an orally active, irreversible and selective BTK inhibitor, with an IC50 of < 1 nM. CNX-774 specifically targets Cysteine 481 of Btk for covalent modification.
  • HY-129772
    Phthalimide-PEG3-C2-OTs

    PROTAC Linker Cancer
    Phthalimide-PEG3-C2-OTs (Compound 5) is a PROTAC linker, which refers to the PEGs composition. Phthalimide-PEG3-C2-OTs can be used in the synthesis of a series of PROTACs. PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.
  • HY-40178
    NH2-C4-NH-Boc

    PROTAC Linker Cancer
    NH2-C4-NH-Boc (compound 15) is a PROTAC linker, which refers to the Alkyl/ether composition. NH2-C4-NH-Boc can be used in the synthesis of a series of PROTACs. PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.
  • HY-112611
    H3B-5942

    Estrogen Receptor/ERR Cancer
    H3B-5942 is a selective, irreversible and orally active estrogen receptor covalent antagonist, inactivates both wild-type and mutant ERα by targeting Cys530, with Kis of 1 nM and 0.41 nM, respectively. H3B-5942 reduces ERα target gene GREB1, shows potent antitumor activity both in multiple cell lines or animals bearing ERα WT or ERα mutations.
  • HY-131014
    FM-479

    JAK Inflammation/Immunology
    FM-479 is the negative control of FM-381 (HY-102046) and has no activity on JAK3 or other kinases. FM-381 is a potent covalent reversible inhibitor of JAK3 targeting the unique Cys909. FM-381 has an IC50 of 127 pM for JAK3, with 410, 2700 and 3600-fold selectivity over JAK1, JAK2 and TYK2, respectively.
  • HY-15843
    MIR96-IN-1

    MicroRNA Apoptosis Cancer
    MIR96-IN-1 targets the Drosha site in the miR-96 (miRNA-96, microRNA-96) hairpin precursor, inhibiting its biogenesis, derepressing downstream targets, and triggering apoptosis in breast cancer cells. MIR96-IN-1 binds to RNAs with Kds of 1.3, 9.4, 3.4, 1.3 and 7.4 μM for RNA1, RNA2, RNA3, RNA4 and RNA5, respectively.
  • HY-129359
    PDP-Pfp

    ADC Linker Cancer
    PDP-Pfp is a reducible ADC linker used for the agents that target for the extracellular loop 1 (ECL1) of TM4SF1 (transmembrane 4 L6 family member 1).
  • HY-B0147A
    Pefloxacin mesylate

    Pefloxacinium mesylate

    Bacterial Antibiotic Infection
    Pefloxacin mesylate is a an antibacterial agent and prevents bacterial DNA replication by inhibiting DNA gyrase (topoisomerse) Target: DNA gyrase Pefloxacin is a synthetic chemotherapeutic agent used to treat severe and life-threatening bacterial infections.
  • HY-B0147
    Pefloxacin

    Pefloxacinium

    Bacterial Antibiotic Infection
    Pefloxacin is a an antibacterial agent and prevents bacterial DNA replication by inhibiting DNA gyrase (topoisomerse) Target: DNA gyrase Pefloxacin is a synthetic chemotherapeutic agent used to treat severe and life-threatening bacterial infections.
  • HY-P1674A
    Murepavadin TFA

    POL7080 TFA

    Bacterial Antibiotic Infection
    Murepavadin (TFA), a 14-amino-acid cyclic peptide, is a highly potent, specific antibiotic for the treatment of bacterial infections caused by Pseudomonas aeruginosa. Murepavadin (TFA) targets the lipopolysaccharide transport portin D .
  • HY-B1418
    Tazobactam

    CL-298741; YTR-830H

    Bacterial Antibiotic Infection
    Tazobactam is a beta Lactamase Inhibitor with antibacterial activity Target: Antibacterial Tazobactam is a pharmaceutical drug that inhibits the action of bacterial β-lactamases, especially those belonging to the SHV-1 and TEM groups.
  • HY-78695
    JQ-1 (carboxylic acid)

    Epigenetic Reader Domain Cancer
    JQ-1 carboxylic acid is a (+)-JQ1 derivative (a BET bromodomain inhibitor). JQ-1 carboxylic acid can be used as a precursor to synthesize PROTACs, which targets BET bromodomains.
  • HY-126320
    EGFR-IN-8

    EGFR c-Met/HGFR Cancer
    EGFR-IN-8 is a dual EGFR and c-Met inhibitor, compound 48. EGFR-IN-8 can be a promising candidate for further development to target EGFR TKI-resistant NSCLC.
  • HY-N2065
    Withaferin A

    NF-κB Ferroptosis Cancer Inflammation/Immunology
    Withaferin A is a steroidal lactone isolated from Withania somnifera, inhibits NF-kB activation and targets vimentin, with potent antiinflammatory and anticancer activities. Withaferin A is an inhibitor of endothelial protein C receptor (EPCR) shedding.
  • HY-122816
    HLY78

    Wnt Cancer Neurological Disease
    HLY78 is an activator of the Wnt/β-catenin signaling pathway, which targets the DIX domain of Axin and potentiates the Axin-LRP6 association to promote Wnt signaling transduction.
  • HY-131633A
    (+)-JQ-1-aldehyde

    Epigenetic Reader Domain Cancer
    (+)-JQ-1-aldehyde is the aldehyde form of (+)-JQ1. (+)-JQ-1-aldehyde can be uesd as a precursor to synthesize PROTACs, which targets BET bromodomains.
  • HY-108494
    CYM50260

    LPL Receptor Cardiovascular Disease
    CYM50260 is a potent and exquisitely selective sphingosine-1-phosphate 4 receptor (S1P4-R) agonist with an EC50 of 45 nM. CYM50260 displays no activity against S1P1-R, S1P2-R, S1P3-R and S1P5-R.
  • HY-B1050
    Gemifloxacin mesylate

    SB-265805S; LB-20304a

    Bacterial Infection
    Gemifloxacin mesylate is an oral broad-spectrum quinolone antibacterial agent, used in the treatment of acute bacterial exacerbation of chronic bronchitis, and mild-to-moderate pneumonia.
  • HY-77839
    Cortodoxone

    11-Deoxycortisol; cortexolone; Reichstein's substance S

    Glucocorticoid Receptor Endogenous Metabolite Inflammation/Immunology Endocrinology
    Cortodoxone is a glucocorticoid steroid hormone that can be oxygenated to cortisol (Hydrocortisone).
  • HY-14615
    [6]-Gingerol

    (S)-(+)-[6]Gingerol; 6-Gingerol

    AMPK Apoptosis Cancer
    [6]-Gingerol is an active compound isolated from Ginger (Zingiber officinale Rosc), exhibits a variety of biological activities including anticancer, anti-inflammation, and anti-oxidation.
  • HY-101748
    Tegadifur

    40497S; FD 1

    Others Cancer
    Tegadifur is a fluorine-containing and anti-metabolic drug.
  • HY-136684
    BrBzGCp2

    S-p-Bromobenzylglutathione cyclopentyl diester

    Others Cancer Neurological Disease
    BrBzGCp2 is a Glyoxalase 1 (GLO1) inhibitor, with a GC50 of 4.23 μM in HL-60 cells. BrBzGCp2 possesses antitumor and neuroprotective activity.
  • HY-17438A
    Cidofovir dihydrate

    HPMPC dihydrate; (S)-HPMPC dihydrate

    CMV Infection
    Cidofovir dehydrate is an injectable antiviral medication for the treatment of cytomegalovirus (CMV) retinitis, which suppresses virus replication by selective inhibition of viral DNA synthesis.
  • HY-13615A
    EC-17 disodium salt

    Others Cancer
    EC-17 (disodium salt) is a folate receptor alpha (FRα) targeting contrast agent with fluorescent properties in the visible light spectrum. The peak excitation and emission wavelengths of EC-17 are 470/520 nm.
  • HY-D1267
    PAO-Nap

    Apoptosis Cancer
    PAO-Nap is the modified PAO attached a naphthalimide fluorophore using aminocaproic acid as a linker. PAO induces oxidative stress-mediated apoptosis in HL-60 cells by selectively targeting thioredoxin reductase.
  • HY-12703
    KSI-3716

    c-Myc Autophagy Cancer
    KSI-3716 is a potent c-Myc inhibitor that blocks c-MYC/MAX binding to target gene promoters. KSI-3716 is an effective intravesical chemotherapy agent for bladder cancer.
  • HY-B0147B
    Pefloxacin mesylate dihydrate

    Pefloxacinium mesylate dihydrate

    Bacterial Antibiotic Infection
    Pefloxacin mesylate dehydrate is a an antibacterial agent and prevents bacterial DNA replication by inhibiting DNA gyrase (topoisomerse) Target: DNA gyrase Pefloxacin is a synthetic chemotherapeutic agent used to treat severe and life-threatening bacterial infections.
  • HY-108547
    Alexidine dihydrochloride

    Fungal Apoptosis Infection
    Alexidine dihydrochloride is an anticancer agent that targets a mitochondrial tyrosine phosphatase, PTPMT1, in mammalian cells and causes mitochondrial apoptosis. Alexidine dihydrochloride has antifungal and antibiofilm activity against a diverse range of fungal pathogens.
  • HY-100806
    Kynurenic acid

    Quinurenic acid

    iGluR Endogenous Metabolite Apoptosis Inflammation/Immunology Neurological Disease Endocrinology
    Kynurenic acid, an endogenous tryptophan metabolite, is a broad-spectrum antagonist targeting NMDA, glutamate, α7 nicotinic acetylcholine receptor. Kynurenic acid is also an agonist of GPR35/CXCR8.
  • HY-N4053
    Heraclenin

    Others Inflammation/Immunology
    Heraclenin, a natural furanocoumarin, significantly inhibits T cell receptor-mediated proliferation in human primary T cells in a concentration-dependent manner by targeting nuclear factor of activated T-cells (NFAT).
  • HY-13613
    Dutasteride

    GG 745; GI 198745

    5 alpha Reductase Apoptosis Cancer
    Dutasteride (GG745) is a potent inhibitor of both 5α-reductase isozymes. Dutasteride may possess off-target effects on the androgen receptor (AR) due to its structural similarity to DHT.
  • HY-107512
    Kynurenic acid sodium

    iGluR Apoptosis Inflammation/Immunology Neurological Disease Endocrinology
    Kynurenic acid sodium, an endogenous tryptophan metabolite, is a broad-spectrum antagonist targeting NMDA, glutamate, α7 nicotinic acetylcholine receptor. Kynurenic acid sodium is also an agonist of GPR35/CXCR8.
  • HY-13217
    Vanoxerine dihydrochloride

    GBR-12909 dihydrochloride; I893 dihydrochloride

    Dopamine Transporter Neurological Disease
    Vanoxerine dihydrochloride (GBR-12909 dihydrochloride) is a competitive, potent, and highly selective dopamine reuptake inhibitor (Ki=1 nM). Vanoxerine dihydrochloride (GBR-12909 dihydrochloride) binds to the target site on the dopamine transporter (DAT).
  • HY-N7449
    Neamine

    Bacterial Cancer Infection Neurological Disease Cardiovascular Disease
    Neamine is a non-toxic derivative derivative of Neomycin and is a broad-spectrum aminoglycoside antibiotic. Neamine is an anti-angiogenesis agent targeting angiogenin. Neamine has potent antibacterial, antitumor and neuroprotective activities.
  • HY-13217A
    Vanoxerine

    GBR 12909; I893

    Dopamine Transporter Neurological Disease
    Vanoxerine (GBR-12909) is a competitive, potent, and highly selective dopamine reuptake inhibitor (Ki=1 nM). Vanoxerine (GBR-12909) binds to the target site on the dopamine transporter (DAT).
  • HY-N6257
    Cafestol

    ERK PGE synthase COX NF-κB Cancer Inflammation/Immunology
    Cafestol, one of the major components of coffee, is a coffee-specific diterpene from. Cafestol is a ERK inhibitor for AP-1-targeted activity against PGE2 production and the mRNA expression of cyclooxygenase (COX)-2 in LPS-activated RAW264.7 cells. Cafestol has strong inhibitory activity on PGE2 production by suppressing the NF-kB activation pathway. Cafestol contributes to its beneficial effects through various biological activities such as chemopreventive, antitumorigenic, hepatoprotective, antioxidative and antiinflammatory effects.
  • HY-108495
    CYM50308

    ML248

    LPL Receptor Cardiovascular Disease
    CYM50308 (ML248) is a potent, selective and high affinity sphingosine-1-phosphate receptor 4 (S1P4-R) agonist with an EC50 of 56 nM. CYM50308 displays 37-fold more selective for S1P4-R than S1P5-R. CYM50308 has no activity at S1P1-R, S1P2-R and S1P3-R subtypes at concentrations up to 25 μM.
  • HY-101939
    RP-001

    LPL Receptor Neurological Disease
    RP-001 is a picomolar short-acting S1P1 (EDG1) selective agonist, with an EC50 of 9 pM. RP-00 induces internalization and polyubiquitination of S1P1. RP-001 has little activity on S1P2-S1P4 and only moderate affinity for S1P5.
  • HY-101939A
    RP-001 hydrochloride

    LPL Receptor Neurological Disease
    RP-001 hydrochloride is a picomolar short-acting S1P1 (EDG1) selective agonist, with an EC50 of 9 pM. RP-00 hydrochloride induces internalization and polyubiquitination of S1P1. RP-001 hydrochloride has little activity on S1P2-S1P4 and only moderate affinity for S1P5.
  • HY-P3108
    Alamandine

    Angiotensin Receptor Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Alamandine, a member of the renin-angiotensin system (RAS), a vasoactive peptide, is an endogenous ligand of the G protein-coupled receptor MrgD. Alamandine targets to protect the kidney and heart through anti-hypertensive actions.
  • HY-N6062
    Perivine

    Perivin

    Others Neurological Disease
    Perivine (Perivin) targets protein retinoblastoma-associated proteins (RbAp48) and resolves the instability of the RbAp48-FOG-1 complex. Perivine can be used for the study of Alzheimer's disease.
  • HY-135232
    MMP-9-IN-1

    MMP Cancer
    MMP-9-IN-1 is a specific matrix metalloproteinase-9 (MMP-9) inhibitor, which selectively target the hemopexin (PEX) domain of MMP-9, but not other MMPs.
  • HY-17369B
    Tirofiban

    L700462; MK383

    Integrin Cardiovascular Disease
    Tirofiban(L700462;MK383) is a potent non-peptide, glycoprotein IIb/IIIa (integrins alphaIIbbetaIII) antagonist Target: integrin IIb/IIIa Tirofiban hydrochloride monohydrate blocks platelet aggregation and thrombus formation.
  • HY-N6850
    Calenduloside E

    HSP Endogenous Metabolite
    Calenduloside E (CE) is a natural pentacyclic triterpenoid saponin extracted from Aralia elata. Calenduloside E (CE) has anti-apoptotic potent by targeting heat shock protein 90 (Hsp90).
  • HY-130253
    IRAK4-IN-6

    IRAK Cancer
    IRAK4-IN-6 is an orally efficacious and selective IRAK4 inhibitor with an IC50 of 4 nM, and targetes MyD88 L265P mutant diffuse large B cell lymphoma.
  • HY-119989
    Cyclopyrimorate

    Others Infection
    Cyclopyrimorate, a highly effective bleaching herbicide for weed control in rice fields, targets homogentisate solanesyltransferase (HST). HST is a downstream enzyme of 4-hydroxyphenylpyruvate dioxygenase in the plastoquinone (PQ) biosynthesis pathway.
  • HY-18312
    PF-4618433

    Pyk2 Metabolic Disease
    PF-4618433 is a potent and selective PYK2 inhibitor, with an IC50 of 637 nM. PF-4618433 may be suitable for the research of osteoporosis, craniofacial and appendicular skeletal defects and for targeted bone regeneration.
  • HY-135868
    Mito-apocynin (C2)

    Mitochondrial Metabolism Neurological Disease
    Mito-apocynin (C2), an orally active mitochondria-targeted triphenylphosphonium (TPP)-based compound, is synthesized by conjugating the Apocynin moiety with a TPP + cation. Mito-apocynin (C2) exhibits antineuroinflammatory effect.
  • HY-19511
    GSK2018682

    LPL Receptor Inflammation/Immunology
    GSK2018682 is an agonist for S1P1 and S1P5 receptor with pEC50s of 7.7 and 7.2, respectively, and has no agonist activity towards human S1P2, S1P3, or S1P4. GSK2018682 is used in the research of multiple sclerosis.
  • HY-10981A
    Lenvatinib mesylate

    E7080 mesylate

    VEGFR FGFR PDGFR RET c-Kit Cancer
    Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities.
  • HY-109000
    Afabicin

    Debio 1450; AFN-1720

    Bacterial Infection
    Afabicin (Debio 1450) is the prodrug of Debio1452, specifically targeting staphylococci without significant activity against other Gram-positive or Gram-negative species. Debio1452 is an inhibitor FabI, an enzyme critical to fatty acid biosynthesis in staphylococci.
  • HY-10517
    Orantinib

    SU6668; TSU-68

    PDGFR FGFR VEGFR Apoptosis Cancer
    Orantinib (SU6668; TSU-68) is a multi-targeted receptor tyrosine kinase inhibitor with Kis of 2.1 μM, 8 nM and 1.2 μM for Flt-1, PDGFRβ and FGFR1, respectively.
  • HY-128938
    EC1167

    Others Cancer
    EC1167 is the linker for EC1169. EC1169 is prostate-specific membrane antigen targeting-tubulysin conjugate. EC1169 has the potential to treat recurrent metastatic, castration-resistant prostate cancer (MCRPC).
  • HY-B1057
    Nefopam hydrochloride

    Fenazoxine hydrochloride

    β-catenin Neurological Disease
    Nefopam hydrochloride (Fenazoxine hydrochloride) is a centrally-acting but non-opioid analgesic drug, for the relief of moderate to severe pain. Nefopam hydrochloride targets β-catenin protein level in mesenchymal cells in-vitro and in-vivo.
  • HY-10981
    Lenvatinib

    E7080

    VEGFR FGFR PDGFR c-Kit RET Cancer
    Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities.
  • HY-107093
    MBC-11

    Others Cancer
    MBC-11 is a first-in-class conjugate of the bone-targeting bisphosphonate etidronate covalently linked to the antimetabolite cytarabine (araC). MBC-11 has the potential for tumor-induced bone disease (TIBD) research.
  • HY-131388
    ABM-14

    Ligand for Target Protein for PROTAC Cancer
    ABM-14 is a ligand for targeting androgen receptor (AR) for PROTAC. ABM-14 binds to a ligand for VHL via linker to form ARCC-4 (HY-130492) to degrade AR.
  • HY-13077
    MK-8245 Trifluoroacetate

    Stearoyl-CoA Desaturase (SCD) Metabolic Disease
    MK-8245 trifluoroacetate is a liver-targeting inhibitor of stearoyl-CoA desaturase (SCD) with IC50 of 1 nM for human SCD1 and 3 nM for both rat SCD1 and mouse SCD1, with anti-diabetic and anti-dyslipidemic efficacy.
  • HY-117985B
    Evogliptin tartrate

    DA-1229 tartrate

    Dipeptidyl Peptidase Metabolic Disease Inflammation/Immunology
    Evogliptin tartrate is a potent, orally bioavailable and selective dipeptidyl peptidase-4 (DPP-4) inhibitor, with antidiabetic activity. Evogliptin tartrate has potential for anti-atherosclerosis therapy that targets arterial inflammation.
  • HY-112197
    PKG drug G1

    Others Cardiovascular Disease
    PKG drug G1 targets C42 of PKG Iα. PKG drug G1 can couple to vasodilation and blood pressure lowering by a C42 PKG Iα-independent mechanism.
  • HY-N7142
    DL-Norepinephrine hydrochloride

    Adrenergic Receptor Neurological Disease Endocrinology
    DL-Norepinephrine hydrochloride is a synthetic phenylethylamine that mimics the sympathomimetic actions of the endogenous norepinephrine.DL-Norepinephrine hydrochloride is a neurotransmitter targets α1 and β1 adrenoceptors, has an increasing effect on subendocardial oxygen tension.
  • HY-133735A
    GRP-60367 hydrochloride

    Others Infection
    GRP-60367 hydrochloride is a first-in-class small-molecule rabies virus (RABV) entry inhibitor with nanomolar potency against some RABV strains. GRP-60367 hydrochloride specifically targets the RABV G protein.
  • HY-100341
    M2I-1

    Others Others
    M2I-1 is a Mad2 inhibitor targeting the binding of Mad2 to Cdc20, an essential protein-protein interaction (PPI) within the spindle assembly checkpoint (SAC).
  • HY-112306
    Ripretinib

    DCC-2618

    c-Kit PDGFR FLT3 VEGFR Apoptosis Cancer
    Ripretinib (DCC-2618) is an orally bioavailable, selective KIT and PDGFRA switch-control inhibitor. Ripretinib (DCC-2618) targets and binds to both wild-type and mutant forms of KIT and PDGFRA specifically at their switch pocket binding sites, thereby preventing the switch from inactive to active conformations of these kinases and inactivating their wild-type and mutant forms. Ripretinib (DCC-2618) also inhibits multiple other kinase targets, such as FLT3 and KDR (or VEGFR-2). DCC-2618 exerts antineoplastic effect and induces apoptosis.
  • HY-P2657
    Verucopeptin

    HIF/HIF Prolyl-Hydroxylase Proton Pump Endogenous Metabolite Cancer
    Verucopeptin is a potent HIF-1 (IC50=0.22 μM) inhibitor and decreases the expression of HIF-1 target genes and HIF-1α protein levels. Verucopeptin strongly inhibits v-ATPase activity by directly targeting the v-ATPase ATP6V1G subunit but not ATP1V1B2 or ATP6V1D. Verucopeptin exhibits antitumor activity against multidrug resistance (MDR) cancers and can be used for cancer research.
  • HY-130618
    Boc-C1-PEG3-C4-OH

    PROTAC Linker Cancer
    Boc-C1-PEG3-C4-OH is a PROTAC linker, which refers to the Alkyl/ether composition. Boc-C1-PEG3-C4-OH can be used in the synthesis of a series of PROTACs. PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.
  • HY-113138
    3-Methyluridine

    N3-Methyluridine

    Endogenous Metabolite Others
    3-Methyluridine (N3-Methyluridine) is a modified RNA nucleoside. 3-Methyluridine is often presents as RNA modification which can be detected in 23S rRNA of archaea, 16S and 23S rRNA of eubacteria, and 18S, 25S, and 28S of eukaryotic ribosomal RNAs.
  • HY-12355
    Siponimod

    BAF-312

    LPL Receptor Others
    Siponimod (BAF-312) is a potent and selective sphingosine-1-phosphate (S1P) receptor modulator. It is selective for S1P1 and S1P5 receptors over S1P2, S1P3, and S1P4 (EC50s of 0.39, 0.98, >10,000, >1,000, and 750 nM, respectively). Used to treat adult multiple sclerosis.
  • HY-133781
    cis-Clopidogrel-MP Derivative

    Clopidogrel-MP-AM

    Others Others
    cis-Clopidogrel-MP Derivative (Clopidogrel-MP-AM) is a 3’-methoxyacetophenone derivative of Clopidogrel active metabolite. Clopidogrel is an orally active platelet inhibitor that targets P2Y12 receptor.
  • HY-19794
    MP-A08

    SphK Cancer
    MP-A08 is a highly selective ATP competitive sphingosine kinase (SPHK1) inhibitor that targets both SphK1 and SphK2 with Ki values of 6.9 ± 0.8 μM and 27 ± 3 μM, respectively.
  • HY-12754
    ML228

    CID-46742353

    HIF/HIF Prolyl-Hydroxylase Cancer
    ML228 (CID-46742353) is a potent the Hypoxia Inducible Factor (HIF) pathway activator with EC50 of 1 μM. ML228 potently activates HIF in vitro as well as its downstream target VEGF.
  • HY-124040
    BI-1950

    Integrin Inflammation/Immunology
    BI-1950 is a highly potent lymphocyte function associated antigen-1 (LFA-1) inhibitor. LFA-1 is an essential component in normal immune system function and a target for drug discovery.
  • HY-15440A
    Fostemsavir

    BMS-663068

    HIV Infection
    Fostemsavir (BMS-663068) is the phosphonooxymethyl prodrug of BMS-626529. Fostemsavir (BMS-663068) is a novel attachment inhibitor that targets HIV-1 gp120 and prevents its binding to CD4 + T cells.
  • HY-N1404
    Sodium aescinate

    Others Cancer Inflammation/Immunology
    Sodium aescinate is a triterpene saponin derived from Aesculus hippocastanum seeds, with anti-inflammatory and antioxidant activities. Sodium aescinate inhibits hepatocellular carcinoma growth by targeting CARMA3/NF-κB pathway.
  • HY-15662
    Tulathromycin A

    Tulathromycin; CP 472295

    Antibiotic Bacterial Infection
    Tulathromycin A (Tulathromycin), a macrolide antibiotic, inhibits protein synthesis (IC50=0.26 µM) by targeting bacterial ribosome. Tulathromycin A is used for the research of respiratory disease in cattle and swine. Immunomodulatory effects.
  • HY-101653
    MHP 133

    AChE mAChR 5-HT Receptor Neurological Disease
    MHP 133 is a drug with multiple CNS targets, and inhibits acetylcholinesterase (AChE) with Ki of 69 μM; also active against muscarinic M1 and M2 receptors, serotonin 5HT4 receptors, and imidazole I2 receptors.
  • HY-B1057S2
    Nefopam D3

    Fenazoxine D3

    β-catenin Neurological Disease
    Nefopam D3 (Fenazoxine D3) is a deuterium labeled Nefopam (Fenazoxine). Nefopam is a centrally-acting but non-opioid analgesic drug, and Nefopam targets β-catenin protein level in mesenchymal cells.
  • HY-B0130A
    Perindopril erbumine

    Perindopril tert-butylamine salt; S-9490 erbumine

    Angiotensin-converting Enzyme (ACE) Apoptosis Cardiovascular Disease Cancer
    Perindopril erbumine (Perindopril tert-butylamine salt) is a potent ACE inhibitor of which is used to treat high blood pressure, heart failure or stable coronary artery disease.
  • HY-B0682A
    Mitiglinide calcium hydrate

    KAD-1229 calcium hydrate; S-21403 calcium hydrate

    Potassium Channel Metabolic Disease
    Mitiglinide calcium hydrate is a drug for the treatment of type 2 diabetes; it is a highly selective KATP channel antagonist.
  • HY-W015114
    L-2-Hydroxyglutaric acid disodium

    (S)-2-Hydroxyglutaric acid disodium

    Histone Demethylase Mitochondrial Metabolism Cancer
    L-2-Hydroxyglutaric acid disodium is an epigenetic modifier and putative oncometabolite in renal cancer. L-2-Hydroxyglutaric acid disodium can inhibit histone demethylases and hence promote histone methylation. L-2-Hydroxyglutaric acid inhibits mitochondrial creatine kinase (Mi-CK) activity with Km and Ki of 2.52 mM and 11.13 mM, respectively.
  • HY-N0598
    Ginsenoside F1

    20(S)-Ginsenoside F1

    Cytochrome P450 Endogenous Metabolite Cancer
    Ginsenoside F1, an enzymatically modified derivative of Ginsenoside Rg1, demonstrates competitive inhibition of CYP3A4 activity and weaker inhibition of CYP2D6 activity.
  • HY-19654B
    (-)-GSK598809

    1S,5R-GSK598809

    Dopamine Receptor Others
    (-)-GSK598809 is an isomer of GSK598809. GSK598809 is a potent and selective dopamine D3 Receptor (DRD3) antagonist.
  • HY-17438
    Cidofovir

    GS 0504; HPMPC; (S)-HPMPC

    CMV Infection Cancer
    Cidofovir is an anti-CMV drug which can suppress CMV replication by selective inhibition of viral DNA polymerase and therefore prevention of viral replication and transcription.
  • HY-13512
    Camostat mesylate

    Camostat mesilate; FOY305; FOY-S980

    Ser/Thr Protease SARS-CoV Infection Inflammation/Immunology
    Camostat mesylate (Camostat mesilate) is an orally active, synthetic serine protease inhibitor for chronic pancreatitis. Camostat mesylate, an inhibitor of TMPRSS2, shows antiviral activity against SARS-CoV-2. Camostat mesylate also inhibits the activity of prostasin, trypsin, and matriptase.
  • HY-Y0152
    Cinchonine

    (8R,9S)-Cinchonine; LA40221

    Apoptosis Parasite Cancer
    Cinchonine is a natural compound present in Cinchona bark. Cinchonine activates endoplasmic reticulum stress-induced apoptosis in human liver cancer cells.
  • HY-12288
    Ozanimod

    RPC-1063

    LPL Receptor Inflammation/Immunology
    Ozanimod (RPC-1063) is a potent and selective S1P1 and S1P5 receptor agonist with EC50s of 410 pM and 11 nM in [ 35S]-GTPγS binding, respectively.
  • HY-12009
    Pazopanib Hydrochloride

    GW786034 (Hydrochloride)

    PDGFR VEGFR FGFR c-Kit c-Fms Autophagy Cancer
    Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with an IC50 of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.
  • HY-B1953
    Thiacloprid

    Parasite Infection
    Thiacloprid, a chloronicotinyl insecticide, is targeted chiefly to control aphid pest species in orchards and vegetables. Thiacloprid destabilizes DNA. Thiacloprid changes the structure and stability of DNA through binding into the minor groove by hydrophobic or hydrogen interactions.
  • HY-100538
    DTP3

    DNA/RNA Synthesis JAK Cancer
    DTP3 TFA is a potent and selective GADD45β/MKK7 inhibitor. DTP3 TFA targets an essential, cancer-selective cell-survival module downstream of the NF-κB pathway.
  • HY-138539
    CBP/p300 ligand 2

    Ligand for Target Protein for PROTAC Cancer
    CBP/p300 ligand 2 is a ligand for target protein for PROTAC of dCBP-1. dCBP-1 is a potent and selective heterobifunctional degrader of p300/CBP.
  • HY-129372
    PDdB-Pfp

    ADC Linker Cancer
    PDdB-Pfp is a cleavable ADC linker used for the agents that target for the extracellular loop 1 (ECL1) of TM4SF1 (transmembrane 4 L6 family member 1).
  • HY-79369
    Succinic anhydride

    ADC Linker Cancer
    Succinic anhydride is a cyclic anhydride and a nonclaevable ADC linker extracted from patent WO2009064913A1. Succinic anhydride can react with compound 4 of the patent to link the prodrug to an amine or hydroxy 1 group of a targeting polypeptide.
  • HY-107093A
    MBC-11 trisodium

    Others Cancer
    MBC-11 trisodium is a first-in-class conjugate of the bone-targeting bisphosphonate HEDP covalently linked to the antimetabolite Ara-C. MBC-11 trisodium has the potential for tumor-induced bone disease (TIBD) research.
  • HY-130296
    Palbociclib-propargyl

    PROTAC CDK6 ligand 1

    Ligand for Target Protein for PROTAC Cancer
    Palbociclib-propargyl is a ligand for target protein CDK6 for PROTAC, and binds to CRBN ligand via a PEG linker to make a PROTAC CP-10. CP-10 shows a DC50 of 2.1 nM for CDK6.
  • HY-134832
    Mito-LND

    Mito-Lonidamine

    Mitochondrial Metabolism Reactive Oxygen Species Autophagy Cancer
    Mito-LND (Mito-Lonidamine) is an orally active and mitochondria-targeted inhibitor of oxidative phosphorylation (OXPHOS). Mito-LND inhibits mitochondrial bioenergetics, stimulates the formation of reactive oxygen species, and induces autophagic cell death in lung cancer cells.
  • HY-112721
    FDI-6

    Others Cancer
    FDI-6 is an inhibitor of FOXM1. FDI-6 binds directly to FOXM1 protein, to displace FOXM1 from genomic targets in MCF-7 breast cancer cells, and induce concomitant transcriptional down-regulation.
  • HY-117602
    TLR7 agonist 3

    Toll-like Receptor (TLR) Inflammation/Immunology
    TLR7 agonist 3 (Compound 2) is a potent antagonist of toll-like receptor 7 (TLR7). TLR7 has an important role in immune activation processes and represents an emerging drug discovery target for the development of immunomodulators.
  • HY-P0122
    iRGD peptide

    c(CRGDKGPDC)

    Integrin Cancer
    iRGD peptide is a 9-amino acid cyclic peptide, triggers tissue penetration of drugs by first binding to av integrins, then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties.
  • HY-106409
    Tefinostat

    CHR-2845

    HDAC Cancer
    Tefinostat (CHR-2845) is a monocyte/macrophage-targeted pan HDAC inhibitor, cleaved into active acid CHR-2847 by the intracellular esterase human carboxylesterase-1 (hCE-1). Anti-monocytoid lineage leukaemias activity.
  • HY-136446
    MYLS22

    Others Cancer Cardiovascular Disease
    MYLS22 is a first-in-class and selective optic atrophy 1 (OPA1) inhibitor. MYLS22 can target endothelial OPA1 to curtail tumor growth and inhibits angiogenesis by impinging on NFkB activity and on angiogenic gene expression.
  • HY-Y0366
    Lauric acid

    Endogenous Metabolite Bacterial Infection
    Lauric acid is a middle chain-free fatty acid with strong bactericidal properties. The EC50s for P. acnes, S.aureus, S. epidermidis, are 2, 6, 4 μg/mL, respectively.
  • HY-100442
    Paquinimod

    ABR 25757

    Others Metabolic Disease Inflammation/Immunology
    Paquinimod (ABR 25757) is a specific inhibitor of S100A8/S100A9. Paquinimod rescues the pneumonia with substantial reduction of viral loads in SARS-CoV-2-infected mice.
  • HY-108490
    VPC 23019

    LPL Receptor Inflammation/Immunology
    VPC 23019, an aryl amide-containing Sphingosine 1-phosphate (S1P) analog, is a competitive antagonist at the S1P1 and S1P3 receptors (pKi= 7.86 and 5.93, respectively) and an agonist at the S1P4 and S1P5 receptors (pEC50= 6.58 and 7.07, respectively).
  • HY-136577
    RP101442

    LPL Receptor Drug Metabolite Inflammation/Immunology
    RP101442, an active metabolite of Ozanimod, is a selective, potent S1PR1 (sphingosine-1-phosphate receptor 1) agonist, with EC50s of 2.6 nM and 171 nM for S1PR1 and S1PR5, respectively.
  • HY-N6744
    Chaetoglobosin A

    Apoptosis Cancer Infection
    Chaetoglobosin A, the active principle within the extract of Penicillium aquamarinium, is a member of the cytochalasan family. Chaetoglobosin A preferentially induces apoptosis. Chaetoglobosin A targets filamentous actin in CLL cells and thereby induces cell-cycle arrest and inhibits membrane ruffling and cell migration.
  • HY-N7674A
    Angoline hydrochloride

    STAT Cancer
    Angoline hydrochloride is a potent and selective IL6/STAT3 signaling pathway inhibitor with an IC50 of 11.56 μM. Angoline hydrochloride inhibits STAT3 phosphorylation and its target gene expression, and inhibits cancer cell proliferation.
  • HY-B0030
    D-Cycloserine

    iGluR Bacterial Antibiotic Infection Neurological Disease
    D-Cycloserine is an antibiotic which targets sequential bacterial cell wall peptidoglycan biosynthesis enzymes. D-Cycloserine is a partial NMDA agonist that can improve cognitive functions. D-Cycloserine can be used for multidrug-resistant tuberculosis research.
  • HY-111895B
    Macropa-NH2 TFA

    Others Others
    Macropa-NH2 TFA is the precursor of Macropa-NCS. Macropa-NCS is conjugated to trastuzumab as well as to the prostate-specific membrane antigen-targeting compound RPS-070 and is a promising therapeutic radionuclide applied in the treatment of soft-tissue metastases.
  • HY-B1881
    Pirimiphos-methyl

    Parasite AChE Infection
    Pirimiphos-methyl is a rapid-acting organophosphorus insecticide and acaricide, causing inhibition of AChE in target organisms. Pirimiphos-methyl is often used for prevention and control of beetles, snout beetles, moths and Ephestia cautella during storage of agricultural grains.
  • HY-138683
    STING-IN-3

    STING Inflammation/Immunology
    STING-IN-3 is an inhibitor of stimulator of interferon genes (STING). STING-IN-3 efficiently inhibits both hsSTING and mmSTING through covalently target the predicted transmembrane cysteine residue 91 and thereby block the activation-induced palmitoylation of STING.
  • HY-N7674
    Angoline

    STAT Cancer
    Angoline is a potent and selective IL6/STAT3 signaling pathway inhibitor with an IC50 of 11.56 μM. Angoline inhibits STAT3 phosphorylation and its target gene expression, and inhibits cancer cell proliferation.
  • HY-100758
    FUBP1-IN-1

    Others Cancer
    FUBP1-IN-1 is a potent FUSE binding protein 1 (FUBP1) inhibitor which interferes with the binding of FUBP1 to its single stranded target DNA FUSE sequence , with an IC50 value of 11.0 μM.
  • HY-133870
    Itaconate-alkyne

    ITalk

    Others Inflammation/Immunology
    Itaconate-alkyne (ITalk) is a specific bioorthogonal probe for quantitative and site-specific chemoproteomic profiling of Itaconation in living cells. Itaconate-alkyne, a functional analogue of Itaconate, exhibits comparable antiinflammatory effect with Itaconate and enables the labeling of bona fide targets of Itaconate.
  • HY-130619
    Boc-C1-PEG3-C4-OBn

    PROTAC Linker Cancer
    Boc-C1-PEG3-C4-OBn (PROTAC Linker 15) is a PROTAC linker, which refers to the PEG composition. Boc-C1-PEG3-C4-OBn can be used in the synthesis of a series of PROTACs, such as PROTAC SGK3 degrader-1 (HY-125878). PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.
  • HY-16984
    GNE-4997

    Itk Inflammation/Immunology
    GNE-4997 is a potent and selective interleukin-2-inducible T-cell kinase (ITK) inhibitor with a Ki of 0.09 nM, and the correlation between the basicity of solubilizing elements in GNE-4997 and off-target antiproliferative effects reduces cytotoxicity.
  • HY-138936
    SSK1

    Apoptosis Inflammation/Immunology
    SSK1, a senescence-specific killing compound, is a β-galactosidase-targeted prodrug attenuates inflammation. SSK1 is activated by lysosomal β-galactosidase and selectively killed senescent cells through the activation of p38 MAPK and induction of apoptosis.
  • HY-136538
    LQZ-7I

    Survivin Cancer
    LQZ-7I is a survivin-targeting inhibitor. LQZ-7I inhibits survivin dimerization. LQZ-7I orally effectively inhibits xenograft tumor growth and induces survivin loss in tumors.
  • HY-114489B
    Haemanthamine hydrochloride

    Apoptosis Influenza Virus Parasite Cancer Infection Neurological Disease
    Haemanthamine hydrochloride is a crinine-type alkaloid isolated from the Amaryllidaceae plants with potent anticancer activity. Haemanthamine hydrochloride targets ribosomal that inhibits protein biosynthesis during the elongation stage of translation. Haemanthamine hydrochloride has pro-apoptotic, antioxidant, antiviral, antimalarial and anticonvulsant activities.
  • HY-15440B
    Fostemsavir Tris

    BMS-663068 Tris

    HIV Infection
    Fostemsavir Tris (BMS-663068 (Tris)) is the phosphonooxymethyl prodrug of BMS-626529. Fostemsavir Tris (BMS-663068 (Tris)) is a novel attachment inhibitor that targets HIV-1 gp120 and prevents its binding to CD4 + T cells.
  • HY-114489A
    Haemanthamine

    Apoptosis Influenza Virus Parasite Cancer Infection Neurological Disease
    Haemanthamine is a crinine-type alkaloid isolated from the Amaryllidaceae plants with potent anticancer activity. Haemanthamine targets ribosomal that inhibits protein biosynthesis during the elongation stage of translation. Haemanthamine has pro-apoptotic, antioxidant, antiviral, antimalarial and anticonvulsant activities.
  • HY-16399
    Pladienolide B

    Apoptosis Cancer
    Pladienolide B is a potent cancer cell growth inhibitor that targets the SF3B1 subunit of the spliceosome. Pladienolide B exerts antitumor activities mediated through the inhibition of pre-mRNA splicing. Pladienolide B induces apoptosis.
  • HY-19713
    LJI308

    Ribosomal S6 Kinase (RSK) Cancer
    LJI308 is a potent pan-ribosomal S6 kinase (RSK) inhibitor, with IC50s of 6 nM, 4 nM, and 13 nM for RSK1, RSK2, and RSK3, respectively. LJI308 inhibits the phosphorylation of RSK (T359/S363) and YB-1 (S102) after irradiation, treatment with EGF, and in cells expressing a KRAS mutation.
  • HY-10968
    CYM5442

    LPL Receptor Neurological Disease
    CYM5442 is a potent, highly-selective and orally active sphingosine 1-phosphate (S1P1) receptor agonist with an EC50 of 1.35 nM. CYM5442 is inactive against S1P2, S1P3, S1P4, and S1P5. CYM5442 activates S1P1-dependent p42/p44-MAPK phosphorylation. CYM5442 exerts retinal neuroprotection. CYM5442 can easily penetrate the central nervous system (CNS).
  • HY-10968A
    CYM5442 hydrochloride

    LPL Receptor Neurological Disease
    CYM5442 hydrochloride is a potent, highly-selective and orally active sphingosine 1-phosphate (S1P1) receptor agonist with an EC50 of 1.35 nM. CYM5442 hydrochloride is inactive against S1P2, S1P3, S1P4, and S1P5. CYM5442 hydrochloride activates S1P1-dependent p42/p44-MAPK phosphorylation. CYM5442 exerts retinal neuroprotection. CYM5442 hydrochloride can easily penetrate the central nervous system (CNS).
  • HY-138506
    DBCO-S-S-acid

    ADC Linker Cancer
    DBCO-S-S-acid is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
  • HY-15729
    Rociletinib

    CO-1686; AVL-301; CNX-419

    EGFR Cancer
    Rociletinib (CO-1686) is an orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR including T790M, and the Ki values for EGFRL858R/T790M and EGFRWT are 21.5 nM and 303.3 nM, respectively.
  • HY-P9927
    Secukinumab

    AIN457

    Interleukin Related Inflammation/Immunology
    Secukinumab (AIN457) is a high affinity, human monoclonal antibody targeted against interleukin (IL)-17A. Secukinumab is the first-in-class anti-IL-17 agent used for the research of plaque psoriasis, ankylosing spondylitis and psoriatic arthritis.
  • HY-108638
    NSC 146109 hydrochloride

    MDM-2/p53 Apoptosis Cancer
    NSC 146109 hydrochloride is a small-molecule p53 activator that target MDMX and can be used for breast cancer research. NSC 146109 hydrochloride is a pseudourea derivative, promotes breast cancer cells to undergo apoptosis through activating p53 and inducing expression of proapoptotic genes.
  • HY-133115
    N-Desmethylnefopam

    β-catenin Neurological Disease
    N-Desmethylnefopam is the main metabolite of Nefopam. N-Desmethylnefopam is a centrally-acting but non-opioid analgesic agent, for the relief of moderate to severe pain. Nefopam targets β-catenin protein level in mesenchymal cells in-vitro and in-vivo.
  • HY-B0497C
    Niclosamide olamine

    BAY2353 olamine

    STAT Parasite Antibiotic Autophagy Cancer Infection
    Niclosamide olamine (BAY2353 olamine) is an anthelmintic that disrupts mitochondrial metabolism in parasitic worms and animal models. Niclosamide olamine inhibits STAT3 (IC50 = 0.25 μM) and stimulates autophagy by reversibly inhibiting mammalian target of Rapamycin complex 1 (mTORC1) signaling.
  • HY-126316
    Zapalog

    FKBP Others
    Zapalog is a photocleavable small-molecule heterodimerizer that can be used to repeatedly initiate, and instantaneously terminate, a physical interaction between two target proteins. Zapalog dimerizes any two proteins tagged with the FKBP and DHFR domains until exposure to light causes its photolysis.
  • HY-17449
    Fosbretabulin disodium

    CA 4DP; CA 4P; Combretastatin A4 disodium phosphate

    Microtubule/Tubulin Apoptosis Cancer
    Fosbretabulin disodium (CA 4DP) is a tubulin destabilizing agent. Fosbretabulin disodium is the Combretastatin A4 prodrug that selectively targets endothelial cells, induces regression of nascent tumour neovessels, reduces tumour blood flow and causes central tumour necrosis.
  • HY-19726
    NSC59984

    MDM-2/p53 Cancer
    NSC59984 induces mutant p53 protein degradation via MDM2 and the ubiquitin-proteasome pathway. NSC59984 acts by targeting GOF-mutant p53 and stimulates p73 to restore the p53 pathway signaling.
  • HY-137331
    FAPI-46

    Others Cancer
    FAPI-46 is a quinoline-based fibroblast activation protein (FAP)-targeted radiotracer. FAPI-46 has higher tumor uptake and prolonged tumor accumulation. FAPI-46 can be used for tumor imaging of a multitude of different cancers.
  • HY-16743
    Ibiglustat

    Venglustat; SAR402671; GZ402671

    Others Metabolic Disease
    Ibiglustat (Venglustat), a potential therapy for PD Parkinson’s disease, SRT in Fabry’s and Gaucher’s, is a selective, allosteric inhibitor of glucosylceramide synthase (GCS) with ability to cross the blood-brain barrier.
  • HY-B0105B
    (-)-Ketoconazole

    (-)-Ketoconazol; (-)-R 41400

    Fungal Infection Inflammation/Immunology
    (-)-Ketoconazole ((-)-R 41400) is one of the enantiomer of Ketoconazole. Ketoconazole is a racemic mixture of two enantiomers, levoketoconazole ((2S,4R)-(−)-ketoconazole) and dextroketoconazole ((2R,4S)-(+)-ketoconazole).
  • HY-100675
    JTE-013

    LPL Receptor Apoptosis Cancer
    JTE-013 is a potent and specific S1P2 (Sphingosine-1-Phosphate 2; EDG-5) antagonist. JTE-013 inhibits the specific binding of radiolabeled S1P to human and rat S1P2 with IC50s of 17 nM and 22 nM, respectively.
  • HY-13418
    Dorsomorphin dihydrochloride

    Compound C dihydrochloride; BML-275 dihydrochloride

    AMPK TGF-β Receptor Autophagy Cancer
    Dorsomorphin dihydrochloride (BML-275 dihydrochloride; Compound C dihydrochloride) is a potent, selective and ATP-competitive AMPK inhibitor, with a Ki of 109 nM. Dorsomorphin dihydrochloride inhibits BMP pathway by targeting the type I receptors ALK2, ALK3, and ALK6. Dorsomorphin dihydrochloride induces autophagy.
  • HY-138687
    PF-07321332

    SARS-CoV Infection Inflammation/Immunology
    PF-07321332 is a potent and orally active SARS-CoV 3C-like protease (3CL PRO) inhibitor . PF-07321332 targets to the SARS-CoV-2 virus and can be used for COVID-19 reseacrch.
  • HY-B0341
    Nicorandil

    SG-75

    Potassium Channel Cardiovascular Disease
    Nicorandil (SG-75) is a potent potassium channel activator and targets vascular nucleoside diphosphate-dependent K + channels and cardiac ATP-sensitive K + channels (KATP). Nicorandil is a nicotinamide ester with vasodilatory and cardioprotective effects and has the potential for angina and forischemic heart diseases.
  • HY-107443
    I-BET762 carboxylic acid

    Molibresib carboxylic acid; GSK525762A carboxylic acid; PROTAC BRD4-binding moiety 2

    Ligand for Target Protein for PROTAC Epigenetic Reader Domain Cancer
    I-BET762 carboxylic acid (Molibresib carboxylic acid) is an I-BET762-based warhead ligand for conjugation reactions of PROTAC targeting on BET. I-BET762 carboxylic acid (Molibresib carboxylic acid) is a BRD4 inhibitor with a pIC50 of 5.1.
  • HY-N0003
    Honokiol

    NSC 293100

    Akt ERK Autophagy HCV Cancer
    Honokiol is a bioactive, biphenolic phytochemical that possesses potent antioxidative, anti-inflammatory, antiangiogenic, and anticancer activities by targeting a variety of signaling molecules. It inhibits the activation of Akt and enhances the phosphorylation of ERK1/ERK2. Honokiol can readily cross the blood brain barrier.
  • HY-124629
    DB2313

    Apoptosis Cancer
    DB2313 is a potent transcription factor PU.1 inhibitor with an apoptosis of 14 nM. DB2313 disrupts the interaction of PU.1 with target gene promoters. DB2313 induces apoptosis of acute myeloid leukemia (AML) cells, and has anticancer effects.
  • HY-W010255
    Phenylglyoxylic acid

    Benzoylformic acid

    Endogenous Metabolite Metabolic Disease
    Phenylglyoxylic acid (Benzoylformic acid) is a metabolite of ethylbenzene and styrene (EB/S) and can be used as a biomarker of exposure to EB/S in human.
  • HY-18702
    Targocil

    Bacterial Infection
    Targocil functions as a bacteriostatic inhibitor of wall teichoic acid (WTA) biosynthesis which can inhibit the growth of methicillin-susceptible S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA) with MIC90s of 2 μg/ mL for both MRSA and MSSA.
  • HY-B1864B
    Kasugamycin hydrochloride hydrate

    Ksg hydrochloride hydrate

    Bacterial Antibiotic Infection
    Kasugamycin hydrochloride hydrate (Ksg hydrochloride hydrate) is an antibiotic which binds both the 30S and 70S ribosome but not isolated 50S subunits. Kasugamycin hydrochloride hydrate (Ksg hydrochloride hydrate) mimics mRNA nucleotides to destabilize tRNA binding and inhibit canonical translation initiation.
  • HY-N6718
    Filipin III

    Fungal Inflammation/Immunology
    Filipin III is the major component of Filipin, a 28-membered ring pentaene macrolide antifungal antibiotic produced by S. filipinensis, S. avermitilis and S. miharaensis. Filipin interacts with membrane sterols causing the alteration of membrane structure.
  • HY-B1864A
    Kasugamycin hydrochloride

    Ksg hydrochloride

    Bacterial Antibiotic Infection
    Kasugamycin hydrochloride (Ksg hydrochloride) is an antibiotic which binds both the 30S and 70S ribosome but not isolated 50S subunits. Kasugamycin hydrochloride (Ksg hydrochloride) mimics mRNA nucleotides to destabilize tRNA binding and inhibit canonical translation initiation.
  • HY-16918
    Heptamidine

    SBi4211

    Others Cancer Inflammation/Immunology
    Heptamidine (SBi4211) is a potent Pentamidine-related inhibitor of the calcium-binding protein S100B (Kd=6.9 μM), selectively kills melanoma cells with S100B over those without S100B. Heptamidine is a useful tool for the investigation of Myotonic dystrophy (DM).
  • HY-128776
    Antitumor agent-19

    Others Cancer
    Antitumor agent-19 is an antitomor agent targeting tumor-associated macrophages (TAMs) to serve as an effective TAMs modulator. The EC50 values of Antitumor agent-19 in the RAW 264.7 cells and the BMDM cells are 17.18 μM and 18.87 μM, respectively.
  • HY-102046
    FM-381

    JAK Inflammation/Immunology
    FM-381 is a potent covalent reversible inhibitor of JAK3 targeting the unique Cys909. FM-381 has an IC50 of 127 pM for JAK3, with 410, 2700 and 3600-fold selectivity over JAK1, JAK2 and TYK2, respectively.
  • HY-15729A
    Rociletinib hydrobromide

    CO-1686 hydrobromide; AVL-301 hydrobromide; CNX-419 hydrobromide

    EGFR Cancer
    Rociletinib hydrobromide (CO-1686 hydrobromide) is an orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR including T790M, and the Ki values for EGFRL858R/T790M and EGFRWT are 21.5 nM and 303.3 nM, respectively.
  • HY-120697
    MSAB

    Wnt β-catenin Cancer
    MSAB is a potent and selective inhibitor of Wnt/β-catenin signaling. MSAB binds to β-catenin promoting its degradation, and specifically downregulates Wnt/β-catenin target genes. MSAB exhibits potent anti-tumor effects selectively on Wnt-dependent cancer cells.
  • HY-N2472
    Medicagenic acid

    Castanogenin

    Bacterial Infection
    Medicagenic acid (Castanogenin) is isolated from the roots of Herniaria glabra L, exhibits potent fungistatic effects against several plant pathogens and human dermatophytes. Medicagenic acid (Castanogenin) has low enzyme inhibitory activities, the target enzymes are xanthine oxidase, collagenase, elastase, tyrosinase, ChE.
  • HY-130297
    PROTAC BCR-ABL1 ligand 1

    Bcr-Abl Cancer
    PROTAC BCR-ABL1 ligand 1, compound GMB-475, is the ligand of PROTAC that allosterically targets BCR-ABL1 protein and recruits the E3 ligase Von Hippel-Lindau, resulting in ubiquitination and subsequent degradation of BCR-ABL1.
  • HY-N0592
    Demethyleneberberine

    NF-κB AMPK Metabolic Disease Inflammation/Immunology
    Demethyleneberberine is a natural mitochondria-targeted antioxidant. Demethyleneberberine alleviates mice colitis and inhibits the inflammatory responses by inhibiting NF-κB pathway and regulating the balance of Th cells. Demethyleneberberine could serve as a AMPK activator for treating non-alcoholic fatty liver disease (NAFLD).
  • HY-129040A
    Iobenguane sulfate

    MIBG sulfate

    Others Cancer
    Iobenguane sulfate (MIBG sulfate) is an analogue of the neurotransmitter norepinephrine with antitumor activity. Radioiodinated Iobenguane sulfate is clinically used as a tumor-targeted radiopharmaceutical in the diagnosis and treatment of adrenergic tumors. Iobenguane sulfate is a high-affinity substrate for cholera toxin that interferes with cellular mono(ADP-ribosylation).
  • HY-128671
    6-​Thioinosine

    6TI; 6-Mercaptopurine riboside

    Nucleoside Antimetabolite/Analog Metabolic Disease
    6-​Thioinosine (6TI) is a purine antimetabolite, acts as an anti-adipogenesis agent, downregulates mRNA levels of PPAR γ and C/EBPα, as well as PPAR γ target protein such as LPL, CD36, aP2, and LXRα.
  • HY-14776
    Quarfloxin

    CX-3543

    DNA/RNA Synthesis Cancer
    Quarfloxin (CX-3543), a fluoroquinolone derivative with antineoplastic activity, targets and inhibits RNA pol I activity, with IC50 values in the nanomolar range in neuroblastoma cells. Quarfloxin disrupts the interaction between the nucleolin protein and a G-quadruplex DNA structure in the ribosomal DNA (rDNA) template.
  • HY-B0846
    Dimethomorph

    Fungal Androgen Receptor Infection
    Dimethomorph is a morpholine fungicide that inhibits fungal cell wall formation. Dimethomorph inhibits mycelial growth of the oomycete fungi, P. citrophthora, P. parasitica, P. capsici, and P. infestans (EC50s=0.1, 0.38, <0.1, and 0.16-0.3 µg/mL, respectively), but is less active against the green algae species C. vulgaris or S. obliquus in vitro (EC50s=47.46 and 44.87 µg/mL, respectively). Dimethomorph inhibits androgen receptor (AR) activity in a reporter assay in MDA-kb2 human breast cancer cells but not in a yeast antiandrogen screen (IC20s=0.263 and 38.5 µM, respectively).
  • HY-B0847
    Propiconazole

    Fungal Reactive Oxygen Species Infection
    Propiconazole is a broad-spectrum triazole fungicide that inhibits the conversion of lanosterol to ergosterol, leading to fungal cell membrane disruption. Propiconazole inhibits S. cerevisiae, but not rat liver, microsomal cytochrome P450 (IC50s=0.04 and >200 µM, respectively). Propiconazole inhibits the growth of T. deformans and R. stolonifer (ED50s=0.073 and 4.6 µg/mL, respectively). Propiconazole increases production of reactive oxygen species (ROS).
  • HY-B0132S
    Norfloxacin-d5

    Bacterial Antibiotic Infection
    Norfloxacin-d5 is a deuterium labeled Norfloxacin. Norfloxacin is a fluoroquinolone antibiotic that inhibits the growth of Gram-positive and Gram-negative bacteria (MICs = 4 μg/mL and 1 μg/mL for S. aureus and P. aeruginosa, respectively). Norfloxacin also inhibits the growth S. pseudintermedius, S. aureus, E. coli, Pasturella, and S. canis isolates from dogs (mean MIC50s = 0.25 μg/mL, 1 μg/mL, 0.03 μg/mL, 1 μg/mL, and 1 μg/mL, respectively).
  • HY-16918A
    Heptamidine dimethanesulfonate

    SBi4211 dimethanesulfonate

    Others Cancer Inflammation/Immunology
    Heptamidine dimethanesulfonate (SBi4211 dimethanesulfonate) is a potent Pentamidine-related inhibitor of the calcium-binding protein S100B (Kd=6.9 μM), selectively kills melanoma cells with S100B over those without S100B. Heptamidine is a useful tool for the investigation of Myotonic dystrophy (DM).
  • HY-16743A
    Ibiglustat (L-Malic acid)

    Venglustat (L-Malic acid); SAR402671 (L-Malic acid); GZ402671 (L-Malic acid)

    Others Metabolic Disease
    Ibiglustat L-Malic acid (Venglustat L-Malic acid), a potential therapy for PD Parkinson’s disease, SRT in Fabry’s and Gaucher’s, is a selective, allosteric inhibitor of glucosylceramide synthase (GCS) with ability to cross the blood-brain barrier.
  • HY-112215
    ARQ 531

    MK-1026

    Btk Cancer Inflammation/Immunology
    ARQ 531 (MK-1026) is a reversible non-covalent and orally active inhibitor of Bruton’s Tyrosine Kinase (BTK), with IC50s of 0.85 nM and 0.39 nM for WT-BTK and C481S-BTK, respectively.
  • HY-B0927
    Hydrastine

    (-)-β-Hydrastine; (1R,9S)-β-Hydrastine

    Others Others
    Hydrastine is a natural alkaloid which is present in Hydrastis canadensis and other plants of the ranunculaceae family.
  • HY-107608
    Leukotriene B4

    LTB4; 5(S),12(R)-DiHETE

    PROTAC Linker Endogenous Metabolite Leukotriene Receptor Cancer Inflammation/Immunology
    Leukotriene B4 (LTB4) is known as one of the most potent chemoattractants and activators of leukocytes and is involved in inflammatory diseases. Leukotriene B4 is also an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.
  • HY-N3945
    Glaucine

    O,O-Dimethylisoboldine; S-(+)-Glaucine; NSC 34396

    Phosphodiesterase (PDE) Calcium Channel Adrenergic Receptor Dopamine Receptor Influenza Virus Infection Inflammation/Immunology
    Glaucine (O,O-Dimethylisoboldine) is an alkaloid isolated from Glaucium flavum Crantz with antitussive, bronchodilation and anti-inflammatory properties. Glaucine is a selective and orally active phosphodiesterase 4 (PDE4) inhibitor with Kis of 3.4 µM in human bronchus and polymorphonuclear leukocytes. Glaucine is also a non-selective α-adrenoceptor antagonist, a Ca 2+ entry blocker, and a weak dopamine D1 and D2 receptor antagonist. Glaucine has antioxidative and antiviral activities.
  • HY-136272
    A 410099.1 amide-PEG3-amine-Boc

    E3 Ligase Ligand-Linker Conjugate Cancer
    A 410099.1 amide-PEG3-amine-Boc is a functionalized IAP ligand for PROTACs that incorporates an IAP ligand and an amide-PEG3 linker with terminal amine. A 410099.1 amide-PEG3-amine-Boc can conjugates with target protein ligands.
  • HY-128384
    Benzyldodecyldimethylammonium chloride dihydrate

    Bacterial Infection
    Benzyldodecyldimethylammonium chloride dihydrate is a quaternary ammonium compound (QAC) and can be used as a biocide to target antibiotic-resistant bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA), multidrug-resistant (MDR) P. aeruginosa et. al. Benzyldodecyldimethylammonium chloride dihydrate, an antimicrobial agent, bacteriostatic or bactericidal properties depending on the concentration.
  • HY-B0436
    Salbutamol hemisulfate

    Albuterol hemisulfate; AH-3365 hemisulfate

    Adrenergic Receptor Autophagy Inflammation/Immunology Endocrinology Cancer
    Salbutamol Hemisulfate (Albuterol hemisulfate) is a short-acting β2 adrenergic receptor agonist Target: β2 Adrenergic Receptor Salbutamol Hemisulfate (Albuterol hemisulfate) is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD.
  • HY-14881
    Bedaquiline

    TMC207; R207910

    Bacterial Antibiotic Infection
    Bedaquiline (TMC207) is a diarylquinoline drug and inhibits Mycobacterium tuberculosis (Mtb) F1FO-ATP synthase through targeting of both the c- and the ε-subunit. Bedaquiline has uncoupler activity. Bedaquiline is used for the multi-drug resistant tuberculosis.
  • HY-136273
    A 410099.1 amide-PEG2-amine-Boc

    E3 Ligase Ligand-Linker Conjugate Cancer
    A 410099.1 amide-PEG2-amine-Boc is a functionalized IAP ligand for PROTACs that incorporates an IAP ligand and an amide-PEG3 linker with terminal amine. A 410099.1 amide-PEG2-amine-Boc can conjugates with target protein ligands.
  • HY-P0023
    Cyclo(-RGDfK)

    Integrin Cancer
    Cyclo(-RGDfK) is a potent and selective inhibitor of the αvβ3 integrin, with an IC50 of 0.94 nM. Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface.
  • HY-D0835
    Hydroxylapatite

    Hydroxyapatite

    Others Others
    Hydroxylapatite (Hydroxyapatite) is a naturally occurring calcium phosphate which is a major mineral component of bone and teeth bones. Nano-scale Hydroxylapatite particles are increasingly being used as carriers for controlled and targeted delivery of bioactive agents like drugs, proteins, and nucleic acids due to their high porosity, negative charge, and biodegradability .
  • HY-136274
    Boc-A 410099.1 amide-alkylC4-amine

    E3 Ligase Ligand-Linker Conjugate Cancer
    Boc-A 410099.1 amide-alkylC4-amine is a functionalized IAP ligand for PROTACs that incorporates an IAP ligand and an amide-alkylC4 linker with terminal amine. Boc-A 410099.1 amide-alkylC4-amine can conjugates with target protein ligands.
  • HY-B2111
    (R)-(+)-Atenolol

    Adrenergic Receptor Others
    (R)-(+)-Atenolol is the less active enantiomer of the (R,S)-atenolol. (R,S)-atenolol is a β-adrenergic receptor antagonist.
  • HY-111895A
    Macropa-NH2 hydrochloride

    Others Cancer
    Macropa-NH2 hydrochloride is the precursor of Macropa-NCS. Macropa-NCS is conjugated to Anti-Human HER2 (HY-P9907) as well as to the prostate-specific membrane antigen-targeting compound RPS-070 and is a promising therapeutic radionuclide applied in the treatment of soft-tissue metastases.
  • HY-120075
    TJ191

    Apoptosis Cancer
    TJ191 is a potent and specific anti-cancer agent that targets low TβRIII-expressing malignant T-cell leukemia/lymphoma cells. TJ191 has no affects on the proliferation of other cancer cells or normal fibroblasts or immune cells. TJ191 can be used for cancer research.
  • HY-134333
    ICCB280

    Apoptosis Cancer
    ICCB280 is a potent inducer of C/EBPα. ICCB280 exhibits anti-leukemic properties including terminal differentiation, proliferation arrest, and apoptosis through activation of C/EBPα and affecting its downstream targets (such as C/EBPε, G-CSFR and c-Myc).
  • HY-12745A
    Nalfurafine hydrochloride

    TRK-820 hydrochloride

    Opioid Receptor Neurological Disease
    Nalfurafine hydrochloride (TRK-820 hydrochloride) is a potent selective and orally active G protein-biased kappa opioid receptor (KOR)-agonist with high translational potential. Nalfurafine hydrochloride (TRK-820 hydrochloride) enhances the therapeutic potential of MOR-targeting analgesics, has the potential for uremic pruritis treatment.
  • HY-17600
    Acalabrutinib

    ACP-196

    Btk Cancer
    Acalabrutinib (ACP-196) is an orally active, irreversible, and highly selective second-generation BTK inhibitor. Acalabrutinib binds covalently to Cys481 in the ATP-binding pocket of BTK. Acalabrutinib demonstrates potent on-target effects and efficacy in mouse models of chronic lymphocytic leukemia (CLL).
  • HY-P0023A
    Cyclo(-RGDfK) TFA

    Integrin Cancer
    Cyclo(-RGDfK) TFA is a potent and selective inhibitor of the αvβ3 integrin, with an IC50 of 0.94 nM. Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface.
  • HY-15003
    ATH686

    FLT3 Apoptosis Cancer
    ATH686 is a potent, selective and ATP-competitive FLT3 inhibitor. ATH686 target mutant FLT3 protein kinase activity and inhibit the proliferation of cells harboring FLT3 mutants via induction of apoptosis and cell cycle inhibition. ATH686 has antileukemic effects.
  • HY-12745
    Nalfurafine

    TRK-820

    Opioid Receptor Neurological Disease
    Nalfurafine (TRK-820) is a potent selective and orally active G protein-biased kappa opioid receptor (KOR)-agonist with high translational potential. Nalfurafine (TRK-820) enhances the therapeutic potential of MOR-targeting analgesics, has the potential for uremic pruritis treatment.
  • HY-12005
    Fingolimod hydrochloride

    FTY720

    LPL Receptor PAK Inflammation/Immunology Cancer
    Fingolimod hydrochloride (FTY720), an analog of sphingosine, is a potent sphingosine 1-phosphate (S1P) receptors modulator. Fingolimod hydrochloride is phosphorylated by sphingosine kinases, particularly by SK2, and then binds S1PR1, 3, 4, and 5. Fingolimod hydrochloride induces the internalization of S1P1, and consequently, inhibits S1P activity. Fingolimod hydrochloride also is a pak1 activator.
  • HY-107661
    Arundic Acid

    ONO-2506; (R)-2-Propyloctanoic acid

    Others Neurological Disease
    Arundic acid (ONO-2506) is an astrocyte-modulating agent, which delays the expansion of cerebral infarcts by modulating the activation of astrocytes through inhibition of S-100β synthesis. Arundic acid has the potential for stroke and Alzheimer’s disease research.
  • HY-16115
    BPH-652

    Others Metabolic Disease
    BPH-652 is a S. aureus dehydrosqualene synthase (CrtM) inhibitor, with a Ki of 1.5 nM and an IC50 of 100-300 nM (S. aureus pigment formation).
  • HY-W096114
    Acid-PEG8-S-S-PEG8-acid

    PROTAC Linker Cancer
    Acid-PEG8-S-S-PEG8-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
  • HY-140114
    Acid-PEG4-S-S-PEG4-acid

    PROTAC Linker Cancer
    Acid-PEG4-S-S-PEG4-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
  • HY-138072
    EMI1

    EGFR Cancer
    EMI1 is an EGFR ex19del/T790M/C797S and EGFR L858R/T790M/C797S inhibitor. EMI1 can be used for the research of mutant EGFR-associated, drug-resistant non-small-cell lung cancer (NSCLC).
  • HY-N6769
    Radicicol

    Monorden

    HSP Bacterial Antibiotic Infection
    Radicicol is an inhibitor of Hsp90 with an IC50 value of 1 μM. Radicicol binds to the ATPase domain of Hsp90 and prevents maturation of Hsp90 clients, leading to proteasomal degradation. Radicicol is an antifungal antibiotic with antimalarial activity, impairs mitochondrial replication by targeting P. falciparum topoisomerase VIB.
  • HY-123561
    MMV008138

    Parasite Infection
    MMV008138 is a species-selective IspD (enzyme 2-C-methyl-d-erythritol 4-phosphate cytidylyltransferase)-targeting antimalarial agent, with an IC50 of 44 nM for PfIspD (P. falciparum IspD). MMV008138 inhibits the growth of P. falciparum Dd2 strain with an IC50 of 250 nM.
  • HY-N1127
    Tricin

    CMV Cancer Infection
    Tricin is a natural flavonoid present in large amounts in rice bran. Tricin can inhibit human cytomegalovirus (HCMV) replication by inhibiting CDK9. Tricin inhibits the proliferation and invasion of C6 glioma cells via the upregulation of focal-adhesion-finase (FAK)-targeting microRNA-7.
  • HY-15827
    NSC 405020

    MMP Cancer
    NSC 405020 is a novel small molecule inhibitor of MT1-MMP that specifically targets PEX domain rather than the catalytic domain of MT1-MMP with IC50 >100 μM and does not inhibit the catalytic activity of MT1-MMP or MMP-2.
  • HY-128976
    10β,17β-dihydroxyestra-1,4-dien-3-one

    DHED

    Estrogen Receptor/ERR Metabolic Disease
    10β,17β-dihydroxyestra-1,4-dien-3-one (DHED) is a brain-targeting bioprecursor prodrug of the main human estrogen, 17β-estradiol, alleviates hot flushes in rat models of thermoregulatory dysfunction of the brain.
  • HY-17469
    Gimeracil

    Gimestat

    Others Cancer
    Gimeracil, a component of an oral fluoropyrimidine derivative S-1, inhibits DNA DSB repair and is a potent inhibitor of DPYD (dihydropyrimidine dehydrogenase, DPD).
  • HY-112583
    MIV-247

    Cathepsin Neurological Disease
    MIV-247 is a selective cathepsin S inhibitor with Kis of 2.1, 4.2 and 7.5 nM for human, mouse and cynomolgus monkey cathepsin S, respectively.
  • HY-P1328
    TAT-14

    Keap1-Nrf2 Others
    TAT-14 is a 14-mer peptide that acts as Nrf2 activator with an anti-inflammatory effect. TAT-14 has no effect on Nrf2 mRNA expression, but increases Nrf2 protein level due to targeting the Nrf2 binding site on Keap1.
  • HY-N2098
    Obtusifolin

    NF-κB Cancer
    Obtusifolin, isolated from the seeds of Cassia obtusifolia, regulates the gene expression and production of MUC5AC mucin in airway epithelial cells via inhibiting NF-kB pathway. Obtusifolin suppresses phthalate esters-induced breast cancer bone metastasis by targeting parathyroid hormone-related protein.
  • HY-B0836
    λ-Cyhalothrin

    Parasite Sodium Channel Infection Endocrinology Neurological Disease
    λ-Cyhalothrin is a high efficiency, broad-spectrum type II synthetic pyrethroid insecticide containing α-cyano group. λ-Cyhalothrin is used to control a wide range of pests in a variety of applications. λ-Cyhalothrin is a neurotoxin that targets sodium channels in the membranes of neurons in the central nervous system.
  • HY-N7043
    Isosilybin A

    Apoptosis Cancer
    Isosilybin A, a flavonolignan isolated from silymarin, has anti-prostate cancer (PCA) activity. Isosilybin A inhibits proliferation and induces G1 phase arrest and apoptosis in cancer cells, which activates apoptotic machinery in PCA cells via targeting Akt-NF-κB-androgen receptor (AR) axis.
  • HY-126323
    TCMDC-135051

    Parasite Infection
    TCMDC-135051 is a highly selective and potent protein kinase PfCLK3 inhibitor with low off-target toxicity. TCMDC-135051 prevents trophozoite-to-schizont transition, disrupts transcription and reduces transmission to the mosquito vector. TCMDC-135051 has antiparasiticidal activity (EC50=320 nM).
  • HY-100433
    PACMA 31

    Others Cancer
    PACMA 31 is an irreversible, orally active protein disulfide isomerase (PDI) inhibitor with an IC50 of 10 μM. PACMA 31 forms a covalent bond with the active site cysteines of PDI. PACMA 31 shows tumor targeting ability and significantly suppresses ovarian tumor growth without causing toxicity to normal tissues.
  • HY-100573
    Necrosulfonamide

    Mixed Lineage Kinase Cancer
    Necrosulfonamide is a necroptosis inhibitor acting by selectively targeting the mixed lineage kinase domain-like protein (MLKL). Necrosulfonamide prevents MLKL-RIP1-RIP3 necrosome complex from interacting with its downstream effectors. MLKL is a critical substrate of RIP3 during the induction of necrosis.
  • HY-16100
    BI 99179

    Fatty Acid Synthase (FASN) Cancer Metabolic Disease
    BI 99179 is a potent and selective type I fatty acid synthase (FAS) inhibitor with an IC50 of 79 nM. BI 99179 is a tool compound suitable for the in vivo validation of FAS as a target for lipid metabolism related diseases. BI 99179 exhibits significant exposure (both peripheral and central) upon oral administration in rats.
  • HY-N4113
    Glycycoumarin

    Autophagy Cancer
    Glycycoumarin is a major bioactive coumarin of licorice. Glycycoumarin inhibits hepatocyte lipoapoptosis through activation of autophagy and inhibition of ER stress-mediated JNK and GSK-3-mediated mitochondrial pathway. Glycycoumarin exerts anti-liver cancer activity by directly targeting T-LAK cell-originated protein kinase .
  • HY-126323B
    TCMDC-135051 hydrochloride

    Parasite Infection
    TCMDC-135051 hydrochloride is a highly selective and potent protein kinase PfCLK3 inhibitor with low off-target toxicity. TCMDC-135051 hydrochloride prevents trophozoite-to-schizont transition, disrupts transcription and reduces transmission to the mosquito vector. TCMDC-135051 hydrochloride has antiparasiticidal activity (EC50=320 nM).
  • HY-122872
    MKK7-COV-9

    p38 MAPK Cancer
    MKK7-COV-9 is a potent and selective covalent inhibitor of MKK7 and targets a specific protein–protein interaction of MKK7. MKK7-COV-9 blocks primary B cell activation in response to LPS with an EC50 of 4.98 μM.
  • HY-120395
    UC-514321

    STAT Apoptosis Cancer Inflammation/Immunology
    UC-514321, a structural analog of NSC370284 with higher activity, directly targets STAT3/5 and represses TET1 expression, but not TET2 or TET3. UC-514321 has the potential to treat acute myeloid leukemia (AML) both in vitro and in vivo, with low toxicity.
  • HY-136477
    Pentagamavunon-1

    PGV-1

    Apoptosis COX VEGFR NF-κB Cancer
    Pentagamavunon-1 (PGV-1), a Curcumin analog with oral activity, targets on several molecular mechanisms to induce apoptosis including inhibition of angiogenic factors cyclooxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF). PGV-1 inhibits NF-κB activation.
  • HY-18666
    D77

    HIV Infection
    D77 is anti-HIV-1 inhibitor targeting the interaction between integrase and cellular LEDGF/p75. D77 inhibits HIV-1(IIIB) replication by EC50 value of 23.8 μg/ml in MT-4 cell (5.03 μg/ml for C8166 cells).
  • HY-N0249
    Saikosaponin C

    Amyloid-β Neurological Disease
    Saikosaponin C is a bioactive component found in radix bupleuri, targets amyloid beta and tau in Alzheimer's disease. Saikosaponin C inhibits the secretion of both Aβ1-40 and Aβ1-42, and suppresses abnormal tau phosphorylation, but shows no effect on BACE1 activity and expression.
  • HY-12090
    Anacetrapib

    MK-0859

    CETP Cardiovascular Disease
    Anacetrapib is a potent CETP inhibitor, with IC50s of 7.9±2.5 nM and 11.8±1.9 nM for rhCETP and C13S CETP mutant, respectively.
  • HY-120722
    TCH-165

    Proteasome Cancer
    TCH-165 is a small molecule modulator of proteasome assembly, which increases 20S levels and facilitates 20S-mediated protein degradation.
  • HY-117386
    Methoxyfenozide

    Others Others
    Methoxyfenozide, a diacylhydrazine insecticide, selectively binds to lepidopteran ecdysone receptors (EcRs) over dipteran EcRs with Kd values of 0.5 and 124 nM, respectively. Methoxyfenozide is lethal to neonatal larvae of S. exigua, S. frugiperda, T. ni, O. nubilalis, L. pomonella, H. zea, and H. virescens (LC50s=0.35, 0.2, 0.11, 0.18, 0.21, 0.79, and 3.12 mg/L, respectively).
  • HY-101817
    Spirendolol

    Li 32-468; S 32-468; Substance 32468

    Adrenergic Receptor Neurological Disease Endocrinology
    Spirendolol is a β adrenergic receptor antagonist.
  • HY-P0184
    Camstatin

    NO Synthase Neurological Disease
    Camstatin, a functionally active 25-residue fragment of PEP-19's IQ motif, binds calmodulin and inhibits neuronal nitric oxide (NO) synthase.
  • HY-111380
    EHT 1610

    DYRK Neurological Disease
    EHT 1610 is a strong inhibitor of DYRK’s family kinases, with IC50s of 0.36, 0.59 nM for DYRK1A and DYRK1B, respectively.
  • HY-13595
    Chrysophanol

    Chrysophanic acid

    EGFR Cancer
    Chrysophanol (Chrysophanic acid) is a natural anthraquinone, which inhibits EGF-induced phosphorylation of EGFR and suppresses activation of AKT and mTOR/p70S6K.
  • HY-18522
    AA26-9

    Phospholipase Metabolic Disease
    AA26-9 is a potent and broad spectrum serine hydrolase inhibitor. AA26-9 targets included serine peptidases, lipases, amidases, esterases, and thioesterases. AA26-9 shows inhibitory activity against approximately 1/3 of the 40+ serine hydrolases detected in immortalized T cell lines .
  • HY-122051
    AC1903

    TRP Channel Metabolic Disease
    AC1903 is a specific and selective inhibitor of TRPC5 and has podocyte-protective properties. AC1903 does no effects on TRPC4 or TRPC6 currents and shows no off-target effects in kinase profiling assays. AC1903 suppresses severe proteinuria and prevents podocyte loss in focal segmental glomerulosclerosis (FSGS) rat model.
  • HY-122534
    Mensacarcin

    Mitochondrial Metabolism ADC Cytotoxin Apoptosis Cancer
    Mensacarcin, a highly complex polyketide, strongly inhibits cell growth universally in cancer cell lines and potently induces apoptosis in melanoma cells. Mensacarcin targets to mitochondria, affects energy metabolism in mitochondria, and activates caspase-dependent apoptotic pathways. Mensacarcin, an antibiotic, can be used as a cytotoxic component of antibody-drug conjugates (ADCs).
  • HY-10545
    Taribavirin

    HBV HCV Infection
    Taribavirin is an orally active inosine monophosphate dehydrogenase inhibitor, has activity against a wide range of viruses, especially the hepatitis C virus and influenza virus. Taribavirin, is a ribavirin prodrug, is designed to concentrate within the liver to target HCV-infected hepatocytes while minimizing distribution within red blood cells (RBCs) and the development of hemolytic anemia.
  • HY-126810A
    NP213 TFA

    Fungal Infection
    NP213 TFA is a rapidly acting, novel, first-in-class synthetic antimicrobial peptide (AMP), has anti-fungal activities. NP213 TFA targets the fungal cytoplasmic membrane and plays it role via membrane perturbation and disruption. NP213 TFA is effective and well-tolerated in resolving nail fungal infections.
  • HY-16706A
    Remodelin hydrobromide

    Histone Acetyltransferase Cancer
    Remodelin, a specific inhibitor of N-acetyltransferase NAT10, can ameliorate Hutchinson-Gilford Progeria Syndrom (HGPS) cellular phenotypes. Remodelin acts in a progerin- and FTI-independent pathway, by targeting and inhibiting NAT10. NAT10 is a protein with histone acetylation activity and primarily identified to be involved in regulation of telomerase activity.
  • HY-100538A
    DTP3 TFA

    DNA/RNA Synthesis JNK Cancer
    DTP3 TFA is a potent and selective GADD45β/MKK7 (growth arrest and DNA-damage-inducible β/mitogen-activated protein kinase kinase 7) inhibitor. DTP3 TFA targets an essential, cancer-selective cell-survival module downstream of the NF-κB pathway.
  • HY-D0162
    Malachite green oxalate

    IKK NF-κB Apoptosis Cancer
    Malachite green oxalate is a triphenylmethane dye which can be used to detect the release of phosphate in enzymatic reactions. Malachite green oxalate is also a potent and selective inhibitor of IKBKE, and inhibits its downstream targets such as IκBα, p65 and IRF3. Malachite green oxalate exhibits antitumor activity in vitro and in vivo.
  • HY-19980
    Eprenetapopt

    APR-246; PRIMA-1Met

    MDM-2/p53 Autophagy Apoptosis Ferroptosis Cancer
    Eprenetapopt (APR-246) is a first-in-class, small molecule that restores wild-type p53 functions in TP53-mutant cells. Eprenetapopt triggers apoptosis in tumor cells. Eprenetapopt also targets the selenoprotein thioredoxin reductase 1 (TrxR1), a key regulator of cellular redox balance.
  • HY-B1369
    Imipenem monohydrate

    N-Formimidoyl thienamycin monohydrate

    Bacterial Antibiotic Infection
    Imipenem monohydrate, a member of the carbapenem class of antibiotics isolated from the soil organism Streptomyces cattleya, is an intravenous β-lactam antibiotic effective against a wide range of Gram-positive and Gram-negative bacteria, including several multi-drug resistant bacterial species. Imipenem acts as cell wall-targeting antibiotic.
  • HY-N8441
    Neriifolin

    17β-Neriifolin

    Na+/K+ ATPase Apoptosis Cancer Inflammation/Immunology
    Neriifolin, a CNS-penetrating cardiac glycoside, is an inhibitor of the Na +, K +-ATPase. Neriifolin can target beclin 1, inhibits the formation of LC3-associated phagosomes and ameliorates experimental autoimmune encephalomyelitis (EAE) development. Neriifolin induces cell cycle arrest and apoptosis in human hepatocellular carcinoma HepG2 cells[2.
  • HY-10293
    Aderbasib

    INCB007839; INCB7839

    MMP Cancer
    Aderbasib (INCB007839) is a potent, orally active and target specific low nanomolar hydroxamate-based inhibitor of ADAM10 and ADAM17. Aderbasib exhibits robust antineoplastic activity and can be used for cancer research, including diffuse large B-cell non-Hodgkin lymphoma, HER2 + breast cancer, gliomas, et al.
  • HY-141429
    AS-99

    Histone Methyltransferase Apoptosis Cancer
    AS-99 is a first-in-class, potent and selective ASH1L histone methyltransferase inhibitor (IC50= 0.79 µM, Kd= 0.89 µM) with anti-leukemic activity. AS-99 blocks cell proliferation, induces apoptosis and differentiation, downregulates MLL fusion target genes, and reduces the leukemia burden in vivo.
  • HY-10545A
    Taribavirin hydrochloride

    HBV HCV Infection
    Taribavirin hydrochloride is an orally active inosine monophosphate dehydrogenase inhibitor, has activity against a wide range of viruses, especially the hepatitis C virus and influenza virus. Taribavirin hydrochloride is a Ribavirin prodrug, is designed to concentrate within the liver to target HCV-infected hepatocytes while minimizing distribution within red blood cells (RBCs) and the development of hemolytic anemia.
  • HY-P1328A
    TAT-14 TFA

    Keap1-Nrf2 Others
    TAT-14 TFA is a 14-mer peptide that acts as Nrf2 activator with an anti-inflammatory effect. TAT-14 TFA has no effect on Nrf2 mRNA expression, but increases Nrf2 protein level due to targeting the Nrf2 binding site on Keap1.
  • HY-130641
    Br-C10-methyl ester

    PROTAC Linker Cancer
    Br-C10-methyl ester is a PROTAC linker, which refers to the alkyl/ether composition. Br-C10-methyl ester is used in the synthesis of a series of PROTACs (MS432).  PROTACs contain two different ligands connected by a linker; one is the VHL ligand portion and the other is for the target protein.
  • HY-124801
    ABMA

    Bacterial Influenza Virus Parasite Infection
    ABMA is a broad-spectrum inhibitor of intracellular toxins and pathogens. ABMA efficiently protects cells against various toxins and pathogens including viruses, intracellular bacteria and parasite. ABMA selectively acts at host cell late endosomes rather than targeting toxin or pathogen itself. ABMA has broad-spectrum anti-infection activity.
  • HY-136404
    Melanin probe-1

    Others Cancer
    Melanin probe-1 is an 18F-picolinamides based PET probe. Melanin probe-1 can be used for PET imaging of malignant melanoma. Melanin probe-1 exhibits high tumor targeting efficiency, excellent tumor imaging contrasts, desirable biodistribution patterns, and good in vivo stability.
  • HY-P2264
    KYL peptide

    Ephrin Receptor Inflammation/Immunology
    KYL peptide, an antagonistic peptide, selectively targets EphA4 receptor. KYL peptide binds to the ligand-binding domain of EphA4, effectively alleviates Aβ-induced synaptic dysfunction and synaptic plasticity defects in AD mice. KYL peptide can promote nerve regeneration after injury and modulating immune responses.
  • HY-117383
    NGI-1

    ML414

    Virus Protease Cancer
    NGI-1 (ML414) is a potent oligosaccharyltransferase (OST) inhibitor, directly targeting and blocking the function of the OST catalytic subunits STT3A and STT3B. NGI-1 is a cell permeable inhibitor and can effectively reduce virus infectivity without affecting cell viability.
  • HY-N7030
    5,7,3',4'-Tetramethoxyflavone

    Fungal Parasite Infection
    5,7,3',4'-Tetramethoxyflavone, one of the major polymethoxyflavones (PMFs) isolated from M. exotica, possesses various bioactivities, including anti-fungal, anti-malarial, anti-mycobacterial, and anti-inflammatory activities. 5,7,3',4'-Tetramethoxyflavone exhibits chondroprotective activity by targeting β-catenin signaling.
  • HY-P0184A
    Camstatin TFA

    NO Synthase Neurological Disease
    Camstatin TFA, a functionally active 25-residue fragment of PEP-19's IQ motif, binds calmodulin and inhibits neuronal nitric oxide (NO) synthase.
  • HY-18169
    MUT056399

    Fab-001

    Bacterial Infection
    MUT056399 (Fab-001) is a highly potent inhibitor of the FabI enzyme of both S. aureus and E. coli with 50% inhibitory concentration IC50s of 12 nM and 58 nM, respectively.
  • HY-100559
    SecinH3

    Apoptosis Endocrinology Metabolic Disease Cancer
    SecinH3 is an antagonist of cytohesins with IC50s of 5.4 μM, 2.4 μM, 5.4 μM, 5.6 μM, 5.6 μM and 65 μM for hCyh1, hCyh2, mCyh3, hCyh3, drosophila steppke and yGea2-S7, respectively.
  • HY-12059A
    AT7867 dihydrochloride

    Akt PKA Ribosomal S6 Kinase (RSK) Cancer
    AT7867 dihydrochloride is a potent ATP-competitive inhibitor of Akt1/Akt2/Akt3 and p70S6K/PKA with IC50s of 32 nM/17 nM/47 nM and 85 nM/20 nM, respectively.
  • HY-100501
    M2698

    MSC2363318A

    Ribosomal S6 Kinase (RSK) Akt Cancer
    M2698 (MSC2363318A) is an orally active, ATP competitive, selective p70S6K and Akt dual-inhibitor with IC50s of 1 nM for p70S6K, Akt1 and Akt3. M2698 can cross the blood-brain barrier and has anti-cancer activity.
  • HY-16690
    BTS

    N-Benzyl-p-toluenesulfonamide; N-Tosylbenzylamine

    Myosin Others
    BTS (N-Benzyl-p-toluenesulfonamide) is a potent and selective inhibitor of skeletal muscle myosin II subfragment 1 (S1) ATPase activity, with an IC50s of ~5 µM for actin- and Ca 2+-stimulated myosin S1 ATPase. BTS specifically inhibits the contraction of fast skeletal muscle fibers.
  • HY-12059
    AT7867

    Akt PKA Ribosomal S6 Kinase (RSK) Cancer
    AT7867 is a potent ATP-competitive inhibitor of Akt1/Akt2/Akt3 and p70S6K/PKA with IC50s of 32 nM/17 nM/47 nM and 85 nM/20 nM, respectively.
  • HY-W018555
    D-Cysteine

    Endogenous Metabolite Bacterial Infection Neurological Disease
    D-Cysteine is the D-isomer of cysteine and a powerful inhibitor of Escherichia coli growth. D-cysteine is mediated by D-amino acid oxidase to produce H2S and is a neuroprotectant against cerebellar ataxias. D-Cysteine could inhibit the growth and cariogenic virulence of dual-species biofilms formed by S. mutans and S. sanguinis.
  • HY-14855
    Tedizolid

    TR 700; Torezolid; DA-7157

    Bacterial Antibiotic Infection
    Tedizolid (TR 700; Torezolid; DA-7157) is a novel oxazolidinone, acting through inhibition of bacterial protein synthesis by binding to 23S ribosomal RNA (rRNA) of the 50S subunit of the ribosome.
  • HY-15564
    AR 231453

    GPR119 Metabolic Disease
    AR 231453 is a potent, specific and orally available GPR119 agonist. AR 231453 can stimulate β-cell replication and improve islet graft function s.
  • HY-112534
    GSTO-IN-2

    Gutathione S-transferase Cancer
    GSTO-IN-2 is a glutathione S-transferase inhibitor with IC50s of 3.6, 16.3, and 1.4 μM for GSTA2, GSTM1, and GSTP1-1.
  • HY-N5056
    DL-Goitrin

    Others Others
    DL-Goitrin, also called (R, S)- report by the spring, consists of the epigoitrin (reported by the R- Spring) and the spring (-S- reported by spring), and the two mutually isomers, and the mixture is the ingredient of Radix.
  • HY-16734A
    Amiselimod hydrochloride

    MT-1303 hydrochloride

    LPL Receptor Cancer
    Amiselimod hydrochloride is a novel sphingosine 1-phosphate receptor-1 (S1P1) modulator, designed to reduce the bradycardia effects associated with fingolimod and other S1P receptor modulators.
  • HY-12493A
    LY-2584702 tosylate salt

    Ribosomal S6 Kinase (RSK) Cancer
    LY-2584702 tosylate salt is a selective ATP competitive inhibitor of p70S6K with an IC50 of 4 nM. In S6K1 enzyme assay, the IC50 of LY-2584702 is 2 nM.
  • HY-13237
    GSK2578215A

    LRRK2 Autophagy Mitophagy Neurological Disease
    GSK2578215A is a potent and highly selective LRRK2 inhibitor, which exhibits IC50s of around 10 nM against both wild-type LRRK2 and the G2019S mutant.
  • HY-12493B
    LY-2584702 hydrochloride

    Ribosomal S6 Kinase (RSK) Cancer
    LY-2584702 hydrochloride is a selective ATP competitive inhibitor of p70S6K with an IC50 of 4 nM. In S6K1 enzyme assay, the IC50 of LY-2584702 is 2 nM.
  • HY-13838
    PLX647

    c-Fms c-Kit Cancer
    PLX647 is an orally active, highly specific dual FMS and KIT kinase inhibitor, with IC50s of 28 and 16 nM, respectively. PLX647 shows selectivity for FMS and KIT o